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Abstract 
Substance misuse remains problematic with current concerns being the rise in acute 
poisoning deaths, particularly opioid-associated, and the ever-widening range of drugs 
available. Strategies for tackling opioid addiction and opioid related-deaths include 
researching alternative routes of therapeutic agent administration. 
Initial urine screening for substance misuse has traditionally employed immunoassays, 
with confirmation of specific analytes by chromatographic methods. Liquid 
chromatography-high resolution mass spectrometry (LC-HRMS) offers untargeted 
analysis without compromising selectivity, and enables users to ascertain putative 
elemental compositions of an analyte, retrospectively interrogate data, and to 
incorporate novel analytes easily. These features enable screening and confirmation of 
drugs in a single method, and may be advantageous for detecting novel psychoactive 
substances (NPS). 
This thesis aims to investigate the role of LC-HRMS in drug analysis in the clinical 
setting. A simple system was developed that is capable of detecting a wide range of 
commonly-encountered drugs and metabolites. Non-selective sample preparation was 
used to enable detection of as many compounds as possible, but significant matrix 
effects were observed. Additional information regarding selected NPS was ascertained 
through retrospective identification of mephedrone metabolites in patient urines, and 
through later incorporation of ethylphenidate, methylphenidate, and ritalinic acid, into 
the method.  
A separate quantitative LC-HRMS method was developed to facilitate pharmacokinetic 
studies of naloxone and naltrexone administered through alternative routes. The method 
was also applied to urine samples, with naloxone-3-glucuronide identified as a potential 
marker to differentiate between Subutex and Suboxone use. 
LC-HRMS has advantages in drug detection, particularly in regard to NPS, and in 
method development. However, application in the clinical setting is restricted by 
requirements for high throughput, timely results, and operation to accepted ‘cutoff’ 
values that introduce awkward compromises in system operation. LC-HRMS may have 
greater application in the forensic setting where more time is available for the analysis 
of a single sample. 
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1.1 Substance Misuse 
Substance misuse refers to the harmful use of generally psychoactive substances, 
including alcohol, tobacco, and illicit drugs. The International Classification of Diseases 
(ICD-10) defines ‘harmful use’ when there is evidence that substance use is causing 
physical or psychological harm. It defines ‘drug dependence’ as occurring if three or 
more indicators of dependence (Table 1.1) have been present for at least one month 
within the past year (World Health Organization, 1993).  
 
Table 1.1 – Indicators of drug dependence according to the International 
Classification of Diseases (World Health Organization, 1993) 
Dependence Syndrome Manifestations 
Strong desire or compulsion to take the substance 
Impaired capacity to control substance-taking behaviour in terms of termination or 
level of use 
A physiological withdrawal state when substance-use is reduced or ceased 
Evidence of tolerance to the effects of the substance 
Preoccupation with substance use 
Persistent substance use despite clear evidence of harmful consequences 
 
The economic cost of drug dependence has been estimated as £15 billion per year in 
Britain (The Centre for Social Justice, 2013), and there are obviously important health 
and social issues too. There is an urgent need for improvement in the management of 
substance misuse-related disorders, and thus it is important to invest in research for 
improvement of substance misuse prevention and treatment strategies. Currently two of 
the main concerns relating to drug misuse are the rise in acute poisoning deaths 
(particularly associated with opioids), and the dynamic and constantly changing market 
for novel psychoactive substances (NPS, EMCDDA, 2016). Tackling these issues is 
multi-disciplinary, ranging from implementation of political policies and optimisation 
of treatment to detection and monitoring of drug misuse.  
1.1.1 Legal Classification of Drugs 
The legal classification of drugs in the United Kingdom (UK) is largely governed by the 
Misuse of Drugs Act (1971) (MDA). The act was introduced with the main purpose of 
preventing the non-medical use of certain drugs, with drugs subject to this act termed 
‘controlled drugs’ (CD). The Act denotes three classes for CD, broadly based on the 
harmfulness attributable to a substance, with Class A drugs having the greatest penalties 
associated when supplying or possessing these compounds (Table 1.2a). The regulations 
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for supply and possession of CD are given in the Misuse of Drugs Regulations (2001), 
which delineates five schedules (Table 1.2b). There has been debate over whether the 
MDA classification accurately reflects the harm associated with a substance, and 
additionally that the legal status of a substance does not correlate with its perceived 
harm. Most notably, alcohol and tobacco (both legal substances with controlled sales) 
have greater perceived harm than some Class A drugs (Nutt et al., 2010; Taylor et al., 
2012). 
 
Table 1.2 – Controlled drug legislation according to a) the Misuse of Drugs Act 
1971 c. 38, and b) the Misuse of Drugs Regulations 2001 No. 3998 
a) 
Drug Class Legal Penalties for i) possession, 
and ii) supply/possession with intent 
to supply 
Examples 
A i) 6 months – 7 years, £5,000 – 
unlimited fine 
ii) 6 months – life imprisonment, 





B i) 3 months – 5 years, £2,500 – 
unlimited fine 







C i) 3 months – 2 years, £500 – 
unlimited fine 








Drug Schedule Medicinal requirements Examples 
1 No medical use  
Possession & supply prohibited 
Lysergic acid 
diethylamide (LSD) 
2 Full CD requirements  
Safe custody requirement 




3 Same prescription requirements as 
Schedule 2  
No requirement to maintain registers 




4 (Part I) No CD prescription requirements 
No safe custody requirements 
Most benzodiazepines 
Z-drugs 
4 (Part II) Anabolic steroids 
5 Exempt from all requirements due to 
low strength 
Need to retain invoices for 2 years 





Over the last decade, NPS have emerged. Most of these drugs are produced through 
altering the chemical structure of well-known psychoactive substances, e.g. 
methylenedioxymetamfetamine (MDMA, ‘ecstasy’). Through these structural 
modifications, the novel compounds often by-passed existing controlled drug 
legislation. In an attempt to control these substances, the British Government introduced 
a ‘temporary class drug order’ which enabled substances to swiftly be brought under the 
MDA and placed under temporary control for up to 12 months. During this time the 
Advisory Council for the Misuse of Drugs (ACMD) decide whether permanent control 
is required or not.  It does not make possession for personal use illegal, but does give 
police the authority to confiscate and destroy these substances.  It also makes import, 
distribution and sale of the substance illegal and these actions can lead to a fine or a 
prison sentence (Home Office, 2011). Further to this, the Psychoactive Substances Act 
(2016) was introduced to restrict the production, sale and supply of all psychoactive 
substances. The only psychoactive substances exempt from this act are substances 
ordinarily consumed as food (e.g. nutmeg), nicotine and tobacco products, caffeine, 
alcohol, medicinal products as defined by The Human Medicines Regulations (2012), 
and drugs that are already controlled by the MDA (1971). The act also affects 
responsible retailers who supply products that contain psychoactive substances, e.g. 
solvents and butane. In doing so, it has replaced the Intoxicating Substances (Supply) 
Act (1985). 
The legal classification of drugs varies between countries, with the main difference in 
legal status noted for cannabis. Cannabis has been legalised for recreational use in 8 
states in the USA, and other countries (e.g. the Netherlands) have more lenient laws for 
personal use.  
1.1.2 Prevalence of Substance Misuse 
Globally, the prevalence of drug misuse has remained fairly stable over the last few 
years (Figure 1.1). Cannabis is consistently the most widely used illicit drug, with an 
estimated 183 million people having used the drug in 2014, equating to 3.8 % of the 
world’s adult population (United Nations Office on Drugs and Crime, 2016). The global 
prevalence of the misuse of opioids such as heroin (impure diamorphine) is estimated at 
0.7 %, ranking opioids as the third most prevalent drug class misused, behind cannabis 
and amfetamines (United Nations Office on Drugs and Crime, 2016). The global 
estimate of opioid dependent individuals (aged 15 years or older) was 10.4 million in 
1990, rising to 15.5 million in 2010 (Degenhardt et al., 2014). 
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Figure 1.1 – Global trends in the estimated prevalence of drug misuse (15-64 year-
olds), 2006-2014  




Opioid addiction remains a problem within the UK, and many users are reliant on 
prescribed opioid substitutes, with 17.3 million and 2.6 million prescriptions for 
methadone and buprenorphine, respectively, issued in England and Wales between 
2007-2012 (Marteau et al., 2015). Whilst the prevalence of opioid misuse is relatively 
low, opioids feature in the greatest number of drug-related deaths (Table 1.3). In 
addition, UK deaths involving heroin or morphine have increased by 64 % from 2012 to 
2014 (Wise, 2015). This increase has also been observed in the USA, with heroin-
related deaths rising by 39 % from 2013 to 2014 (United Nations Office on Drugs and 
Crimes, 2015). Accurate identification of deaths due to heroin administration may be 
hindered by the rapid metabolism of diamorphine (the principal active component of 
heroin) and its unique metabolite 6-acetylmorphine (6-AM), meaning morphine may be 
the only compound detected in samples of body fluids or tissues obtained post-mortem 
(Figure 1.2). In this situation administration of heroin as opposed to morphine cannot be 
distinguished from analytical results alone, unless other markers of heroin use such as 
meconin or 6-acetylcodeine are also present.  
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Table 1.3 – Drug use prevalence in England and Wales (Home Office, 2015) and 
drug-related deaths (Office for National Statistics, 2016)  
Drug-related deaths are counted when the named drug or drug group was detected; other 
drugs and/or alcohol may also have been detected in some cases. 
Drug 
Prevalence of use in general 
population (use in the last 
year, age 16-59 y) 
Number of 
deaths in 2015 
   
Cannabis 6.7 % 21 
Cocaine 2.4 % 320 
MDMA 1.7 % 57 
Amfetamine 0.6 % 90 
Opioids (Diamorphine/morphine) 0.1 % 1,989 (1,201) 
 
Figure 1.2 – Metabolic pathway of diamorphine, morphine and codeine  






























































1.1.3 Opioid Receptors and Pharmacology 
Opioid receptors are a group of inhibitory G protein-coupled receptors (GPCR) 
distributed widely through the brain, spinal cord and digestive tract. They form part of 
an endogenous system with three main classes of opioids being present in the body: 
endorphins, enkephalins, and dynorphins. These opioids act as neurotransmitters and 
neuromodulators at the three major subclasses of ‘classical’ opioid receptor: delta (δ), 
kappa (κ), and mu (µ), to produce analgesia. Opioid drugs act at these same receptors, 
and are classified according to their receptor interaction into four groups: agonists, 
antagonists, partial agonists and agonist-antagonists (Table 1.4). Two other opioid 
receptors exist; the nociceptin receptor and the opioid growth factor receptor. However, 
these share little sequence similarity to the ‘classical’ receptors and possess little or no 
affinity for opioids (Butour et al., 1997). 
Table 1.4 – Classification of opioid drugs  
Agent Class Example/s Action 
Agonist Morphine  Methadone 
Activation of all receptor subclasses, though 
with different affinity 
Antagonist Naloxone  Naltrexone 
Devoid of agonist activity at all receptor 
subclasses; may displace an agonist from a 
receptor 
Partial agonist Buprenorphine Agonist activity at one or more, but not all 
receptor subclasses 
Agonist-antagonist Nalorphine Agonist activity at one type and antagonist 
activity at another type of receptor subclass 
 
When taken orally, most opioids have low bioavailability meaning that only a small 
proportion of the dose reaches the brain and elicits the desired effect. This is a result of 
first-pass metabolism where much of the drug is metabolised in the intestine and/or the 
liver prior to reaching the systemic circulation. Drug bioavailability may be increased 
by administration directly into the systemic circulation. Those who abuse opioid 
agonists typically inject or inhale the drug in order to ‘achieve a greater high’. Opioid 
antagonists may also be given by non-oral routes to improve bioavailability, e.g. 
naloxone is typically injected. 
Opioid tolerance, dependence, and addiction are all manifestations of changes to the 
brain as a result of chronic opioid use. Opioid agonists activate the mesolimbic pathway 
(the reward pathway) causing dopamine release in part of the brain (the nucleus 
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accumbens), eliciting a feeling of pleasure (Kosten and George, 2002). The constant 
overstimulation of this pathway plays a central role in the neurobiology of opioid 
addiction. Repeated opioid exposure alters the brain so that it may function apparently 
normally when opioid agonists are present, and functions abnormally when they are 
absent. Clinically these alterations cause opioid tolerance, where a higher dose is 
required to achieve the same opioid effect, and opioid dependence, where an individual 
will experience withdrawal on cessation of opioid administration. Withdrawal has two 
stages, the acute stage where mainly physical features predominate (e.g. nausea, 
vomiting, abdominal cramps, diarrhoea), and the post-acute stage where symptoms are 
mainly psychological (e.g. anxiety, depression, irritability) and have a longer duration. 
Opioid misuse falls into two categories; illicit drug misuse (e.g. heroin), and 
prescription drug misuse (e.g. oxycodone) where opioids may be obtained through legal 
or illegal routes. These two categories often cross-over, for example heroin users may 
use prescription opioids to prevent withdrawal if heroin is not available. Awareness of 
prescription medicine misuse has increased over the last few years. It has been most 
pronounced in the USA, where opioid prescriptions increased from 76 million in 1991 
to 207 million in 2013 (National Institute on Drug Abuse, 2014), and prescription drug 
misuse is second only to cannabis use across all age groups (Hernandez and Nelson, 
2010; Hughes et al., 2016). There is also evidence of problematic opioid analgesic use 
outside the USA, particularly in Europe and Australia (Morley et al., 2017). Whilst 
misuse of prescription medication is not currently thought to be as serious an issue in 
the UK, data suggest that there may be a trend towards the situation in the USA that 
warrants attention (Giraudon et al., 2013; Morley et al., 2017; Weisberg et al., 2014).  
Strategies for tackling opioid addiction and opioid related-deaths can be at two levels: to 
reduce associated deaths through greater provision of the antidote (naloxone), and to 
research further into improvement of maintenance/detoxification treatments. The most 
effective pharmacological approach to the treatment of opioid dependency is opioid 
substitution therapy (OST) using agonists. OST  has been shown to decrease the adverse 
consequences of heroin use, including drug-related crime and HIV risk (Cone and 
Preston, 2002). Buprenorphine and methadone (Figure 1.3) are both used for OST, and 
are effective for the treatment of heroin dependence (Mattick et al., 2009, 2014). 
Methadone is a chiral compound and is prescribed as a racemic mixture, however only 
R-methadone is responsible for therapeutic effect through its affinity for µ opioid 
receptors. The S-enantiomer is a poor µ agonist, and has been postulated to be 
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responsible for adverse cardiac effects associated with methadone use (Lin et al., 2009). 
Buprenorphine also acts at the µ opioid receptor, but possesses additional antagonist 
activity at κ opioid receptors. Through their agonist activity both methadone and 
buprenorphine can act as substitutes for heroin. OST is available in most European 
countries (Table 1.5). Methadone use is more prevalent in the UK; however other 
countries favour the use of buprenorphine (e.g. France, Turkey). In 2005, the World 
Health Organisation (WHO) added methadone and buprenorphine to the WHO Model 
List of Essential Medicines for opioid addiction treatment (World Health Organisation, 
2005).  
Figure 1.3 – Structures of opioid agonists used for treatment of opioid dependency 













Unfortunately, side effects such as constipation, excess sweating, drowsiness and 
decreased libido are associated with OST (Tetrault and Fiellin, 2012). In addition, there 
is a risk of acute poisoning, particularly with methadone. Another disadvantage of 
agonist therapy is that prescribed agonist drugs may be sold illicitly so that the user may 
purchase their preferred drug. Diversion of opioid agonists used for maintenance 
treatment is a challenge faced worldwide (Dasgupta et al., 2010; Johnson and Richert, 
2015a; Larance et al., 2011; Nordmann et al., 2012). Studies report between a fifth and 
a quarter of individuals prescribed maintenance therapy have diverted their medication 
(Johnson and Richert, 2015b; Larance et al., 2011). In some countries opioid agonists 
developed for treatment purposes have now become the most widely-abused opioid in 
that country, e.g. buprenorphine in Finland (Aalto et al., 2007; EMCDDA, 2005; 
Launonen et al., 2015). 
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Table 1.5 – Summary of the availability of opioid substitution therapy across 
Europe (Data from EMCDDA, 2013) 
Country Year opioid substitution therapy was introduced 
Most common form of 
substitution therapy  
Austria 1987 Slow-release oral morphine 
Belgium 2002 Methadone 
Bulgaria 1995 Methadone 
Croatia 1991 Buprenorphine 
Cyprus 2007 Buprenorphine 
Czech Republic 1998 Buprenorphine 
Denmark 1970 Methadone 
Estonia 2001 Methadone 
Finland 1974 Buprenorphine 
France 1995 Buprenorphine 
Germany 1992 Methadone 
Greece 1993 Buprenorphine 
Hungary 1994 Methadone 
Italy 1975 Methadone 
Ireland 1992 Methadone 
Latvia 1996 Methadone 
Lithuania 1995 Methadone 
Luxembourg 2002 Methadone 
Malta 1987 Methadone 
Netherlands 1968 Methadone 
Norway 1998 Buprenorphine 
Poland 1993 Methadone 
Portugal 1977 Methadone 
Romania 1998 Methadone 
Slovakia 1997 Methadone 
Slovenia 1990 Methadone 
Spain 1990 Methadone 
Sweden 1967 Information not available 
Turkey 2010 Buprenorphine 
United Kingdom 1968 Methadone 
 
Naloxone and naltrexone (Figure 1.4) both act as antagonists at opioid receptors. Both 
may interact with all receptor subclasses (Shader, 2003), but have greatest affinity at µ 
opioid receptors (Helm et al., 2008). At present the main clinical use of antagonists, 
principally naloxone, is in treatment of acute opioid overdose. Antagonist-based 
treatment for opioid dependency is not widely used, with the major criticism of this 
strategy being short retention times in treatment, and increased risk of overdose due to 


















Naloxone  Naltrexone 
 
When compared to agonist therapy, antagonists offer some significant benefits 
including no abuse potential, and no tolerance associated with use. In addition, 
antagonists are associated with minimal adverse effects. Socially antagonist therapy 
may be deemed a more acceptable approach to treatment of opioid dependency, and in 
some countries is the only treatment option (e.g. Russia, Krupitsky et al., 2010).  
Antagonists, namely naloxone, have also been utilised to deter opioid abuse through co-
formulation with partial agonists or agonists such as buprenorphine and oxycodone 
(Colucci et al., 2014; DePriest and Miller, 2014; Gershell and Goater, 2006; Schaeffer, 
2012; Soyka, 2015; Vocci et al., 2005). When these preparations are taken as intended 
(orally or sublingually) they have the desired effect due to the low oral bioavailability of 
naloxone, however when misused (e.g. injected or insufflated, i.e. ‘snorted’) the 
naloxone reaches sufficient concentration at the receptors to block the effect of the 
opioid and induce symptoms of opioid withdrawal. Co-formulation has also been 
explored to try and reduce undesirable side effects of agonists, such as constipation, 
associated with therapeutic opioid administration through addition of a neutral 
antagonist (e.g. 6-β-naltrexol) that preferentially antagonises opioid effects on the 





1.1.4 The Changing Drug Scene 
Over the last decade there has been a rapid and continuous growth in the use of NPS 
(‘legal highs’, ‘designer drugs’, ‘research chemicals’) (Figure 1.5). Typically these 
products have been marketed as ‘plant food’ or ‘herbal incense’ not intended for human 
consumption. These products mimic the psychoactive effects of drugs of abuse, but 
were not illegal due to slight structural deviations from controlled drugs as discussed 
previously. Due to the uncontrolled nature of production, NPS marketed as containing a 
particular substance often do not contain the compound specified, but rather a variety of 
other substances, and in some cases may only contain caffeine (Brandt et al., 2010).  As 
a result, individuals are unaware of what they actually are taking and the potency of the 
compound(s) ingested.  In addition, as little or no pharmacological or toxicological 
information exists for these substances long-term risks, in addition to short-term risks, 
remain unknown. The majority of emerging NPS are either synthetic cannabinoids, or 
cathinone derivatives, although derivatives of other drugs such as benzodiazepines and 
opioids are also marketed.  
Figure 1.5 – Number and main groups of NPS notified for the first time to the 
EMCDDA Early Warning System, 2005-2013 (Taken from Stephenson and 




1.1.4.1 Novel Stimulants 
Mephedrone (4-methylmethcathinone, ‘4-MMC’, ‘Meow Meow’, ‘Miaow’, ‘White 
Magic’, ‘M-Cat’, ‘Bubble’) was one of the first NPS to appear and has been one of the 
most publicised, being reported by the UK media in March 2010 following several 
deaths said to be associated with the drug.  Mephedrone was portrayed as a ‘legal’ 
alternative to MDMA.  On 16 April 2010, mephedrone and other substituted cathinones 
became classified as Class B drugs (The Misuse of Drugs Act 1971 (Amendment) 
Order, 2010).  However, many novel stimulants have been developed since that time 
and continue to be sold (Table 1.6). 
As well as structural alteration of illicit psychoactive drugs, alteration of pharmaceutical 
drugs with stimulant properties has been reported. Methylphenidate is a 
psychostimulant prescribed as first-line treatment in Attention Deficit Hyperactivity 
Disorder (ADHD), but may also be abused for its stimulant properties. When 
methylphenidate is taken concurrently with ethanol, S,S-ethylphenidate may be formed 
by enantioselective transesterification (Dinis-Oliveira, 2017; Patrick et al., 2013). More 
recently, ethylphenidate has been marketed as a ‘legal high’ (Ho et al., 2015; Krueger et 
al., 2014). Details of six other phenidate analogues marketed as ‘legal highs’ have been 
published (Klare et al., 2017; Markowitz et al., 2013).  
1.1.4.2 Synthetic Cannabinoids 
Synthetic cannabinoids (‘Spice’, ‘K2’) are highly potent drugs that bind to the same 
receptors as ∆9-tetrahydrocannabinol (∆9-THC), the primary psychoactive substance in 
cannabis. Many of the synthetic cannabinoids were originally synthesised as 
pharmacological probes for investigating the endogenous cannabinoid system and 
developing potential pharmacotherapies (Diao and Huestis, 2017). A huge range of 
synthetic cannabinoids exist with minor structural changes between compounds (Table 
1.7). By April 2015, 858 synthetic cannabinoids had been scheduled in Japan 
(Uchiyama et al., 2015), and many more are likely to be developed. Considerable 
morbidity and mortality has been associated with the use of synthetic cannabinoids, 
with the risk of hospital admission estimated as 30 times higher than that associated 













Table 1.6 – Chemical structures and names of selected novel stimulants  










R1 = H  
R1 = I  
 
 
R1 = NH2  
R1 = NH-CH3  
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R1 = O-CH3, R2 = H 






























R1 = NH2, R2 = H 
R1 = NH-CH3, R2 = H 













R1 = F, R2 = H, R3 = H 
R1 = H, R2 = F, R3 = H 
R1 = H, R2 = H, R3 = F 
R1 = O-CH3, R2 = H, R3 = H 
R1 = H, R2 = O-CH3, R3 = H 
















R1 = H, R2 = H, R3 = H 
R1 = O-CH3, R2 = H, R3 = H 
R1 = Cl, R2 = H, R3 = H 
R1 = H, R2 = Cl, R3 = H 

















R1 = C2H5, R2 = H, R3 = H 
R1 = CH3, R2 = CH3, R3 = H  
R1 = CH3, R2 = Cl,  R3 = Cl  
R1 = C2H5, R2 = Cl, R3 = Cl 








Table 1.6 (cont.) – Chemical structures and names of selected novel stimulants  
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Table 1.7 – Chemical structures and names of selected synthetic cannabinoids  








R1 = C5H11, R2 = H 
R1 = CH3, R2 = H  
R1 = C4H9, R2 = H  
R1 = C5H11, R2 = Cl  














R1 = H 
R1 = CH3 














R1 = H, R2 = C6H13 













Table 1.7 (cont.) – Chemical structures and names of selected synthetic 
cannabinoids  






R1 = H 
R1 = O-CH3 
R1 = CH3 
R1 = F 
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R1 = CH2-Ph 
R1 = C5H10F 















R1 = H, R2 = H, R3 = H 
R1 = OH, R2 = (CH3)2, R3 = H 













































1.1.4.3 Designer Benzodiazepines  
Benzodiazepines are widely misused for their sedative and hypnotic effects, typically as 
part of a poly-drug abuse pattern. Cocaine users often take benzodiazepines to 
ameliorate the ‘crash’ during withdrawal, which may give rise to symptoms such as 
anxiety, dysphoria and insomnia (Sofuoglu et al., 2005).  Opiate users commonly take 
benzodiazepines to enhance the ‘high’, with use of diazepam by heroin addicts 
prevalent nowadays (Fatséas et al., 2009; Vogel et al., 2013).  Benzodiazepines licensed 
for use in countries outside of the UK have been sold as ‘legal highs’ within the UK, in 
particular phenazepam (Maskell et al., 2011b). More recently, designer benzodiazepines 
have become a rapidly growing class of drugs of abuse in their own right. The first 
designer benzodiazepines to become available online were diclazepam, flubromazepam, 
and pyrazolam (Figure 1.6). Most of these compounds were originally synthesised as 
drug candidates by pharmaceutical companies, but none are approved for medicinal use 
in any country (Moosmann et al., 2015). Active metabolites of benzodiazepines have 
been marketed as designer drugs, e.g. fonazepam (desmethylflunitrazepam) and 
nifoxipam (3-hydroxydesmethylflunitrazepam) are both active metabolites of 
flunitrazepam (Katselou et al., 2017). 
Figure 1.6 – Comparison of the chemical structures of selected designer 












1.1.4.4 Designer Opioids 
The number of new opioids recorded since 2009 is much lower (less than 20) in 
comparison to other classes of NPS. Synthetic opioids include MT-45, U-47700, AH-
7921 and fentanyl derivatives. Both MT-45 and AH-7921 (‘Doxylam’) were originally 
synthesised in the 1970s by pharmaceutical companies. Both compounds are thought to 
have similar potency to morphine (Zawilska and Andrzejczak, 2015). Numerous 
fentanyl derivatives have been reported over the last few years (Helander et al., 2016, 
2017; Zawilska, 2017). The fentanyl derivatives pose an especially serious concern for 
public health because of their high potency (Table 1.8) and because they are often sold 
under the guise of, or mixed with, heroin to unsuspecting users. Clusters of opioid 
overdose and deaths due to fentanyl-adulterated heroin have been reported in Australia 
(Rodda et al., 2017), and in the USA (Bode et al., 2017). Acetylfentanyl has also been 
sold as oxycodone pills (Stogner, 2014), and fentanyl and U-47700 have been sold as 
‘Norco’ (hydrocodone and paracetamol) tablets (Armenian et al., 2017; Sutter et al., 
2017). In these cases, overdose is likely and if not treated may cause death. Naloxone 
will reverse overdoses; however higher dosing and prolonged infusion may be required 
(Sutter et al., 2017). Most fentanyl analogues exhibit extensive metabolism, meaning 
that identification and detection of metabolites as opposed to the parent drug is 
important, particularly if there is a delay between consumption and sampling (Allibe et 
al., 2017). 
 
Table 1.8 – Comparison of the relative potency of fentanyl and selected derivatives 
to morphine 
Data from Higashikawa and Suzuki, 2008 
ED50 – median effective dose, LD50 – median lethal dose 
 
Compound ED50  (mg/kg) 
LD50  
(mg/kg) 
Potency ratio to 
morphine 
Fentanyl 0.0061 62 54 
Acetylfentanyl 0.021 9.3 16 
Butyrylfentanyl 0.047 - 7 







1.2 The Role of the Clinical Toxicology Laboratory in Drug Testing 
1.2.1 Poisoning 
Acute poisoning is a relatively common reason for presentation to hospital. 
Toxicological analyses can provide important information for certain drugs (e.g. 
paracetamol, lithium) which guides the clinical management of the patient. In other 
cases, patient treatment is guided by the toxidrome, i.e. the features the patient presents 
with, and specific identification of the toxin may not be immediately necessary. This is 
particularly true for many illicit drugs where no specific antidote exists, and treatment 
typically consists of supportive measures. Opioid toxicity has a very specific toxidrome 
of coma, pinpoint pupils and respiratory depression, and can be reversed through 
administration of naloxone in adequate dosage. Later identification of the toxin by the 
laboratory may help to confirm the diagnosis and guide longer term treatment of the 
patient.  
On the other hand, toxicological analyses can play a useful role in the diagnosis of 
poisoning when it may not be suspected, where the use of certain antidotes is being 
contemplated, or where the use of active elimination therapy is being considered 
(Flanagan and Watson, 2009). It may also be relevant in identifying cases of 
Munchausen Syndrome or Munchausen-by-proxy, where a poisoning may be a result of 
self-medication or inappropriate drug administration by a carer, respectively (Holstege 
and Dobmeier, 2006).  
1.2.2 Identification of Unknown Substances 
Analysis of unknown substances may be useful in different scenarios. Identifying 
substances (e.g. tablets, powders) found on a patient through toxicological analyses may 
aid clinical management in cases of poisoning, particularly if the patient is unconscious. 
Drug identification may be particularly relevant when it is a NPS, as even the user may 
be unaware of what drug they have taken so direct analysis of the substance can provide 
conclusive results. Substance identification may also be of use when an individual is 
taking non-prescribed medications (e.g. dietary supplements, herbal remedies) as the 





1.2.3 Treatment of Drug Addiction 
Use of toxicological analyses can aid treatment of drug addiction through providing the 
clinician with accurate information as to the current drug use of an individual. The 
results can be used to identify if drugs are still being misused, and also to assess 
whether a patient is adhering to prescribed medication. In terms of drug dependency, 
this may involve substitution or detoxification medication (e.g. methadone or 
buprenorphine for opioid dependency) or medication to ease withdrawal symptoms (e.g. 
antispasmodics such as mebeverine, and anxiolytics such as benzodiazepines). 
1.2.3.1 Sample Adulteration 
It is relatively common for drug misusers to attempt to influence their urine drug results 
(Dasgupta, 2007). For negative results, individuals may drink a large volume of fluid 
prior to the test in an attempt to dilute the urine, or water may be directly added to the 
urine sample. Other substances (e.g. bleach, detergents, salt) may be added to the urine 
sample in an attempt to interfere with the laboratory tests (Jaffee et al., 2007). 
Conversely, samples may be adulterated to give positive results through direct addition 
of drugs to appear as if individuals are taking prescribed medication, e.g. methadone.  
The laboratory may be able to identify cases of adulteration through a number of 
measures (Table 1.9). Low creatinine and specific gravity values may indicate dilute 
urine. However, a dilute sample does not necessarily indicate that the urine was 
intentionally diluted (Chaturvedi et al., 2013; Holden and Guice, 2014). The complete 
absence of creatinine is indicative of a specimen not being consistent with human urine 
(e.g. tea, orange squash, water).  
Creatinine measurement is also useful for comparing drug use in one individual over a 
period of time as drug concentrations can be normalised to creatinine to account for 
differences in hydration at the time of sampling. This is particularly relevant for 
assessing whether the re-use of drugs (most notably cannabis due to its high 







Table 1.9 – Urine validity tests and possible causes for increased/decreased values 
a Taken from Dasgupta, 2003 
Validity Test Normal Rangea Cause for decrease Cause for increase 
Creatinine  >1.8 mmol/L Direct dilution of urine 
(e.g. addition of water), 
excessive fluid intake 
Exercise, creatine 
ingestion 
pH 4.0-10.0 Addition of acidic 
chemical (e.g. vinegar, 
lemon juice) 
Addition of basic 




32.5-37.2 oC  Cold urine suggests the 





1.005-1.030 Renal failure, diabetes 
insipidus, excessive 
fluid intake 
Addition of salt, 
glycosuria, 
dehydration 
The laboratory may also identify cases of adulteration through measuring parent drug 
concentrations, in particular assessing the parent drug-to-metabolite ratio. Selective 
methodology is required to measure metabolites, typically using chromatography. 
Immunoassays are usually unable to differentiate between parent drug and metabolites 
due to their structural similarities. Some immunoassay manufacturers have tried to 
overcome this by targeting metabolites, e.g. 2-ethylidene-1,5-dimethyl-3,3-diphenyl-
pyrrolidine (EDDP) as opposed to methadone, in separate assays.   
Assays have also been developed to attempt to identify intravenous (IV) abuse of 
disaccharide-containing formulations of buprenorphine and methadone through 
detection of sucrose and lactose in urine (Jungen et al., 2013, 2017). When taken orally, 
disaccharidases present in the small intestine break down the disaccharides into 
monosaccharides. However, when injected intravenously disaccharides are excreted 
unchanged in urine. 
1.2.3.2 Therapeutic Drug Monitoring 
Therapeutic drug monitoring (TDM) of drugs used in relapse prevention, maintenance, 
or withdrawal treatment in substance-related disorders is not established in clinical 
practice. In order to assess whether TDM may be beneficial, assays to measure the drug 
(and relevant metabolites) need to be developed and data from a varied population 
collected to establish if there is a correlation between plasma concentration and effect 
(either efficacy or toxicity). TDM has been suggested for buprenorphine, methadone 
and naltrexone (Brünen et al., 2011), although there is much debate over whether it 
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would be beneficial. Additional problems may arise due to difficulty in obtaining a 
blood sample from an IV drug user, and handling of higher risk samples due to a greater 
prevalence of blood-borne diseases.   
1.2.3.2.1 Methadone and Buprenorphine 
Both methadone and buprenorphine exhibit significant inter-individual variation in 
metabolism, much of which is due to individual variability in cytochrome P450 (CYP) 
enzymes, and methadone particularly can be a difficult drug to administer safely 
requiring initial dose titration (Tetrault and Fiellin, 2012). TDM may be beneficial in 
the first days of therapy to establish an effective dose in individual patients, and also 
when an individual is switched from methadone to buprenorphine to help decide the 
exact schedule of methadone dose reduction and buprenorphine escalation (Mercolini et 
al., 2007). 
Lower plasma total methadone concentrations have been associated with greater 
likelihood of abuse of non-prescribed opioids (Wolff et al., 1996). Minimum plasma 
concentrations for methadone of 100-400 µg/L have been reported to be essential for 
adequate maintenance dosage (Holmstrand et al., 1978; Loimer and Schmid, 1992), and 
for buprenorphine of at least 0.8 µg/L to avoid opioid withdrawal symptoms (Kuhlman 
et al., 1998).  
Currently, it is deemed that the monitoring of adherence to methadone or 
buprenorphine, and the efficacy of treatment (judged by abstinence from other opioids) 
can best be achieved through routine urinalysis. 
1.2.3.2.2 Naltrexone 
The effectiveness of naltrexone therapy in alcohol dependency is well documented (Goh 
and Morgan, 2017; Rösner et al., 2010). However, large-scale studies have not been 
evaluated to the same extent for opioid dependency particularly for extended-release 
formulations of naltrexone, and there are data lacking to assess correlation of naltrexone 
plasma concentration and clinical response. These data may provide justification for 
TDM of naltrexone to aid individualisation of dosing regimens to improve the outcome 
of naltrexone treatment. A target naltrexone plasma concentration of 1 µg/L has been 
suggested for blocking a clinically relevant dose (e.g. 25 mg) of  intravenously 
administered diamorphine (Kunøe et al., 2014). As well as providing information to 
maximise efficacy of naltrexone treatment, TDM may also be beneficial in minimising 
toxicity. A correlation between urinary 6-β-naltrexol (naltrexone’s main plasma 
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metabolite) concentration and side effects (e.g. headache, nausea, anxiety) has been 
reported (King et al., 1997). Reported concentrations of plasma naltrexone and 6-β-
naltrexol are variable (Table 1.10). To date, a large-scale study to ascertain plasma 
naltrexone concentrations achieved during therapy for opioid addiction has not been 
performed. A pilot study conducted by Jarvis et al. (2016) looking at factors associated 
with using opiates whilst under treatment with extended-release naltrexone concluded 
that future research should incorporate measurement of plasma naltrexone 
concentration. 
Table 1.10 – Plasma naltrexone and 6-β-naltrexol concentrations after oral 
administration of naltrexone 
Study N Dose (mg) 
Time since 





   
 
  
Huang et al. (1997) 5 25 5.5 1.4-9.9 13.7-29.7 
Huang et al. (1997) 3 25 27.5 0.1-0.4 - 
Huang et al. (1997) 5 25 125.5 - 0.3-0.6 
Heinälä et al. (2012) 87 50 2-4 0-70 15-136 
Verebey et al. (1976) 4 100 4 8.9-32.4 49.3-85.1 
Huang et al. (1997) 5 100 5.5 6-27 57.4-106.8 
Huang et al. (1997) 5 100 27.5 0.4-0.9 - 
Huang et al. (1997) 5 100 125.5 - 0.8-2.1 
Verebey et al. (1980) 4 400 16 4.8-20.4 143.9-251.8 
 
1.2.3.3 Pharmacokinetic Studies  
Assays may be developed for the measurement of drugs in a research context, primarily 
for pharmacokinetic studies. In terms of drugs of abuse, this may be looking at different 
routes of drug administration, or comparison of drug formulations (e.g. extended release 
versus immediate release) to improve clinical outcomes. 
1.2.4 Analytical Methods  
Many analytical methods may be used for drug analysis in biological samples, and 
depending on the clinical requirements may yield qualitative or quantitative results. The 
choice of methodology will often depend on the chemical properties of the analyte, 
required turn-around-time (i.e. the time from sample receipt to reporting results), and 
the cost of the test. The most crucial aspect of any method is that it must produce 
accurate, reliable and reproducible results. To assess this, any new method developed 
must undergo full method validation before it is used routinely. Validation of qualitative 
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methods does not need to be as comprehensive as that for a quantitative method, but 
should include tests for ascertaining selectivity, precision, matrix effect, recovery, 
detection limits, analyte carryover, and stability (Trullols et al., 2004). When 
developing a method, both the pre- and post- analytical stages must also be considered. 
Of particular importance is ensuring the sample is collected, transported and stored in a 
suitable manner (Flanagan, 2004). 
1.2.4.1 Immunoassay  
Immunoassays offer the benefit of speed, high throughput, and ease of automation. For 
this reason, immunoassays have typically been used for initial drug screening purposes 
(e.g. amfetamine and opioid group assays). However, the utility of immunoassays is 
often limited by their low specificity. For example, a positive opioid result may not aid 
clinical management of a patient as use of an over-the-counter (OTC) medication (e.g. 
codeine) cannot be distinguished from illicit drug use (e.g. heroin). The clinical picture 
may also be confused by false positive results occurring from immunoassays, for 
example amfetamine assays are prone to interference from many prescribed drugs 
(Table 1.11). The necessity of confirming immunoassay-positive results through use of 
more specific techniques, usually chromatography-based, causes an increase in turn-
around-time and laboratory expenditure.    
In addition, only a fraction of toxicologically relevant substances can be covered by 
currently available immunoassay techniques. Many important analytes (e.g. gamma-
hydroxybutyrate (GHB)) do not have commercially available immunoassays. 
The cross-reactivity and ability of immunoassays to detect NPS is currently unclear. 
Stimulant-type NPS are often structurally related to amfetamine or MDMA. However 
amfetamine-group immunoassays often may not have sufficient cross-reactivity to these 
novel compounds and thus drug use may go undetected (Beck et al., 2014). Similarly, 
synthetic cannabinoids are unlikely to cross-react with cannabis immunoassays where 
antibodies are typically raised against THC derivatives due to the significant structural 
differences in these novel compounds from THC itself. Immunoassays for detecting 
synthetic cannabinoids are being marketed, with the majority to date targeting JWH-018 
and structurally-related cannabinoids (Barnes et al., 2014, 2015). However, due to the 
time and expense in developing an immunoassay it is likely that when the assay 
becomes available it will no longer be suitable as current NPS will have changed and 
thus may exhibit minimal cross-reactivity, meaning their use goes undetected. 
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Table 1.11 – Reported interferences in urine immunoassays 
Immunoassay Interference Reference 
Amfetamine Dimethylamylamine (DMAA) Vorce et al. (2011) 
Labetalol (via the metabolite  
3-amino-1-phenylbutane) 
Yee and Wu (2011) 
Mebeverine Kraemer et al. (2001) 
Bupropion Casey et al. (2011); Vidal 
and Skripuletz (2007) 
Chlorpromethazine/promethazine Melanson et al. (2006) 
Fenofibrate Kaplan et al. (2012) 
Phentermine Marin et al. (2009) 
Trazodone (via the metabolite 
meta-chlorophenylpiperazine, 
mCPP) 
Logan et al. (2010); 
Roberge et al. (2001) 
Benzodiazepine Oxaprozin Matuch-Hite et al. (1995); 
Nishikawa et al. (1999) 
Buprenorphine Opioids (high concentration) Pavlic et al. (2005) 
Amisulpride/sulpiride Birch et al. (2013) 
Tramadol Shaikh et al. (2008) 
Cannabis Efavirenz Oosthuizen and Laurens 
(2012); Rossi et al. (2006) 
Opioid Gatifloxacin Straley et al. (2006) 
Rifampicin de Paula et al. (1998) 
 
1.2.4.2 Chromatographic Methods 
Chromatography is a separation method based on partitioning of compounds, as a result 
of their physicochemical properties, between a stationary phase and a mobile phase. The 
mobile phase (e.g. liquid, gas) carries the components of a sample through the 
stationary phase (e.g. silica) where separation occurs. As a result, an analyte has a 
characteristic time that it takes to pass through a system (from injector to detector), 
termed the retention time (RT). A longer RT indicates a stronger interaction between the 
analyte and stationary phase at constant mobile-phase flow.  
Early methods for drug detection used thin layer chromatography (TLC) to provide 
qualitative information on analytes present in a sample. However, interpretation of TLC 
plates is highly subjective, the required reagents are often toxic, and data are not very 
reproducible (Flanagan et al., 2007). 
Gas chromatography (GC) has been widely used in analytical toxicology, particularly in 




sensitive detection method. Selectivity can be improved through use of electron capture 
detection (ECD) for halogen-containing compounds (e.g. benzodiazepines), or mass 
spectrometry (MS). GC remains the gold standard for analysis of volatile compounds, 
e.g. ethanol, methanol, butane, acetone. 
Liquid chromatography (LC) is a more versatile method than GC, and is well suited to 
analysis of hydrophilic and thermally labile compounds. As a result sample preparation 
is often simpler than that associated with GC. Numerous LC parameters can be varied to 
achieve analyte separation including mobile phase composition, column stationary 
phase chemistry, column temperature, and use of gradient elution. LC can be performed 
in several modes, including reverse-phase (accounting for the majority of methods), 
normal phase, hydrophilic interaction chromatography (HILIC), ion exchange, and size 
exclusion. Reverse-phase chromatography uses a polar eluent (e.g. acetonitrile, 
methanol) and a non-polar stationary phase surface (typically silica modified by the 
addition of octadecyl (ODS, C18) or octyl (C8) silyl moieties. Numerous detection 
methods may be coupled to LC including ultra-violet (UV) absorbance, fluorescence, 
and MS. 
1.2.4.3 Mass Spectrometry  
A mass spectrometer generates ions, and then separates them based upon their mass-to-
charge ratio (m/z). The basic components of a mass spectrometer include: an inlet 
device for sample introduction, an ion source, a mass analyser, a detector and a data 
system (Figure 1.7). 




The method of ionisation is largely dependent on how the sample is being introduced. 
When coupled to LC, the most common methods of ionisation are either electrospray 
ionisation (ESI) or atmospheric pressure chemical ionisation (APCI). For GC, either 
electron ionisation (EI) or chemical ionisation (CI) may be used. Other specialist 
ionisation techniques have also been developed, e.g. matrix-assisted laser desorption 
ionisation (MALDI). Ionisation methods may be termed ‘hard’ where the molecules 














fragmentation, or ‘soft’ where little energy is applied resulting in minimal 
fragmentation. EI is the most common example of hard ionisation. Fragmentation that 
occurs during ionisation is termed ‘in-source fragmentation’. Ionisation may be 
performed in either positive (typically generating [M+H]+ ions) or negative (typically 
generating [M-H]- ions) mode.  
Many types of mass analyser are available including: quadrupole, time-of-flight (TOF), 
magnetic sector, and ion trap. Combinations of analysers are also possible, for example 
quadrupole time-of-flight (Q-TOF). The resulting signal from the mass analyser is 
converted into useful data by the detector, which the analyst can then interpret using an 
associated data system. 
Analyte detection may be based either on the precursor ion, or on product ions 
measured by the mass analyser. Product ions are formed when using tandem mass 
spectrometry (MS/MS, MS2), which involves selection and fragmentation of a precursor 
ion and measurement of one or more product ions. Typically quantitative methods have 
been performed on triple quadrupole instruments (QQQ) using selected reaction 
monitoring (SRM) or multiple reaction monitoring (MRM) where one or more 
precursor ions are selected in the first quadrupole, fragmented in a collision cell, and 
then one or more product ions are selected in the final quadrupole for detection (Figure 
1.8). Qualitative, or screening, methods are more often performed on scanning 
instruments (e.g. TOF, ion traps) where data are collected for all ions within a specified 
m/z range and utilises the presence of precursor ions for analyte detection and 
identification. A more selective experiment for monitoring parent ions is selected ion 
monitoring (SIM), where data are only collected for the m/z ratios of interest, which 
may be more applicable to targeted methods. Different scan experiments may all be 
included in a single method, but increasing the number of experiments will lead to a 
reduction in the number of scans over a chromatographic peak. 
 












Gas chromatography-mass spectrometry (GC-MS) has long been regarded as the ‘gold 
standard’ for unknown drug screening (‘systematic toxicological analysis’, STA), 
particularly for forensic work. The main advantage of GC-MS is that most instruments 
use standardised MS conditions, meaning that mass spectra of the same compound 
measured by different analysts on different instruments produce the same results. As a 
result, universal mass spectral libraries based on EI data can be reliably searched to aid 
compound identification. However, GC-MS has the disadvantage of time-consuming 
sample preparation steps, such as derivatisation, which is often not suitable for clinical 
samples where a fast turnaround of results is required for patient treatment. There are 
other known pitfalls associated with GC-MS such as degradation of thermally labile 
compounds leading to artefacts, for example conversion of methadone to its metabolite 
EDDP (Galloway and Bellet, 1999). 
Due to its increased versatility, development of LC-MS (and LC-MS/MS) methods for 
clinical drug detection is becoming a preferable alternative to immunoassay and GC-MS 
methods. However, searchable databases are still lacking compared to those available 
for GC-MS, mainly due to the lack of reproducibility of collision-induced dissociation 
(CID) spectra, which are sensitive to instrument design and operational parameters such 
as ionisation source settings, eluent composition, flow rate, and the presence of organic 
eluent modifiers (Hough et al., 2000; Josephs and Sanders, 2004). LC-MS(/MS) 
methods are associated with high specificity, particularly tandem MS methods, although 
pre-selection of analytes is required and thus the analysis is targeted. Collection of full-
scan data, where all precursor ions within a selected m/z range are detected, avoids the 
targeting limitations of MS/MS, but can mean that selectivity is reduced due to the 
presence of background noise (Jagerdeo and Schaff, 2016). High-resolution mass 
spectrometry (HRMS) can often overcome this issue by allowing an analyte signal to be 
extracted from a near-isobaric background signal.  
1.2.4.4 High Resolution Mass Spectrometry  
MS resolving power is the ability of a mass spectrometer to separate ions with different 
m/z values, and is calculated using the width of mass spectral peaks at half their 
maximum height (full width half maximum, FWHM, Figure 1.9). The International 
Union of Pure and Applied Chemistry (IUPAC) definition (Murray et al., 2013) for 




Equation 1.1 – IUPAC definition of resolution  
 
Resolution is m/z dependent, and the measured, or observed, resolution will therefore 
vary across an acquired mass spectrum which covers a large m/z range. The observed 
resolution, and the observed variation in resolution as a function of m/z, is dependent on 
the mass analyser used. 
High MS resolving power is necessary to separate adjacent peaks from one another and 
to ensure that only one ion contributes to the measurement, thus enhancing selectivity. 
Mass accuracy (typically expressed in parts per million, ppm) determines how close the 
measured (observed) m/z is to the theoretical m/z (Equation 1.2). The terms “high 
resolution” and “high mass accuracy” (or “accurate mass”) are commonly used when 
resolution >20,000 FWHM and mass accuracy below 5 ppm, respectively, are achieved 
(Balogh, 2004). High resolution in conjunction with accurate mass measurements 
enables the elemental composition of a compound to be ascertained, which has 
particular importance for identification of unknown substances in a drug screen. 
Figure 1.9 – FWHM method for determining resolution for a mass spectrometer 
measured at a given ion (taken from Balogh, 2004) 
 
 




Within clinical laboratories, HRMS instruments are either TOF or orbitrap (OT) 
instruments. TOF instruments measure ion m/z based on the measurement of elapsed 
time from the pusher plate to the detector, whereas OT instruments measure m/z by the 
frequency of ion oscillation in a magnetic and electric field. TOF instruments have the 
advantage of maintaining rapid scanning rates at high mass resolution, unlike OT where 
resolution is directly proportional to the acquisition time, i.e. the longer the acquisition 
time the higher the resolving power. TOF instruments also have a higher upper m/z 
limit; however as the majority of drugs are small molecules this is not a significant 
advantage in the context of toxicological analyses. Slower MS scan rates can lead to 
reduction of data points across a chromatographic peak, thus it is important that 
increasing the MS resolution does not comprise the integrity of a chromatographic peak, 
where at least 10 data points are required for reliable quantitation (Holčapek et al., 
2012). However, TOF instruments are more prone to environmental changes 
(temperature, humidity) and as a result must be situated in a tightly regulated 
environment to maintain mass stability (Ojanperä et al., 2012). More modern TOF 
instruments have design modifications to overcome these issues, e.g. super-insulated 
flight tubes. 
High-resolution instruments are usually operated in an untargeted manner, which means 
that accurate mass information is collected on every ion that reaches the detector. This 
is advantageous for several reasons, but most importantly, it allows for the detection and 
identification of compounds that are unexpected, e.g. newly emerging NPS. However, 
complications of detecting NPS arise through i) a lack of understanding of metabolic 
profiles and hence which compounds will be present in different biological sample 
matrices, ii) a lack of reference materials, and iii) low analyte concentration due to the 
high potency of some NPS, e.g. synthetic cannabinoids.    
While much of the interest in LC-HRMS revolves around identifying unexpected 
compounds, the vast majority of samples submitted for urine drug screening will 
contain common drugs. HRMS may be a promising approach in a clinical situation 
where a combination of unknown screening for novel compounds and targeted 
screening for well-established drugs of abuse is required (Maurer and Meyer, 2016). 
HRMS data may be processed for specific analytes appropriate for a routine urine drug 
screen, but in addition the full data for a sample are collected and unknown screening 
can be conducted manually in retrospect. The advantages and disadvantages of using 
LC-HRMS for urine drug screening are summarised in Table 1.12.  
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Table 1.12 – Advantages and disadvantages of LC-HRMS as compared to targeted 
LC-MS/MS methods  
Advantages Disadvantages 
• Untargeted compounds may be 
identified 
• Retrospective analysis of data is 
possible 
• Method development is simpler and 
faster 
• Flexibility to add novel 
drugs/metabolites quickly to existing 
screening methods 
 
• Loss of sensitivity as a result of full 
scan data collection 
• Data analysis may be complex due 
to the vast amount of data collected 
on each sample 
• HRMS instruments are more 
expensive 
• Data evaluation software is 
insufficient for broad screening and 
requires skilled operators 
 
1.3 Aims and Objectives of This Work 
To explore the role of the laboratory in routine screening for substance misuse, with the 
aim of improving services to give clinicians more information regarding their patient’s 
drug use. A novel method using LC-HRMS will be developed and validated for this 
purpose. Application of this method for routine urine drug screening and identification 
of unknown substances will be explored. 
To audit the clinical data resulting from routine urine drug screens over a period of one 
year with the aim of establishing current trends of drug use from the surrounding 
population.  In addition, the data will be interrogated to identify any pitfalls of drug 
testing (e.g. sample adulteration) and demonstrate how the laboratory may be able to 
identify these problems and aid clinicians in overcoming them. 
To explore how the laboratory can assist with new approaches to drug treatment 
strategies. A novel LC-HRMS method will be developed and validated with the purpose 
of performing pharmacokinetic studies on opioid antagonists administered via 










2 Qualitative Drug Analysis by LC-HRMS: Application to routine 



















As described in Chapter 1, LC-HRMS may be a promising approach for routine drug 
screening in a clinical situation where a combination of unknown screening for novel 
compounds and targeted screening for well-established drugs of abuse is required. The 
framework currently used by many laboratories consists of initial immunoassay 
screening followed by confirmatory chromatographic methods. This approach is poorly 
suited to laboratories where most samples are positive for at least one analyte, which 
results in most samples undergoing duplicate testing. Despite a high initial capital 
outlay, the use of LC-HRMS for combined screening and confirmation of drugs of 
abuse may result in considerable time and long-term financial savings. In addition, less 
ambiguous results are generated through detection of specific analytes as opposed to 
drug classes, and there is the potential to detect a wide array of drugs, metabolites and 
adulterants in a single analysis. 
Many LC-HRMS drug screening methods have been published including screening for 
cardiovascular drugs (Helfer et al., 2015), NPS (Concheiro et al., 2015; Montesano et 
al., 2016; Sundström et al., 2013), diuretics (Girón et al., 2012), and for several classes 
of drugs of abuse (Li et al., 2013; Marin et al., 2012). Most published methods were 
developed for forensic as opposed to clinical analysis. One of the challenges posed by 
clinical analysis is that sample throughput is greater and turn-around-times often need to 
be faster than in forensic work. It is therefore important that the methods used are robust 
in terms of scope, sample throughput and ease of operation to be useful in clinical as 
opposed to forensic laboratories (Sundström et al., 2013). 
One of the current limitations associated with routine clinical use of HRMS for drug 
screening is the lack of software that easily and unambiguously identifies analytes of 
interest (Meyer, 2013). Without such software, non-targeted analysis is based on 
experienced analysts visually recognising large peaks in the total ion chromatogram 
(TIC) and ascertaining molecular formula matches (Meyer and Maurer, 2016). Further 
investigation of possible molecular formulae is necessitated, requiring internet and 
literature searches to enable putative identification. Due to the huge quantities of data 
generated for each sample, manual processing is not feasible for routine services and is 




The use of accurate mass measurements (accurate to 3 or 4 decimal places rather than 
nominal or unit mass measurements of +0.1 amu) aids compound identification through 
significantly reducing the number of compounds potentially giving rise to a peak. 
However, there are a large number of isobaric drugs and metabolites that can hinder 
analyte identification (Guale et al., 2013). Comparison of a measured accurate mass to a 
theoretical exact mass can therefore only provide a screening result that needs further 
confirmation. Additional confirmatory parameters such as relative retention time (to an 
internal standard), specific product ions, and detection of metabolites (where possible) 
markedly increases the reliability of analyte identification. Identification of putative 
metabolites through accurate mass alone is not sufficient as metabolites of isomeric 
compounds may have the same accurate mass as a result of a common metabolic 
process, e.g. demethylation (loss of a methylene moiety). By using multiple 
confirmatory parameters, the reliability of compound identification is comparable to a 
targeted analysis.  
2.1.1 Biological Matrices 
The selection of a suitable biological matrix to detect drug use is largely dependent on 
the timeframe of drug use that is of interest. The detection window for drug exposure 
varies according to which sample is used in the analysis (Figure 2.1). 
 
Figure 2.1 – Typical detection windows for drugs of abuse in various common 
biological samples 
















Urine is the most commonly used matrix for monitoring drug use in individuals 
undergoing drug rehabilitation therapy. This is largely as collection is non-invasive and 
yields a large sample volume with relatively high drug and metabolite concentration. In 
addition, analytically urine offers the benefit of requiring minimal sample preparation as 
protein should not be present in the sample. A disadvantage associated with urine 
collection for drugs of abuse measurement is that samples may be easily adulterated in 
an attempt to mask drug-taking behaviour.  
Drugs of abuse may be measured in blood (typically plasma or serum), but this is 
usually only of benefit when quantitation is required to assess impairment. Obtaining 
blood from an intravenous drug user can also prove challenging. Oral fluid has been 
advocated as an alternative matrix to urine for screening for drugs of abuse (Bosker and 
Huestis, 2009; Vindenes et al., 2011). Drug concentrations in oral fluid are said to 
reflect the free, unbound parent drug and lipophilic metabolites circulating in the blood. 
Oral fluid has the benefit of being a non-invasive and non-private sample, and samples 
are more difficult for users to adulterate. However, analytically oral fluid is a more 
complex matrix than urine and analyte concentration may be very low, especially for 
acidic drugs which do not readily partition into oral fluid (Cone and Huestis, 2007). 
Problems may also be encountered in regard to adsorption to collection devices, 
particularly for lipophilic drugs, giving low analyte recovery (Bosker and Huestis, 
2009). 
Hair analysis offers the possibility of longer detection times when compared to other 
matrices, and may offer a means of evaluating an individual’s drug use history. Hair 
analysis is rarely conducted for clinical purposes, and is more often used in workplace 
drug testing and in forensic or legal cases (e.g. drug-facilitated crimes) (Xiang et al., 
2015). There are however problems with hair analysis, particularly concerning external 
contamination, cosmetic treatments, ethnical bias and the rate of drug incorporation 
(Kintz et al., 2006). 
2.1.2 Qualitative Measurement of Drugs 
In urine drug testing, most results are reported as positive (present) or negative (absent) 
for a substance based upon a cutoff concentration (Figure 2.2). The cutoff concentration 
selected is based upon optimising drug detection but minimising the number of false 
positive results, and largely originates from the use of immunoassay for drug screening. 











concentrations are also used for confirmatory drug analyses, and may be lower than 
screening cutoffs due to the more specific methodology used (see Section 2.3.4 for 
further information). When using selective methodology such as LC-HRMS, it may be 
more appropriate to use the limit of analytical detection as opposed to the cutoff 
concentration for certain cases (e.g. samples from children, suspected drug-facilitated 
assault). 










2.1.3 Sample Preparation  
The aim of sample preparation is to improve assay sensitivity/selectivity and remove 
compounds present in the sample matrix that may interfere in the analysis (Dams et al., 
2003; Peters and Remane, 2012). A ‘matrix effect’ is defined as the effect of other 
compounds in the sample matrix on the quantitation of the analyte. In LC-MS, 
endogenous or other compounds that co-elute with an analyte may either suppress or 
enhance ionisation of an analyte in the source of the mass spectrometer. As the presence 
of these substances may vary between samples it is important that internal standards are 
used to compensate if possible for any variation in analyte ionisation to ensure accurate 
quantitation. Regardless of the preparation technique used, an internal standard should 
be added at the beginning of the process to account for any variation during 
extraction/dilution. 
Many modes of sample preparation exist. Selection of an appropriate method will often 
depend on the required level of sensitivity, the chemical properties of the analyte(s), the 
number of analytes, and the matrix being analysed.  
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For drug analysis, the most commonly used selective sample preparation techniques are 
liquid-liquid extraction (LLE) and solid-phase extraction (SPE). LLE involves 
extraction of an analyte from a biological matrix into an immiscible organic solvent and 
is based upon the partition coefficient of the analyte between the matrix and the solvent. 
For ionisable compounds, typically, the extraction pH should be 2 units more than the 
pKa for basic analytes and 2 units less than the pKa for acidic analytes. Under these 
conditions analytes will be <1 % ionised and hence partition into the organic solvent 
will be favoured (Flanagan et al., 2007). The extraction pH may need to be a 
compromise when several different compounds are being assayed. For drug analysis, 
LLE is not suitable for extracting glucuronide metabolites due to their hydrophilic 
nature. 
SPE involves analyte absorption onto a solid phase, commonly with reverse-phase 
chemistry (e.g. C8, C18). To capture a broader range of compounds ‘mixed-mode’ SPE 
columns may be used which utilise two or more retention mechanisms. As with LLE, 
SPE has the benefit of allowing analyte concentration in an extract, which may be 
beneficial for compounds present at low concentration in samples. SPE is more 
compatible with automation than LLE, and thus has advantages for high-throughput 
batch analysis of samples.  
TurboFlow technology (ThermoFisher Scientific), a form of SPE, is a column-based on-
line sample preparation system that utilises the principles of size-exclusion 
chromatography and specific column-based chemistry. TurboFlow enables the direct 
injection of biological samples allowing sample preparation to be simplified and 
throughput increased (Couchman, 2012). Sample is loaded onto the TurboFlow column 
under aqueous conditions allowing the analyte to bind to the column packing whilst 
proteins and other matrix components flow to waste. The analytes are then eluted from 
the TurboFlow column, and transferred to the analytical LC column. TurboFlow offers 
the benefit of automated sample preparation, which minimises human error thus making 
methods more robust, and also reduces the time required to perform an assay.  
Dilution is a non-selective technique which may be a beneficial approach for analysing 
a wide range of analytes. However, it is likely that matrix effects will be higher than if a 
selective method is used. For matrices containing low protein concentration (e.g. urine), 
centrifugation followed by dilution may be satisfactory. For matrices containing protein 
(e.g. whole blood, plasma), protein precipitation using acid (e.g. trichloroacetic) or an 
organic solvent (e.g. acetonitrile) may be used for non-selective sample preparation.  
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2.1.3.1 Urine Hydrolysis  
Many drugs (e.g. opioids, benzodiazepines) are predominantly excreted in urine as 
conjugates, typically with D-glucuronic acid or with sulfate. As a result, urine samples 
may be hydrolysed prior to analysis to convert these conjugated metabolites to the 
unconjugated analyte. Hydrolysis may be non-specific through use of an acid (e.g. 
hydrochloric acid). Acid hydrolysis is very effective, but the resultant solutions may 
corrode metal instrument components resulting in increased maintenance frequency and 
cost. Acid hydrolysis may also destroy specific metabolites, e.g. 6-AM, complicating 
interpretation of results (Sitasuwan et al., 2016; Zezulak et al., 1993). As a result most 
laboratories perform selective hydrolysis using an enzyme solution, typically β-
glucuronidase for glucuronide analysis. Hydrolysis is needed for sensitive GC-MS 
analysis, but is not required when LC-MS is used as direct analysis of polar conjugates 
is possible (Peters, 2011). LC-MS methods which use a hydrolysis step must ensure that 
solubilised β-glucuronidase is removed from the solution before HPLC analysis. This is 
because if β-glucuronidase is not removed the column lifetime will be shortened due to 
enzyme precipitating in the column and causing increased back pressure. Whilst 
sensitivity may be improved through hydrolysis, information regarding metabolism and 
time since drug intake is lost, information that may prove useful when interpreting 
results.   
When hydrolysis is used, drug concentrations are reported as a ‘total’. For example, 
‘total morphine’ reflects both the unconjugated ‘free’ morphine in a urine sample and 
morphine produced as a result of hydrolysis of morphine-3-glucuronide and morphine-
6-glucuronide. Where hydrolysis is not used, ‘total’ drug concentrations can be 
calculated (Equation 2.1) by converting conjugated metabolites to the ‘free’ drug 
equivalent (assumes complete conversion to ‘free’ drug).     
 




Molecular weight ‘free’ drug 
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2.1.4 Analytes in a Routine Drug Screen 
A wide range of drugs are misused, including well-established drugs of abuse (e.g. 
heroin, cocaine, cannabis, metamfetamine, MDMA), prescription medication (e.g. 
buprenorphine, oxycodone, methadone, methylphenidate, pregabalin), and NPS. Ideally 
a routine drug screen will detect as many of these compounds as possible; however, the 
majority of clinical drug screening methods currently only target well-established drugs 
of abuse and methadone/buprenorphine. 
As well as targeting parent drugs in a routine screening method, inclusion of 
metabolites is important for detection of sample adulteration and for providing 
information on the time since drug administration. Metabolite measurement may also be 
used in place of detecting the parent drug when the plasma half-life of a drug is very 
short (e.g. cocaine use may be identified through detection of its major metabolite, 
benzoylecgonine). 
Clinical management of individuals poisoned with some common drugs of abuse is well 
defined. Whilst treatment of poisoning is typically symptom-directed supportive care, 
identification of which substances are present can guide treatment of an individual in 
certain scenarios. Rapidly detecting fetal exposure to licit and illicit drugs is of 
considerable medical value. It is particularly relevant for diagnosing neonatal abstinence 
syndrome (NAS), a post-natal opioid withdrawal that can occur in a newborn whose 
mother was dependent on opioids whilst pregnant, and where the neonate may require 
OST.  
Psychosis can be associated with acute recreational drug toxicity. However, there are 
limited data available on how common this is and which drugs are most frequently 
implicated (Vallersnes et al., 2016). Psychosis may also be a result of chronic drug use, 
with epidemiological evidence demonstrating that regular or heavy cannabis use 
increases the risk of developing psychotic disorders (Gage et al., 2016). Synthetic 
cannabinoids and high potency cannabis (containing high THC concentration relative to 
cannabidiol) are thought to pose the greatest risk (Murray et al., 2016). Accurate 
detection of such drugs may aid clinical differentiation of the likely cause of a 
psychosis. 
The pharmacology of NPS is poorly understood and clinical management is 
complicated by the associated unpredictable effects. A major health problem arises from 
that the fact that mixtures are inhomogeneous with regard to their active ingredients, 
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particularly with synthetic cannabinoids (World Health Organisation, 2014a). 
Publications are limited to case reports, and no large randomised controlled trials to 
assess population pharmacokinetics and toxicity have been conducted. Establishing 
accurate data on the prevalence, use and effects of NPS remains crucial to establishing 
successful management of the problems associated with these drugs. In the absence of 
rapid urine or blood tests to confirm the use of NPS assessment has to be clinical, based 
on patient history if available, and recognising the clinical presentation, which to date is 
not well documented. 
2.1.5 Aims 
To develop a LC-HRMS method capable of detecting and identifying commonly 
encountered drugs in urine from substance abusers. The method will ideally replace the 
two-step methodology of immunoassay followed by LC-MS. The method will be 
developed so that it is adaptable to include other analytes, e.g. NPS.  
2.1.6 Ethics Considerations 
Patient samples used for method development will be excess samples collected for 
clinical purposes and submitted to the laboratory for urine drug screening. No records 




















2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
Analyte reference standards and the majority of internal standards were supplied as 
solutions (either in methanol or acetonitrile) from Cerilliant (Sigma, Poole UK). 
Amfetamine-13C6 hydrochloride was from Chiron (Trondheim, Norway). Mephedrone-
D3 hydrochloride and norketamine-13C6 hydrochloride powder were from Alsachim 
(Illkirch-Graffenstaden, France). External quality control (EQC) samples were from 
ACQ Science GmbH (Rottenburg am Neckar, Germany). 
HPLC grade acetonitrile, ammonium formate and formic acid were from Sigma-Aldrich 
(Poole, UK). HPLC grade methanol was from Rathburn (Walkerburn, UK).  Water was 
deionized (18 mΩ, Elga, Marlow, UK). Positive and negative ion mass calibration 
solutions were from ThermoFisher Scientific. Analyte-free human urine was obtained 
from a volunteer. HPLC vials and caps were from Kinesis (St. Neots, UK), and 0.5 mL 
polypropylene tubes were from Sarstedt (Nümbrecht, Germany). DRI creatinine, 
CEDIA barbiturate, benzodiazepine, cannabis, cocaine, methadone metabolite, and 
buprenorphine assays, calibrators, and IQCs were from ThermoFisher Scientific 
(Microgenics, Passau, Germany). LiquichekTM urine chemistry controls (creatinine 
IQC) were from Bio-Rad (Watford, UK). 
2.2.2 Instrumentation  
An automated dilutor was used for sample preparation (Hamilton MicroLab 530 C, 
Esslab, UK). An Ultimate 3000 Dionex HPLC system (ThermoFisher Scientific) 
consisting of two pumps, autosampler and column oven compartment was used with a 
Q ExactiveTM mass spectrometer (ThermoFisher Scientific). Instrument control was 
performed using TraceFinderTM software (version 3.3, ThermoFisher Scientific).  
For all post-acquisition data processing, peak areas were generated by filtering full-scan 
data using a mass extraction window of ±10 ppm based on theoretical m/z values 
(external mass calibration carried out on alternate days using positive and negative ion 
mass calibration solutions).  
Immunoassays were performed according to the manufacturer’s instructions using an 
Indiko Plus analyzer (ThermoFisher Scientific). Assays were calibrated as necessary 
using the calibrators supplied, and supplied internal quality control (IQC) solutions 
were analysed prior to the analysis of patient samples.  
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2.2.3 Liquid Chromatography 
System eluents were as follows: (A) 10 mmol/L ammonium formate with 0.1 % (v/v) 
formic acid in deionised water, and (B) 0.1 % (v/v) formic acid in acetonitrile:methanol 
(1+1). Prepared samples were analysed directly (50 µL) using an Accucore Phenyl-
Hexyl HPLC column (2.7 µm aps, 100 x 2.1 mm I.D., ThermoFisher Scientific).  The 
column was fitted with a 0.5 µm pre-column filter (ThermoFisher Scientific) and was 
maintained at 40 °C. Gradient elution (total flow 0.3 mL/min) was used. In summary, 
the starting conditions were 98 % A 2 % B held for 1.5 min, then ramped to 100 % B 
over 8.5 min, held for 3 min, then returned to initial conditions for 2 min to re-
equilibrate. During re-equilibration, the flow rate was increased to 0.6 mL/min to 
improve column washing. The total analysis time was 15 min. 
2.2.4 Mass Spectrometry 
MS was carried out in positive ionisation mode using heated ESI [spray voltage 4.5 kV; 
temperatures: vaporiser 350 oC, capillary 250 oC; auxiliary, sheath and sweep gases 10, 
55, and 0 (arbitrary units, respectively), S-lens voltage 70 V]. Full-scan MS data were 
acquired using a resolution setting of 70,000 defined as FWHM at m/z 200, with a scan 
range of 100-750 m/z (Orbitrap settings: maximum injection time 200 ms, automatic 
gain control (AGC) 3 x 106 ions). Alternate all-ion fragmentation (AIF) MS2 scans were 
collected to confirm peak identity following higher-energy collisional dissociation 
(HCD) in the HCD cell [collision gas nitrogen, stepped normalised collision energy 50 
V (±50 %)]. The settings for the MS2 data were: resolution 17,500, scan range 70-750 
m/z, maximum injection time 200 ms and AGC target 3 x 106 ions.  
2.2.5 Assay Calibration and Acceptance Criteria 
Calibration standards (N = 3) and a matrix blank (analyte-free human urine) were 
included at the beginning and end of each batch analysis, with both IQCs included after 
the first set of calibrators and immediately before the last set of calibrators. Alternate 
IQC solutions were analysed in singleton after every 10 patient samples throughout the 
batch. EQC samples were analysed with each batch. Assay acceptance criteria were (i) 
linear (R2 >0.98) calibration curves for each analyte, and (ii) at least 67 % (4 out of 6) 
of IQC samples within 20 % of their respective nominal value.  
Peak area ratios (analyte to IS) obtained on analysis of the calibration standards were 
plotted against concentration to construct calibration graphs. Linear regression 
intercepts were not forced through zero, and no line weighting was applied. 
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2.2.6 Preparation of Calibration and Internal Quality Control Solutions  
Nominal concentrations for calibration and IQC solutions are given in Table 2.1. 
Individual stock solutions for each analyte (100 mg/L) were prepared in methanol. 
Working solutions were prepared for the amfetamine analytes (amfetamine, 
metamfetamine, MDMA and mephedrone, all 50 mg/L free base in deionised water) and 
buprenorphine analytes (buprenorphine, norbuprenorphine, buprenorphine glucuronide 
and norbuprenorphine glucuronide, all 10 mg/L in methanol). Appropriate volumes of 
each stock solution or working solution were evaporated to dryness in volumetric flasks 
under a stream of compressed air (Table 2.2).  Appropriate volumes of amfetamine 
working solution were pipetted into each volumetric flask to avoid loss during the dry-
down step before reconstitution with analyte-free human urine. After thorough mixing 
and equilibration (24 h, 2-8 °C), calibration and IQC solutions were stored in 
approximately 150 µL portions in 0.5 mL polypropylene tubes at -20 °C until required. 
 
Table 2.1 – Drug screening assay: Nominal concentrations of analytes in 
calibration and IQC solutions 
*Street heroin markers: papaverine, noscapine and 6-acetylcodeine 
‡Norbuprenorphine, buprenorphine glucuronide and norbuprenorphine glucuronide 
#N-Desmethyltramadol and O-desmethyltramadol 











Amfetamine 100 200 1,000 150 250 
Metamfetamine 100 200 1,000 150 250 
MDMA 100 200 1,000 150 250 
Mephedrone 100 200 1,000 150 250 
Benzoylecgonine 75 150 1,000 112.5 187.5 
Morphine  150 300 1,000 225 375 
Morphine-3-glucuronide 150 300 1,000 225 375 
Codeine 150 300 1,000 225 375 
Codeine glucuronide 150 300 1,000 225 375 
Dihydrocodeine 150 300 1,000 225 375 
Pholcodine 150 300 1,000 225 375 
6-AM  5 10 50 7.5 12.5 
Street heroin markers* 5 10 50 7.5 12.5 
Methadone & EDDP 125 250 1,000 187.5 312.5 
Buprenorphine & metabolites‡ 2.5 5 50 3.75 6.25 
Ketamine & norketamine 25 50 100 37.5 62.5 





Table 2.2 – Drug screening assay: Preparation of calibrator and IQC solutions 
(final volume calibrators 50 mL, IQCs 100 mL; human urine) 































  Stock 
concentration 
(mg/L) 











Benzoylecgonine 100 37.5 75 500 112.5 187.5 
Morphine 100 75 150 500 225 375 
Morphine-3-glucuronide 100 75 150 500 225 375 
Codeine 100 75 150 500 225 375 
Codeine-6-glucuronide 100 75 150 500 225 375 
Dihydrocodeine 100 75 150 500 225 375 
6-AM 10 25 50 500 75 125 
Papaverine 10 25 50 500 75 125 
Noscapine 10 25 50 500 75 125 
6-Acetylcodeine 10 25 50 500 75 125 
Methadone 
100* 62.5 125 500 187.5 312.5 EDDP 
Ketamine 
100* 12.5 25 50 37.5 62.5 Norketamine 
Tramadol 100 50 100 500 150 250 
N-Desmethyltramadol 
100* 50 100 500 150 250 O-Desmethyltramadol 






2.2.7 Internal Standard Solution  
A working internal standard (IS) solution containing 25 µg/L amfetamine-13C6, 
metamfetamine-D14, MDMA-D5, mephedrone-D3, codeine-D6, morphine-D3, 
dihydrocodeine-D6, ketamine-D4, norketamine-13C6, tramadol-13C-D3; 10 µg/L 
benzoylecgonine-D3, methadone-D3; 5 µg/L norbuprenorphine-D3, buprenorphine-D4, 
and 6-AM-D3 was prepared by appropriate dilution of individual stock solutions with 
eluent A. The solution was stored at 2-8 oC when not in use.  
2.2.8 Immunoassay Procedures 
Immunoassays were performed according to the manufacturer’s instructions using an 
Indiko Plus analyser (ThermoFisher). All assays were calibrated daily using the 
supplied calibrators. The supplied IQC solutions were analysed daily prior to the 
analysis of patient samples. 
2.2.9 Sample Preparation 
Centrifuged urine samples/calibrators/IQCs (50 µL) were diluted with 450 µL working 
IS solution using an automated Hamilton dilutor directly into HPLC vials. The vials 
were capped and transferred to a pre-cooled (10 oC) autosampler tray. 
2.2.10 Method Validation Protocol 
The method was validated according to the US Food and Drug Administration (FDA) 
Centre for Drug Evaluation and Research (CDER) guidance for bioanalytical method 
validation (FDA/CDER, 2013). Intra- and inter-assay accuracy and precision were 
measured by replicate analysis (N = 10) of the IQC solutions and cutoff calibrator on 
the same day and by singlicate analysis on different days (N = 5), respectively. To 
ensure accuracy of results, past external quality assurance (EQA) samples (LGC 
Proficiency Testing Drugs of Abuse in Urine Scheme rounds 108-115, stored at -20 oC 
since the original analysis and thawed at room temperature prior to re-analysis) were 
assayed and the results compared to the assigned values. The limit of detection (LoD) 
was ascertained through successive serial dilution (1+1, v/v, with analyte-free urine) of 
the low calibrator and was based upon the concentration at which the signal-to-noise 
ratio was >3, and the variation (relative standard deviation, RSD) was <20 % (N = 5). 
The mass accuracy for a typical batch was ascertained to ensure masses did not deviate 
outside a 10 ppm window. To investigate ion suppression, solutions containing all 
analytes at the relevant cutoff concentration were prepared in (i) analyte-free human 
urine from 20 independent sources, and (ii) eluent A. Prepared solutions were diluted 
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(1+9, v/v) with eluent A and analysed. The ratio of the peak area of each analyte to that 
of the relevant internal standard was compared for each analyte in the presence and 
absence of matrix. Analyte carryover was assessed through consecutive analysis of a 
urine sample containing low (L) and high (H) analyte concentration in the order 
L,L,L,H,H,H,L,L,L (L: cutoff calibrator, H: all analytes 100 mg/L). 
2.2.11 Patient Samples 
500 urine samples submitted for routine drug analysis, received by the laboratory in 
September 2015, were analysed using existing immunoassay procedures and the 
developed LC-HRMS method. Samples were sent to the laboratory to monitor misuse of 
drugs, adherence to prescribed OST (e.g. methadone), and to aid patient diagnosis (e.g. 
admission to hospital with drug overdose). 
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2.3 Results and Discussion 
2.3.1 Analyte Selection 
The main consideration for the initial selection of analytes to include in the assay was to 
ensure continuation of a comparable service to that currently offered by the laboratory, 
i.e. all the major analytes that cross-react significantly with the immunoassays should be 
included in the LC-HRMS method. Developing the method in accordance with service 
user requirements was also important, and as a result ketamine and tramadol were added 
to the test repertoire. At the time of initial method development, mephedrone was one of 
the most prevalent NPS and thus was included in the LC-HRMS method. No other NPS 
were included initially, but scope to add analytes was taken into account during method 
development. A complete list of analytes selected for the initial method development is 
given in Table 2.3. 
 
Table 2.3 – Drug screening assay: Analytes selected for the initial method 
development 
Drug Class Specific analytes 
Amfetamines Amfetamine, metamfetamine, MDMA 
Barbiturates Amobarbital, butabarbital, phenobarbital, pentobarbital, 
secobarbital 
Benzodiazepines 
Diazepam, temazepam, temazepam glucuronide, oxazepam, 
oxazepam glucuronide, chlordiazepoxide, demoxepam, lorazepam, 
lorazepam glucuronide, clonazepam, 7-aminoclonazepam, 
nitrazepam, 7-aminonitrazepam, alprazolam 
Buprenorphine Buprenorphine, norbuprenorphine, buprenorphine glucuronide, 
norbuprenorphine glucuronide 





Ketamine Ketamine, norketamine 
Methadone Methadone, EDDP 
NPS Mephedrone 
Opioids 6-AM, morphine, morphine-3-glucuronide, codeine, codeine-6-glucuronide, dihydrocodeine 
Street Heroin 6-Acetylcodeine, noscapine, papaverine 




2.3.2 Liquid Chromatography Method Development 
2.3.2.1 Choice of LC Column 
The selected analytes have different physicochemical properties meaning that the LC 
column selected must be suitable for a broad range of compounds; and in particular 
needs to be capable of retaining polar metabolites such as glucuronides. Most published 
methods for drug screening have used reverse-phase chromatography with gradient 
elution (Table 2.4).   
Table 2.4 – Some published LC methods for screening for drugs of abuse  
Abbreviations: aps – average particle size, I.D. – Internal diameter, C18 – octadecyl,  
HSS – High strength silica, PFP – pentafluorophenyl, BEH – Ethylene Bridged Hybrid, 
EC – End capped 
No. of analytes LC Column Details Reference 
30 C18 (50 x 3.0 I.D. mm; 2.5 µm aps, Waters Xterra) Feng et al. (2007) 
35 HSS T3 (100 x 2.1 I.D. mm, 1.8 µm aps, Waters Acquity) Hegstad et al. (2014) 
38 Phenyl-hexyl (100 x 2.1 I.D. mm, 2.6  µm 
aps, ThermoFisher Accucore) Helfer et al. (2016) 
38 C18 (50 x 2.1 I.D. mm, 1.6  µm aps, Cortex) 
Jagerdeo and Schaff 
(2016) 
65 PFP (50 x 2.1 I.D. mm, 3  µm aps, ThermoFisher Hypersil Gold) Li et al. (2013) 
67 C18 (100 x 3 I.D. mm, 1.8 µm aps, Zorbax Eclipse Plus) Marin et al. (2012) 
37 C18 (100 x 2.1 I.D. mm, 2.7 µm aps, Agilent Technologies Poroshell) 
McMillin et al. 
(2015) 
356 Phenyl-hexyl (100 x 3 I.D. mm, 3 µm aps, ThermoFisher Betasil) Mueller et al. (2011) 
616 Phenyl-hexyl (100 x 3 I.D. mm, 3 µm aps, ThermoFisher Betasil) Roche et al. (2016) 
33 BEH Phenyl (50 x 2.1 I.D. mm, 1.7 µm 
aps, Waters Acquity) Rosano et al. (2016) 
27 C18 (50 x 2.1 I.D. mm, 5 µm aps, ThermoFisher Hypersil Gold) 
Schaefer et al. 
(2013) 
35 EC-C18 (50 x 3.0 I.D. mm, 2.7 µm aps, Agilent Technologies Poroshell) Shin et al. (2014) 
21 
BEH C18 (50 x 2.1 I.D. mm, 1.7 µm aps, 




Three columns were selected for evaluation during initial method development; C18, 
PFP and phenyl-hexyl (all 100 x 2.1 I.D. mm, ThermoFisher). To compare the columns, 
a simple gradient elution profile (2-100 % organic eluent [0.1 % (v/v) formic acid in 
acetonitrile:methanol (1+1)] over 15 minutes) was used, with 10 mmol/L ammonium 
formate with 0.1 % (v/v) formic acid as the aqueous eluent. A portion (50 µL) of an 
aqueous solution containing all analytes (100 µg/L) was analysed. Methadone and 
EDDP were strongly retained on the PFP column leading to significant carryover for 
these analytes on subsequent analyses. In addition, retention of morphine glucuronide 
was poorer on the PFP column (Figure 2.3). For most analytes the phenyl-hexyl column 
provided sharper chromatographic peaks than the C18 column, and thus was selected 
for further method development.  
 
Figure 2.3 – Extracted ion chromatograms to show the retention of morphine 
glucuronide (m/z 462.1759) on a) C18, b) phenyl-hexyl, and c) PFP columns [all 100 




























2.3.2.2 Eluent Selection 
When first testing the phenyl-hexyl column, a simple gradient (2-100 % organic eluent 
[0.1 % (v/v) formic acid in acetonitrile:methanol (1+1)] over 15 minutes) was used. The 
column temperature was maintained at 40 oC, and the total LC flow rate was 0.3 
mL/min. 10 mmol/L ammonium formate with 0.1 % (v/v) formic acid was used as the 
aqueous eluent. Three organic eluents were investigated; 0.1 % (v/v) formic acid in (i) 
acetonitrile, (ii) acetonitrile:methanol (1+1), and (iii) methanol. Chromatographic peaks 
broadened with increasing methanol content, particularly the early eluting peaks (e.g. 
morphine, Figure 2.4). However, retention of morphine glucuronide was poor when 
using solely acetonitrile as the organic eluent. As a compromise 0.1 % (v/v) formic acid 
in acetonitrile:methanol (1+1) was selected for the organic eluent. 
 
Figure 2.4 – Extracted ion chromatograms for morphine (m/z 286.1438) using 0.1 
% (v/v) formic acid in a) acetonitrile, b) acetonitrile:methanol (1+1), and c) 




























2.3.3 Mass Spectrometry Method Development 
2.3.3.1 Ionisation Mode and Polarity Switching 
Most of the analytes studied are basic and ionise in positive mode. Barbiturates, 
however, are weakly acidic and will only ionise in negative mode. In order to detect all 
analytes, the method would need to include both positive and negative mode scans. 
However, the time taken to switch between polarities resulted in a severe reduction in 
the data points that could be obtained over the chromatographic peaks. This was 
particularly apparent for low concentration analytes such as buprenorphine (Figure 2.5).  
Instead of including negative ion scans over the whole analysis, the possibility of 
including negative scan segments at only the relevant times when barbiturates elute was 
explored. The retention times of the barbiturates ranged from 8.0-9.5 min, during which 
many other analytes eluted (e.g. buprenorphine, EDDP), thus splitting positive and 
negative ion scans into different time segments was not feasible in practice.  
2.3.3.2 Optimisation of Source Conditions 
The majority of source parameters are optimised according to the LC flow rate. The 
parameters that are more analyte-specific include the ion transfer capillary temperature 
and the positioning of the ESI probe. The ion transfer capillary temperature is critical 
for the majority of compounds. When the temperature is too low, ions may not be fully 
desolvated. Higher temperatures may improve desolvation for some analytes but may 
also start to degrade more thermally labile analytes. The distance between the ESI probe 
and the source inlet may be set at 4 different positions (A, B, C, or D, Figure 2.6), with 
the distance typically greatest when a higher LC flow rate is used (position D). 
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Figure 2.5 – Analysis of the cutoff solution to compare the number of data points 
over a) morphine, and b) buprenorphine chromatographic peaks when collecting 













Positive ion mode only 
 
 
















Positive ion mode only 
 
 


















Figure 2.6 – Schematic illustration of the ESI probe and source housing on the Q-
Exactive mass spectrometer 
 
 
The capillary temperature was investigated at 250 and at 350 oC. Analyte peak area in 
the low and cutoff calibrator solutions was compared at the two temperatures to 
ascertain the optimum value to use (Figure 2.7). The amfetamine and metamfetamine 
peak areas were significantly reduced when the capillary was at 350 oC. As a result, the 
capillary temperature was set at 250 oC for the method. 
To ascertain the optimum distance of the ESI probe from the mass spectrometer source, 
the cutoff calibrator solution was analysed with the probe at three different positions (B, 
C and D; D being the furthest distance from the source). Most analytes showed 
increased peak area when the probe was further from the source, thus position D was 
selected for the method (Figure 2.8). 
To ascertain the other source conditions, including gas flow rates, spray voltage and 
vaporiser temperature, the instrument software was used to give the default settings 
based on a LC flow rate of 0.3 mL/min. 
ESI probe tip 
Source inlet 










Figure 2.7 – The influence of capillary temperature on analyte peak area in the low calibrator (light grey) and cutoff (dark grey) solutions  






























































Figure 2.8 – The influence of increasing the distance of the ESI probe from the source on analyte peak area in the cutoff solution  























































2.3.3.3 Mass Resolution 
Mass resolution relates to the ability of a mass spectrometer to separate peaks of one 
mass from another, with higher resolution giving improved selectivity. However, 
increasing mass resolution increases the time required for each scan. To identify 
unknown substances, the mass resolution needs to be as high as possible to give the 
greatest selectivity. However, there must still be enough data points across 
chromatographic peaks to enable accurate quantitation. To ascertain the optimum 
resolution setting for the full scan experiment, the cutoff calibrator was analysed at each 
resolution setting and the number of data points under chromatographic peaks visually 
compared (Figure 2.9) 
 
Figure 2.9 – Extracted ion chromatograms (m/z 310.2165) to show the reduction in 
MS scans collected over the methadone peak due to an increase in mass resolution 
































2.3.3.4 Product Ions 
Product ions may be used to confirm peak identity. Two types of fragmentation scan 
experiments were evaluated to decide that to use in the method; data-dependent MS2 
(ddMS2) and all-ion fragmentation (AIF). ddMS2 scan experiments fragment the top 5 
precursor ions (based on intensity) in the preceding full scan, whereas AIF experiments 
fragment all the precursor ions seen in the preceding full scan.  
For both experiments, conditions in the HCD cell were set as follows; collision gas: 
nitrogen, stepped normalized collision energy (NCE): 35 V [±50 %], and settings for the 
MS2 data collection were: resolution 17,500, maximum injection time 200 ms, AGC 
target 3 x 106 ions. The scan range for the AIF experiment was set as 70-750 m/z.  
The ddMS2 scans had less background noise, particularly at low m/z values, and as a 
result the MS2 spectra were clearer (Figure 2.10). However, if an analyte of interest is at 
low concentration or co-elutes with other analytes, an MS2 scan may not be triggered 
when using ddMS2. Additionally, when using ddMS2 the number of full scan spectra 
will be reduced as 5 separate MS2 scans are conducted after each full scan, as opposed 
to 1 MS2 scan when using AIF. AIF has the further advantage of detecting all product 
ions present, but as the fragmentation is not specific (i.e. resultant product ions in the 
MS2 spectra are from all compounds eluting at that time) it is difficult to associate 
product ions to specific precursor ions.  
To capture as much information as possible, AIF was used in the developed method. An 
important consideration when using AIF was to ensure that confirming product ions for 
analytes were not generated by the corresponding internal standard to minimise the 
possibility of false positive results. Individual aqueous solutions of analytes and internal 




























































Morphine MS2 spectrum using AIF 
b) 
Morphine MS2 spectrum using ddMS2 
Benzoylecgonine MS2 spectrum 
using ddMS2 





2.3.4 Selection of ‘cutoff’ concentrations 
Many guidelines for recommended drug cutoff concentrations have been published. The 
concentration used is largely dictated by whether the sample is submitted for clinical 
reasons or for workplace drug testing, with the latter usually having lower cutoff 
concentrations. The suggested cutoff concentrations also differ according to the 
methodology being used, i.e. whether the test is for screening (largely based on 
immunoassay) or confirmation (largely based on chromatographic assays) purposes. A 
summary of recommended cutoff concentrations is given in Table 2.5. Where no formal 
cutoff concentrations were documented, a literature search was conducted to establish 
urine concentrations and provide an evidence-based cutoff concentration for analytes.  
No clear guidance exists for urinary cutoff concentrations for street heroin markers (e.g. 
6-acetylcodeine, noscapine, and papaverine). Urinary 6-acetylcodeine concentrations 
are typically lower than 6-AM concentrations. One method stated a lower limit of 
quantification (LLoQ) of 1 µg/L for 6-acetylcodeine and most samples tested had 6-
acetylcodeine concentrations less than 30 µg/L (O’Neal and Poklis, 1997; 1998). 
Noscapine and papaverine are also present at low concentration in urine from heroin 
users because they undergo extensive metabolism with less than 1 % of a dose being 
excreted unchanged in urine (Belpaire et al., 1978; Tsunoda and Yoshimura, 1981). The 
cutoff for street heroin metabolites was assigned as 10 µg/L, to be concordant with the 
cutoff for 6-AM.  The full list of cutoff concentrations for the method developed is 
given in Table 2.6. 
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Table 2.5 – Recommended analyte ‘cutoff’ concentrations for drug screening and 
confirmation in urine samples 
aDependent on specific opioid, total morphine 300 µg/L, total codeine or 
dihydrocodeine 2000 µg/L 
‡Presence of any metabolite above cutoff (i.e. norbuprenorphine, buprenorphine 





































































































































LGC Standards (2016) 















































LGC Standards (2016) 
Beck et al. (2014) 
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Table 2.6 – Drug screening assay: Cutoff concentrations selected for the LC-
HRMS method developed 
*
 Dihydrocodeine glucuronide concentration estimated based upon dihydrocodeine 
calibration curve 
#
 Conversion to buprenorphine equivalents and summed 
†
 Norketamine converted to ketamine equivalent and summed 
‡
 Metabolites converted to tramadol equivalents and summed 





Total morphine 300 
Total codeine 300 







Buprenorphine metabolites# 5 
Ketamine & norketamine† 50 
Tramadol & metabolites‡ 200 




2.3.5 Selection of Internal Standards 
Stable isotope-labelled analogues of some analytes were selected as internal standards 
(Table 2.7). Naturally-occurring isotopes of an analyte (e.g. those containing 13C instead 
of 12C) may result in interference with the internal standard (Duxbury et al., 2008). To 
minimise this risk, the compounds chosen were at least 3 amu different from the 
corresponding analyte.  
Table 2.7 – Drug screening assay: Internal standards and associated analytes 





Morphine-D3 Morphine, morphine-3-glucuronide, pholcodine 
Codeine-D6 Codeine, codeine glucuronide 
Dihydrocodeine-D6 Dihydrocodeine 
6-AM-D3 6-AM, 6-acetylcodeine, noscapine, papaverine 
Methadone-D3 Methadone, EDDP 
Benzoylecgonine-D3 Benzoylecgonine 
Buprenorphine-D4 Buprenorphine, buprenorphine glucuronide 
Norbuprenorphine-D3 Norbuprenorphine, norbuprenorphine glucuronide 
Ketamine- D4 Ketamine 
Norketamine-13C6 Norketamine 
Tramadol-13C-D3 Tramadol, O-desmethyltramadol, N-desmethyltramadol 
 
For amfetamine initially two deuterated analogues, amfetamine-D5 and amfetamine-D11, 
were investigated for use as an internal standard. Neither analogue co-eluted with 
amfetamine (Figure 2.11). As a result, matrix effects were not fully compensated for 
using either internal standard (Table 2.8). To overcome this issue, a 13C-labelled 
analogue, amfetamine-13C6, was purchased. Amfetamine-13C6 co-eluted with 
amfetamine and as a result matrix effects were better compensated for. The relative 
peak area of amfetamine to that of each stable isotope was assessed in 10 urine samples 
(all analytes 200 µg/L) and showed large variation with both deuterated analogues, 
which could cause inaccurate results (Table 2.9). In contrast, the relative peak area of 





Figure 2.11 – Chromatographic separation of amfetamine (black, 5.8 min) and 
different stable isotopes; amfetamine-13C6 (red, 5.8 min), amfetamine-D5 (green, 




Table 2.8 – Observed matrix effects for amfetamine and selected stable isotopes 
Analyte Mean Matrix effect (%) 
Relative matrix effect to Amfetamine 
(%) 
Amfetamine 78 - 
Amfetamine-13C6 79 101 
Amfetamine-D5 87 112 

























Table 2.9 – Variation in the relative peak area of amfetamine to different stable 
isotopes between 10 urine samples containing amfetamine, amfetamine-13C6, 
amfetamine-D5, amfetamine-D11 (all 200 µg/L) 
 
Relative peak area of amfetamine to internal standard 
Amfetamine-13C6 Amfetamine-D5 Amfetamine-D11 
1 0.84 0.79 0.68 
2 0.79 0.86 0.98 
3 0.84 0.79 0.65 
4 0.85 0.73 0.60 
5 0.85 0.78 0.65 
6 0.83 0.70 0.59 
7 0.84 0.77 0.68 
8 0.84 0.93 0.86 
9 0.83 0.73 0.63 
10 0.84 1.02 0.98 
Mean 0.83 0.81 0.73 
SD 0.02 0.10 0.15 
% RSD 2 12 21 
 
2.4 Sample Preparation  
A literature search was performed to ascertain the sample preparation methods that had 
been used for urine drugs of abuse screening. Most methods used either solid-phase 
extraction, or sample dilution. As one of the aims of the method was to enable 
retrospective detection of analytes (i.e. retrospective data interrogation), it was decided 
to use a non-selective sample preparation method to ensure that unknown substances 
were not missed as a result of using solid-phase extraction.  
Published methods for drug analysis in urine have used 5-fold (Andersson et al., 2008; 
Gustavsson et al., 2007; Svensson et al., 2007), 10-fold (Eichhorst et al., 2009), or 50-
fold (Politi et al., 2007) dilution. 50-fold dilution was considered too great as some 
analytes (e.g. buprenorphine) are present at low concentration during abstinence 
treatment. Thus, a 10-fold dilution was adopted for use in the method developed to 




2.5 Practical Considerations 
2.5.1 Benzodiazepines 
Development of a comprehensive screening method for benzodiazepines is complicated 
due to the large number of benzodiazepine drugs prescribed and used. In addition, 
benzodiazepines undergo extensive metabolism and as a result many metabolites are 
found in urine. Interpretation of results is also challenging as identifying the drug 
ingested can be difficult since many benzodiazepines share a common metabolic 
pathway (Figure 2.12). For example, detection of oxazepam glucuronide is possible 
following ingestion of diazepam, chlordiazepoxide and/or temazepam as well as 
following ingestion of oxazepam itself. Detection of unique metabolites, e.g. 
demoxepam from chlordiazepoxide, or in some cases the parent drug itself can aid the 
interpretation of analytical results. 
Whilst detection of benzodiazepine drugs is possible with the method developed, it was 
thought that more than 20 benzodiazepine analytes would have to be included in the 
assay to provide comparable results to the immunoassay currently in use. The time 
taken for checking peak integrations, and then for interpretation of results was 
considered too great for a routine service. For most cases, identification of an individual 
benzodiazepine that has been ingested is not clinically significant. Specific 
identification may be useful when an individual is prescribed a benzodiazepine, but in 
addition misuse of a different benzodiazepine is suspected. The best approach may be to 
offer an additional test for benzodiazepine differentiation that can be requested when 
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Figure 2.12 – Common metabolic pathway of selected benzodiazepine drugs  




Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, is rapidly 
and extensively metabolised after administration (Figure 2.13). The major urinary 
metabolite is 11-COOH-THC glucuronide, with assays typically targeting this analyte 
or 11-COOH-THC itself after urine hydrolysis.  
Figure 2.13 – Metabolic pathway of tetrahydrocannabinol in man  
Key: tetrahydrocannabinol (THC), 11-hydroxy tetrahydrocannabinol (11-OH-THC), 11-
nor-9-carboxy tetrahydrocannabinol (11-COOH-THC), 8-hydroxy tetrahydrocannabinol 









































11-OH-THC, 11-COOH-THC and 11-COOH-THC glucuronide showed good 
chromatographic retention using the method developed (Figure 2.14). It was noted that 
in-source breakdown of the glucuronide to parent drug occurred, but this was not 
deemed problematic as 11-COOH-THC and the glucuronide were resolved 
chromatographically. However, when analysing these compounds at relevant 
concentrations in urine samples the sensitivity of the assay was poor (Figure 2.15). The 
current cutoff concentration in use with the immunoassay method is 50 µg/L, with the 
developed LC-HRMS method only 11-COOH-THC had a true chromatographic peak 
distinguishable from background noise at 50 µg/L. 
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Figure 2.14 – Extracted ion chromatograms of individual aqueous solutions (each 1 
mg/L) of a) 11-OH-THC, b) 11-COOH-THC, and c) 11-COOH-THC glucuronide 
 
 
Figure 2.15 – Extracted ion chromatograms to show a) 11-OH-THC, b) 11-COOH-
THC, and c) 11-COOH-THC glucuronide in human urine at (i) 25 µg/L, (ii) 50 




































(i)                                     (ii)                                            (iii) 
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Time constraints associated with implementation of the developed LC-HRMS method 
into routine service meant that further work to try and improve sensitivity could not be 
conducted. Due to this, the immunoassay remained in use for cannabis detection.  
The immunoassay exhibits good sensitivity, but false positives may arise due to the 
presence of the antiretroviral drug efavirenz in urine samples (Oosthuizen and Laurens, 
2012; Rossi et al., 2006).  Efavirenz (Sustiva®, Bristol-Myers Squibb) is prescribed on 
its own or as a combination tablet (Atripla®, Bristol-Myers Squibb) also containing 
emtricitabine and tenofovir. Retrospective interrogation of LC-HRMS data can be 
undertaken to confirm the presence of these drugs if a positive immunoassay 




Figure 2.16 – Extracted ion chromatograms to show the presence of efavirenz (a), 
emtricitabine (b), and tenofovir (c) in the absence of THC-COOH (d) and its 
glucuronide (e) in a patient urine sample (top) which screened positive for 
cannabis by CEDIA (apparent cannabinoid concentration = 76 µg/L), compared to 
a patient urine sample (bottom) which was confirmed positive by the presence of 




2.6 Method Validation 
Intra- and inter-assay accuracy and precision are summarised in Tables 2.10 and 2.11. 
The accuracy for analytes present in past EQA samples ranged from 79-118 % (Table 
2.12). The LoD for all analytes ranged between 2.5-63 µg/L. The LoD of individual 
analytes are summarised in Table 2.13, which also details the cutoff concentrations 
selected for the method (Section 2.3.4). For all analytes the LoD was at least half the 
concentration of the cutoff concentration. Typical chromatograms for all analytes are 
shown in Figure 2.17. Typical mass accuracies are given in Table 2.14. For most 
analytes, carryover was less than 20 %. However, significant carryover was seen for 
buprenorphine (128 %) and norbuprenorphine (39 %). When buprenorphine is taken 
therapeutically, urine buprenorphine concentration is low, often less than 5 µg/L. 
However, in cases of sample adulteration with buprenorphine, urine buprenorphine 
concentration may be 50 mg/L or more. In these cases, subsequent samples have to be 
repeated to ensure that the possibility of carry-over has been eliminated. The internal 
standards used were seen to compensate well for ion suppression/enhancement for all 




Table 2.10 – Drug screening assay: Intra-assay accuracy and precision data  
Accuracy (% nominal QC values) and precision (% RSD) 
































































































































































































Table 2.10 (cont.) – Drug screening assay: Intra-assay accuracy and precision data  
Accuracy (% nominal QC values) and precision (% RSD) 





































































































































































Table 2.11 – Drug screening assay: Inter-assay accuracy and precision data  
Accuracy (% nominal QC values) and precision (% RSD) 
































































































































































































Table 2.11 (cont.) – Drug screening assay: Inter-assay accuracy and precision data  
Accuracy (% nominal QC values) and precision (% RSD) 









































































































































































Table 2.12 – Drug screening assay: EQA accuracy data  
Accuracy (% nominal concentration)  
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Table 2.12 (cont.) – Drug screening assay: EQA accuracy data 
Accuracy (% nominal concentration)  
#LGC Proficiency Testing Drugs of Abuse in Urine Scheme 
*Morphine is reported as ‘total’ morphine with a calculation used to convert morphine-
3-glucuronide to its morphine equivalent. This is to reflect post-hydrolysis 
concentrations as most other laboratories do not directly measure glucuronides, but 







































































































Table 2.13 – Drug screening assay: Summary of detection limits for each analyte 
and comparison to the selected cutoff concentration  
Analyte LoD  (µg/L) 
Cutoff  
(µg/L) 
Amfetamine 13 200 
Metamfetamine 50 200 
MDMA 13 200 
Mephedrone 13 200 
Morphine 19 300 
Morphine-3-glucuronide 38 300 
Codeine 19 300 
Codeine glucuronide 19 300 
Dihydrocodeine 19 300 
6-AM 5 10 
Pholcodine 19 300 
Methadone 63 250 
EDDP 16 250 
Benzoylecgonine 19 150 
Buprenorphine 2.5 5 
Norbuprenorphine 2.5 5 
Buprenorphine glucuronide 2.5 5 
Norbuprenorphine glucuronide 2.5 5 
Ketamine 13 50 
Norketamine 13 50 
Tramadol 13 200 
O-Desmethyltramadol 50 200 
N-Desmethyltramadol 50 200 
6-Acetylcodeine 2 10 
Noscapine 3 10 





Figure 2.17 – Drug screening assay: Extracted ion chromatograms of all analytes 







































































Table 2.14 – Drug screening assay: Typical mass accuracy for each analyte  
The mean measured [M+H]+ for each analyte was calculated from the analysis of 





















Amfetamine 136.1121 136.1119 -1.10 136.1118 -2.21 
Metamfetamine 150.1277 150.1275 -1.74 150.1273 -2.76 
MDMA 194.1176 194.1173 -1.22 194.1171 -2.35 
Mephedrone 178.1226 178.1224 -1.39 178.1222 -2.57 
Morphine 286.1438 286.1432 -2.16 286.1429 -3.21 
Morphine-3-
glucuronide 462.1759 462.1750 -2.04 462.1744 -3.20 
Codeine 300.1594 300.1588 -2.17 300.1585 -3.14 
Codeine glucuronide 476.1915 476.1908 -1.60 476.1903 -2.57 
Dihydrocodeine 302.1751 302.1744 -2.33 302.1741 -3.23 
6-AM 328.1543 328.1536 -2.14 328.1533 -3.29 
Pholcodine 399.2278 399.2271 -1.96 399.2266 -3.17 
Methadone 310.2165 310.2158 -2.31 310.2156 -3.20 
EDDP 278.1903 278.1897 -2.27 278.1894 -3.41 
Benzoylecgonine 290.1387 290.1381 -2.10 290.1378 -3.12 
Buprenorphine 468.3108 468.3101 -1.52 368.3097 -2.55 
Norbuprenorphine 414.2639 414.2629 -2.24 414.2625 -3.23 
Buprenorphine 
glucuronide 644.3429 644.3420 -1.61 644.3413 -2.65 
Norbuprenorphine 
glucuronide 590.2960 590.2953 -1.21 590.2947 -2.26 
Ketamine 238.0993 238.0990 -1.29 238.0987 -2.46 
Norketamine 224.0837 224.0833 -1.73 224.0831 -2.70 
Tramadol 264.1958 264.1954 -1.83 264.1950 -3.00 
O-Desmethyltramadol 250.1802 250.1796 -2.35 250.1793 -3.49 
N-Desmethyltramadol 250.1802 250.1796 -2.41 250.1793 -3.59 
6-Acetylcodeine 342.1700 342.1693 -2.07 342.1689 -3.33 
Noscapine 414.1547 414.1539 -2.08 414.1535 -3.14 
Papaverine 340.1543 340.1542 -0.58 340.1537 -1.89 
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Table 2.15 – Drug screening assay: Summary matrix effects data 
Solutions containing all analytes at the relevant cutoff concentration were prepared in (i) 
analyte-free human urine from 20 independent sources, and (ii) eluent A. Prepared 
solutions were diluted (1+9, v/v) with eluent A and analysed. The peak area of each 
analyte/internal standard was compared in the presence and absence of matrix to 
calculate the matrix effect.  
Analyte Mean Matrix Effect (%) 
Relative Matrix Effect 
(%) 
Amfetamine-13C6 79 - 
Amfetamine 78 101 
Metamfetamine-D14 40 - 
Metamfetamine 52 130 
MDMA-D5 44 - 
MDMA 45 102 
Mephedrone-D3 39 - 
Mephedrone 31 79 
Morphine-D3 46 - 
Morphine 46 100 
Morphine-3-glucuronide 31 67 
Pholcodine 25 54 
Codeine-D6 50 - 
Codeine 46 92 
Codeine glucuronide 73 146 
Dihydrocodeine-D6 44 - 
Dihydrocodeine 46 105 
Methadone-D3 79 - 
Methadone 84 106 
EDDP 80 101 
Benzoylecgonine-D3 75 - 
Benzoylecgonine 77 103 
6-AM-D3 67 - 
6-AM 66 99 
6-Acetylcodeine 66 99 
Noscapine 52 78 
Papaverine 67 100 
Buprenorphine-D4 104 - 
Buprenorphine 103 99 
Buprenorphine glucuronide 129 124 
Norbuprenorphine-D3 62 - 
Norbuprenorphine 75 121 
Norbuprenorphine glucuronide 73 118 
Ketamine-D4 56 - 
Ketamine 64 114 
Norketamine-13C 68 - 
Norketamine 67 101 
Tramadol-13C-D3 64 - 
Tramadol 70 109 
N-Desmethyltramadol 64 100 
O-Desmethyltramadol 68 106 
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2.6.1 Isobaric Interferences 
Mass spectrometry is a highly selective method, but it has limitations. Interference may 
arise from isobaric analytes, for example. To overcome this, compounds should be 
resolved chromatographically and/or produce different MS2 fragments in order to 
correctly identify the compound present. Known isobaric interferences were 
investigated to ensure the compound of interest could be distinguished from its isobar/s.   
Complete LC resolution was achieved for the isobaric compounds tested, and different 






Table 2.16 – Drug screening assay: Chromatographic resolution and MS product 
ion spectra for some isobaric substances 
#
 Ions resulting from a water loss excluded 















Norcodeine 225.0910 121.0648 5.75 
Norhydrocodone 199.0755 241.0860 6.30 




































N-Desmethylvenlafaxine 215.1430 6.81 




O-Desmethyltramadol 58.0651 6.39 




2.7 Patient Sample Comparison 
There were 500 urine samples from 343 individuals. Demographic information was 
available for 373 samples. Of these, 251 (67 %) were from males and 122 (33 %) from 
females. The median (range) age at the time of sampling was 40 years (0-78). Patient 
results are summarised in Table 2.17. Differences in results between the two methods 
were largely attributed to either false-positive results by immunoassay, or different 
analyte cutoff concentrations being used for the two methods. 
2.7.1 Immunoassay False-Positives 
The buprenorphine immunoassay has low specificity, with the highest number of false-
positives associated with this assay. Fifty-two samples (10.4 %) were classed as positive 
by immunoassay but neither buprenorphine nor its metabolites were detected by LC-
HRMS. The immunoassay is prone to interference from high opioid concentration 
within a urine sample (Pavlic et al., 2005). Forty-eight of these samples had a CEDIA 
opioid concentration >2000 µg/L. In the remaining samples, other drugs known to 
interfere with the immunoassay were detected (amisulpride N = 2, nalbuphine N = 1, 
and trimethoprim N = 1).  
As previously discussed, the amfetamine immunoassay is prone to interference from 
many therapeutic drugs. Eight samples (1.6 %) were classed as negative by LC-HRMS 
(i.e. amfetamine, metamfetamine, MDMA, and mephedrone not detected). Ranitidine 
(N = 2), mebeverine (N = 2), atomoxetine (N = 2) and ephedrine (N = 1) were identified 
in the samples which likely accounts for the positive amfetamine immunoassay result 
due to structural similarity to metamfetamine, the compound the immunoassay is 









Table 2.17 – Contingency tables summarising patient results when using LC-
HRMS versus immunoassay for drug screening 
LC-HRMS was taken as the reference method, with immunoassay sensitivity and 




Sensitivity 95 %     Specificity 98 % 
Cocaine (as benzoylecgonine) 













Positive 19 8 
 Immunoassay 
Positive 151 0 
Immunoassay 
Negative 1 472 
 Immunoassay 
Negative 10 339 
  
Methadone Metabolite (EDDP)   
Sensitivity 100 %     Specificity 98 %          
Opioids 













Positive 187 6 
 Immunoassay 
Positive 207 11 
Immunoassay 
Negative 0 307 
 Immunoassay 
Negative 0 282 
 
Buprenorphine and metabolites 









Positive 98 52 
Immunoassay 






Figure 2.18 – Comparison of the structures of ranitidine, mebeverine, ephedrine, 
and atomoxetine to metamfetamine  












































2.7.2 Immunoassay False-Negatives 
One false-negative was observed for buprenorphine. In this sample, only 
norbuprenorphine glucuronide was detected by LC-HRMS. Norbuprenorphine 
glucuronide does not cross-react when analysed by CEDIA (<0.015 % cross reactivity, 
ThermoFisher Scientific, 2016) and thus would explain the negative result.  
The amfetamine-group CEDIA is calibrated using S-metamfetamine, with S/R-
amfetamine having 88 % of the cross-reactivity of metamfetamine (ThermoFisher 
Scientific, 2014). One sample had a calculated amfetamine concentration of 716 µg/L 
by LC-HRMS and 470 µg/L by CEDIA, which may relate to the reduced cross-







2.7.3 Differences in Analyte Cutoff Concentration 
The use of different cutoff concentrations between CEDIA and the LC-HRMS methods 
account for the apparent differences in the cocaine and methadone results.  
A lower cutoff for benzoylecgonine was selected for the LC-HRMS method to be in-
line with EWDTS guidelines (150 µg/L) than was used for the CEDIA (300 µg/L). If 
the CEDIA cutoff was decreased to 150 µg/L only 1 result differed (CEDIA: 116 µg/L, 
LC-HRMS: 160 µg/L).  
A higher cutoff for EDDP was selected for the LC-HRMS method to be in-line with 
EWDTS guidelines (250 µg/L) than was used for the CEDIA (100 µg/L). If the CEDIA 
cutoff concentration was increased to 250 µg/L only 2 results differed (CEDIA: 256 and 
385 µg/L, and LC-HRMS: 207 and 240 µg/L, respectively). 
2.7.4 Additional Immunoassay Cross-reactivity   
For the opioids, the calculated immunoassay concentration is a composite result derived 
from all opioids in the sample cross-reacting to a greater or lesser extent, whereas the 
LC-HRMS method measures selected opioids. The 11 samples which were opioid 
negative by LC-HRMS all had a CEDIA concentration of <750 µg/L. Morphine was 
detected by LC-HRMS in all samples, but at a concentration below the cutoff 
concentration, with total morphine ranging from 166-287 µg/L. Minor metabolites of 
morphine (e.g. normorphine, hydromorphone) which are not targeted using the LC-
HRMS method may cross-react with the immunoassay method and account for the 
higher observed opioid concentration. 
2.7.5 Analytes without Immunoassay Available  
No immunoassay was used in the laboratory for the detection of tramadol or ketamine. 
Within the 500 patient urine samples analysed as part of the routine drug screening 
cross-validation, tramadol (and its metabolites) was detected in 14 samples (2.8 %), and 







2.8 Conclusions  
An LC-HRMS method has been developed and validated that is suitable for clinical 
drug detection. The use of LC-HRMS as a drug screening method negates the need for 
prior immunoassay analysis for most drug classes, reducing cost and turn-around-times. 
A compromise had to be drawn with analysis of some analytes remaining by 
immunoassay to offer a practical method in the clinical laboratory. A similar ‘hybrid’ 
approach has been adopted by a clinical laboratory in America (McMillin et al., 2015).  
The use of LC-HRMS for routine drug detection in a clinical setting has two key 
advantages; retrospective data analysis and rapid incorporation of new analytes into the 
method. The developed method offers a novel approach to clinical drug analysis by 
enabling specific drugs of abuse to be targeted as well as providing the capacity to 
detect other analytes through the collection of full scan MS data. This enables 
retrospective data analysis without the need to re-analyse the sample if the presence of 
additional compounds is queried at a later stage. The amount of data produced for each 
sample is large, and thus storage of data is an important consideration to ensure data are 
available for such retrospective work. The method is easily adaptable to include other 
analytes that may be required in a routine urine drug screen. Since initial development 
of the method, methylphenidate, ethylphenidate, and ritalinic acid have been added as 
additional analytes (Chapter 4). The versatility of the assay allows new drugs of abuse 
to be incorporated into the method without detriment to the original panel of analytes. 
Improving detection of NPS is of increasing importance to enable accurate diagnosis 
and treatment of individuals who abuse these substances. 
The decision to use immunoassay for selected drugs was largely based on analytical 
challenges. Barbiturates are not ionized using positive-mode MS and the time taken to 
switch between ionisation modes resulted in too few data points across chromatographic 
peaks. For cannabis there was an issue with assay sensitivity. The immunoassays for 
cannabis and barbiturates are more selective than many of the other drug 
immunoassays, and thus false positives are unlikely. In addition, the number of samples 
screening positive for barbiturates has fallen over time and it is likely that most samples 
will not contain these analytes. As barbiturates are rarely encountered, whether they 
should be included in a routine drug screen is questionable. It may be more appropriate 
to offer barbiturates as an additional test; this will be explored in Chapter 6 when 
auditing clinical data. For the benzodiazepine class of drugs, a large number of analytes 
would need to be included to offer a comparative result to the CEDIA. This was not 
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deemed practical for a routine clinical service as there was not clinical justification for 
the time and cost implications. The benzodiazepine immunoassay is not prone to false 
positives, but may give negative results for more potent, short-acting benzodiazepines 
such as clonazepam. Note finally that if a false positive or negative cannabis or 
benzodiazepine immunoassay result is queried, retrospective interrogation of the LC-
HRMS data can be conducted to confirm the presence or absence of benzodiazepines 
and THC derivatives. 
2.8.1 Further Work 
The work presented here highlights some of the challenges facing comprehensive 
screening for drugs of abuse in a routine clinical setting. The main issues relate to the 
huge amount of data generated when using HRMS and the lack of software to reliably 
process it. If inclusion of new analytes is to be undertaken, this should be driven by 
clinical requirement. Currently there is interest in the detection of synthetic 
cannabinoids, although due to the sheer number of these compounds and their likely 
low concentration in urine a separate method may be needed. 
Incorporation of cannabis detection into the LC-HRMS method through improving 
assay sensitivity should be further investigated. As THC-derivatives elute away from 
the majority of analytes, inclusion of a different MS scan experiment may be possible 
without impacting other analytes. A targeted MS scan, such as selected ion monitoring 
(SIM) may improve sensitivity.   
Currently the developed method is only validated for urine samples. Validation of the 
method for oral fluid could be investigated as there is clinical interest in utilising this 
matrix to avoid problems associated with patients adulterating urine samples. As oral 
fluid is a more complex matrix than urine, development of a suitable sample preparation 
method would be needed. In addition, the collection device to use would need to be 









3 Qualitative Drug Analysis by LC-HRMS: Application to 






















3.1.1 The Purpose of Unknown Screening 
Identifying drugs present in substances such as tablets or powders found on a patient via 
toxicological analyses may aid clinicians in the diagnosis of poisoning, particularly if 
the patient is unconscious. In some cases, unknown substance screening not only 
enlightens clinicians as to what has actually been consumed, but also informs the 
individual themselves. Drug users may take a substance believing it is a one drug when 
in actual fact it may be a different compound entirely; this particularly applies to NPS 
that are constantly changing. In addition, it may not be the actual drug that is causing 
adverse clinical features, but other substances (adulterants) present within the powder or 
pill being taken; again the user is often unaware that these compounds are being 
consumed.  
Analysis of a biological sample, such as urine, is necessary to actually confirm that an 
individual has taken a substance. Drug identification is more challenging in urine than 
in the substance itself as (i) potent drugs may be present at very low concentration, (ii) 
the parent drug may not be present due to metabolism, and in some cases metabolites 
may not be well documented, and (iii) endogenous compounds will be present that may 
complicate the analysis. 
3.1.2 Drug Identification  
Many tablets and capsules have no discerning features and cannot be identified reliably 
by sight alone. In some cases, even labelled tablets may not contain the expected 
compounds. For example, the brand name of NPS products often remain the same, but 
the constituents change. Analysis of NPS products has shown that the stated contents 
frequently do not match the compounds actually present in the product (Ford and Berg, 
2017). Similarly, synthetic cannabinoids, which are typically sprayed onto inert plant 
material to mimic the appearance of traditional cannabis, are visually indistinguishable 
from tobacco. Unlike cannabis, synthetic cannabinoids do not possess a distinctive 







3.1.3 Detection of Adulterants  
3.1.3.1 Herbal Medicines and Dietary Supplements  
Despite herbal medicine not being incorporated into Western primary healthcare, 
purchase of herbal medicines over-the-counter (OTC), or over the internet, is increasing 
with the trend toward use for ‘general well-being’. Many individuals omit to mention 
herbal medicines when asked to disclose medications they are taking, which can make it 
challenging for clinicians to discern the cause of a change in health or in concentrations 
of prescribed drugs due to pharmacokinetic interactions. These products suffer from a 
lack of regulation and standardisation, meaning the user may be unaware of what they 
are actually consuming. Whilst labelled as ‘natural’, the apparent efficacy of a herbal 
preparation may indeed be due to the presence of synthetic pharmaceutical agents as 
opposed to any herbal component. Herbal remedies marketed for erectile dysfunction 
have been found to contain sildenafil and/or sildenafil analogues such as tadalafil and 
homosildenafil, for example. The US FDA Forensic Center analysed 40 dietary 
supplements advertised as sexual enhancers and found that 19 contained synthetic drugs 
(Gratz et al., 2004). Other than licensed pharmaceutical drugs, synthetic drugs that have 
been banned due to associated health risks have also been detected in herbal products. 
Herbal slimming formulas in many countries, including the UK, Australia, and Canada, 
have been found to contain sibutramine, fenfluramine, and phenolphthalein, for example 
(Calahan et al., 2016; Yen and Ewald, 2012).  
3.1.3.2 Illicit Drugs  
The purity of illicit drugs varies significantly, with most ‘cut’ through the addition of 
adulterants to increase their weight or alter their physical properties. Cutting agents are 
generally either inert bulking agents, or pharmaceutically active ingredients; the latter 
may enable greater dilution of the drug without the user perceiving any quality 
reduction due to mimicking of the illicit drugs effects (e.g. benzocaine in cocaine 
powders). Variation in purity between drug batches is problematic at two levels; firstly 
because users may not modify the quantities used and could consume more drug than 
intended leading to acute toxicity, and secondly the adulterants added may have direct 
toxicity. Detection of adulterants present in a drug may aid diagnosis of a clinical 
condition. Commonly used bulking agents include boric acid, lactose, mannitol and 
creatine, which typically have low toxicity. Pharmaceutically active cutting agents are 
of greater concern as there may be harm associated with their use. For example, 
levamisole present in cocaine powders can cause agranulocytosis and skin necrosis 
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(Larocque and Hoffman, 2012). Currently in Europe, the main adulterants found in 
heroin are paracetamol and caffeine, and phenacetin, levamisole, caffeine, diltiazem, 
hydroxyzine and lidocaine are commonly found in cocaine (Broséus et al., 2016). 
The presence of NPS as adulterants in cocaine powders has also been reported, albeit 
infrequently. In 2012, methylone was identified in 1.65 % of MDMA tablets analysed 
by a drug checking service in Switzerland; and methylone, 4-methylethcathinone (4-
MEC), and mephedrone were identified in 8.8 %, 10.2 %, and 9.5 %, respectively, of 
MDMA tablets analysed by the drug checking service ‘Checkit!’ in Austria (Giné et al., 
2014).  
3.1.4 The Use of HRMS for Unknown Compound Identification  
The main justification for using HRMS is that by measuring accurate masses of analytes 
putative molecular formulae for an unknown compound can be calculated. This is not 
possible when using nominal mass spectrometers as different molecular formula cannot 
be distinguished. For example, codeine and metoclopramide both have a nominal mass 
of 300.1 amu, but their exact masses are distinct, 300.1594 and 300.1473 respectively, 
due to different elemental compositions (Figure 3.1). 
 










nominal mass = 300.1 amu










nominal mass = 300.1 amu





Another advantage of using HRMS is that unlike triple quadrupole instruments, the 
masses of analytes do not have to be selected prior to analysis. Thus, when using 
targeted methods for unknown drug screening, only drugs from a pre-defined list will be 
screened for. Other drugs which may be present will not be detected and this could lead 
to reporting of false negative results. Due to dwell time and time segment restrictions, 
selected reaction monitoring methods generally include a limited number of analytes to 
ensure enough data points are collected over chromatographic peaks. 
3.1.5 Aim 
This chapter explores the use of the LC-HRMS method developed (Chapter 2) for 
identifying drugs in biological and in non-biological samples and aims to assess 





3.2.1 Sample Preparation 
Sample preparation depends upon the nature of the sample to be analysed, but can 
broadly be divided into whether it is biological or not. Typical protocols used for each 
sample type are outlined below. 
3.2.1.1 Solid Substances  
All physical features of the solid material were recorded, particularly for tablets, 
including the size, shape, colour, and any markings present. The sample was extracted 
with methanol (Figure 3.2), with tablets being crushed using a pestle and mortar prior to 
the extraction. 
 
Figure 3.2 – Sample extraction protocol for solid unknown substances 
Place a portion (approx. 1 mg) of the substance into a glass tube 
Add 1 mL methanol and screw-cap 
 
 
Transfer portion of extract (~500 µL) to an Eppendorf tube 
 
 
Transfer 10 µL supernatant to a glass HPLC vial 
Add 990 µL deionised water and cap vial* 
 
 
Analyse 10 µL by LC-HRMS 
 
*If precipitation of a component in the substance occurs, centrifuge (13,500 rpm, 5 min) 
and transfer supernatant to a clean HPLC vial for analysis. 
 
3.2.1.2 Urine Samples  
Samples were prepared as described in Section 2.2.9.  
3.2.2 Analytical Method 
The LC-HRMS method (Chapter 2) was used for the analysis of all unknown 
substances.  
Sonicate 10 min 
Roller mix 20 min 
Centrifuge (13,500 rpm, 5 min) 
 





The main resources used to aid substance identification are described below.  
3.2.3.1 Qual Browser 
Qual Browser is part of the XcaliburTM software provided by ThermoFisher Scientific. 
Qual Browser allows raw data to be viewed both as chromatograms and mass spectra. 
Chromatographic data can be viewed as either the total ion chromatogram (TIC), or as 
an extracted ion chromatogram (XIC). For identifying unknown substances, the TIC is 
examined to identify any chromatographic peaks in the sample analysis. From this, the 
observed m/z at a specific time, or over a time range, can be ascertained to identify the 
precursor ion/s present. Similarly, product ions may be identified from MS2 data.    
Studying the mass spectrum to identify the isotope pattern of a precursor ion may 
provide extra information about the structure of an analyte. For instance, if a chlorine 
atom is present in the structure a mass peak 2 amu above the precursor ion (M+2) will 
be apparent due to the natural occurrence of 37Cl. The ratio of the two resulting mass 
peaks will be approximately 3:1 (the natural abundance of 35Cl to 37Cl 75:25). In a 
similar manner, if the compound contains two chlorine atoms a mass peak 4 units above 
the precursor ion (M+4) will be apparent in addition to the M+2 peak. The presence of 
bromine in a molecule can also be identified by the presence of an M+2 peak; however, 
the ratio of the M+ and M+2 peaks will be approximately 1:1 (the natural abundance of 
79Br and 81Br 50.5:49.5, Figure 3.3). 
Possible molecular formulae can be generated by the software for any m/z present in the 
mass spectrum (z
 
= 1 assumed), with the mass deviation of the proposed structure from 
the observed m/z given in milli mass units (mmu). 
Figure 3.3 – Simplified graphs to show the relative intensities of the molecular ion 
and its major isotope peaks when chlorine and bromine are present in a structure 

















One Cl atom present 














One Br atom present 













Two Cl atoms present 







ChemSpider is an on-line database (www.chemspider.com) provided by the Royal 
Society of Chemistry containing over 58 million chemical structures. For compound 
identification, a search against molecular formulae can be conducted to list compounds 
with this structure.  
When conducting a ChemSpider search, the structure generated by Xcalibur needs to 
either have a hydrogen atom removed or added to account for ionisation of the 
compound in positive or negative ion mode, respectively.  
3.2.3.3 mzCloud 
mzCloud is an on-line database (www.mzcloud.org) provided by HighChem LLC 
(Bratislava, Slovakia) with many partners including universities across the world and 
instrument manufacturer ThermoFisher Scientific. The database is constantly evolving 
with new compounds being added; currently 7,055 compounds are described (accessed 
21/11/2017). The database comprises high-resolution mass spectra with each record 
containing compound name, synonyms, chemical structure, precursor m/z, and raw mass 
spectra for MS/MS or multi-stage MSn. For each mass spectrum, information such as 
the CID and HCD are included to aid the analyst to choose data that are comparable to 
the method being used. Searches can be conducted using compound name, 
monoisotopic mass and chemical structure.  
3.2.3.4 TICTAC 
TICTAC Communications Ltd. is a leading provider of drug identification and other 
information to the criminal justice and healthcare sectors, and is based at St George’s 
University of London (www.tictac.org.uk). As part of their service, a database 
providing visual drug identification for solid drugs (tablets, capsules, patches and 
stamps) has been established that currently contains over 32,700 medicines, drugs and 
products that may be confused with drugs. Searches are based upon the physical 
characteristics of a drug, for example colour, size, score marks, and any images or text 
present. Results are then returned that match the criteria entered, listing the compounds 






3.2.4 Identification Criteria 
To improve the reliability and confidence in identification of a compound, as many 
identification criteria as possible should be used. To be certain of analyte identification, 
a reference material for the compound is required to enable a direct comparison with the 
results of sample analysis, particularly for retention time and product ions. Where a 
reference standard is not available, only tentative identification is possible. 
3.2.4.1 Retention Time 
Retention time is one of the most important identification criteria; however it is only 
useful if a reference material is available for the compound of interest. For NPS, often a 
reference compound is not commercially available or may be too costly to purchase. 
3.2.4.2 Monoisotopic Molecular Mass 
Accurate mass reduces the number of possible analytes as compared to using nominal 
mass spectrometers; however, compound identification based on accurate mass alone is 
insufficient (Remane et al., 2016). A mass error of <5 ppm is accepted for comparison 
of an observed m/z to the theoretical m/z. 
3.2.4.3 Product Ions 
Where possible, structure-specific ions should be used to confirm an analytes identity as 
opposed to non-specific losses (e.g. water loss equates to a product ion 18 amu less than 
the precursor ion). Identifying a greater number of product ions can increase selectivity. 
3.2.4.4 Ionisation Mode 
Some analytes will only ionise either in positive, or in negative ion mode. However, 
there are some analytes that will ionise in both modes; in this case identification of the 
compound can be enhanced through the presence of a chromatographic peak at the same 
retention time in both the positive and negative ion scans. 
3.2.4.5 Isotope Pattern 
As mentioned in Section 3.2.3.1, the presence of an M+2 peak can act to confirm the 
presence of a halogen atom (typically chlorine in the case of drugs) within a structure. 
This can reduce the potential number of molecular formula matches for a given m/z. 
3.2.4.6 Metabolites 
Identification of metabolites in urine samples is important when confirming exposure to 
a compound. Moreover, the parent drug may not always be present in urine, particularly 
if the drug undergoes extensive metabolism, or if drug intake was not recent. 
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3.3 Method Application to Case Studies  
3.3.1 A ‘Diet Pill’ Purchased from the Internet 
A 24-year-old female bought ‘diet pills’ from uncertified sources and presented to her 
general practitioner with clinical features of toxicity that included nausea, headaches, 
tremor and severe constipation. A single white and green capsule was submitted for 
analysis (Figure 3.4). The TIC showed a large peak at 9.52 min with some smaller 
peaks between 8-11 min (Figure 3.5). The observed m/z at 9.52 min was 280.1819, and 
a single chlorine atom was identified in the compound through the presence of the M+2 
peak (Figure 3.6). Another chromatographic peak at 9.05 min was identified, with m/z 
319.0957. A literature search was conducted to identify compounds that had been 
detected in counterfeit diet pills to guide further investigation (Table 3.1). 
The observed m/z for the peak at 9.52 min was close to the theoretical m/z for 
sibutramine (mass error -2.86 ppm), and the observed m/z for the peak at 9.05 min close 
to the theoretical m/z for phenolphthalein (mass error -2.51 ppm). In addition, 
sibutramine contains a single chlorine atom in its structure which fitted the observation 
of the M+2 peak seen at 9.52 min. Product ions for sibutramine (139.0305, 125.0151, 
127.0120) and phenolphthalein (225.0546, 197.0597, 105.0335) were identified through 
analysis of a reference solution (Sigma Aldrich) and from mzCloud, respectively. All 
product ions were present in the relevant MS2 spectra, confirming the presence of 
sibutramine and phenolphthalein in the capsule contents (Figure 3.7).  
Sibutramine is a serotonin noradrenaline reuptake inhibitor (SNRI) which has been used 
in the treatment of obesity. In recent years, the market for dietary supplements has 
grown and many products are available over the internet. Both sibutramine and 
phenolphthalein have been reported as commonly detected components of many 
different weight-loss tablets (Tang et al., 2011). However, many countries including the 
UK have withdrawn the drug from use due to concerns over potential adverse 
cardiovascular side effects such as hypertension, tachycardia, myocardial infarction 
(Azarisman et al., 2007). Phenolphthalein has been used as a laxative, but the drug has 








Table 3.1 – Reported substances identified in counterfeit diet pills (source data: 
Tang et al., 2011; Yen and Ewald, 2012) 
Compound Molecular Formula [M+H]+ (m/z) 
Sibutramine C17H26ClN 280.1827 
Benfluorex C19H20F3NO2 352.1519 
Fenfluramine C12H16F3N 232.1308 
Phenolphthalein C20H14O4 319.0965 
Bisacodyl C22H19NO4 362.1387 
Phentermine C10H15N 150.1277 
Aminorex C9H10N2O 163.0866 
L-Carnitine C7H15NO3 162.1125 
Chlorogenic acid (green coffee extract) C16H18O9 355.1024 
Epigallocatechin (green tea extract) C15H14O7 307.0812 
Caffeine C8H10N4O2 195.0877 
a)  b)  
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Figure 3.5 – Analysis of the capsule extract showing a) the TIC, b) an XIC for m/z 




Figure 3.6 – Mass spectra of the precursor ions for the compounds eluting at a) 












































































Figure 3.7 – MS2 spectra to show the product ions present at a) 9.52 min, and b) 



























































3.3.2 Tablets Found on an Individual on Admission to Hospital 
A 16-year-old female presented to hospital, at which point tablets were found in her 
clothing. The clinicians could not ascertain what these tablets were, and wanted to 
establish whether they were relevant to her hospital presentation. Three distinct tablets 
were submitted for analysis (Figure 3.8). 
Figure 3.8 – Physical appearance and dimensions of the 3 unknown tablets 






11 mm diameter 17 x 8 mm 6 mm diameter 
3 mm thick 5 mm thick 2 mm thick 
 
3.3.2.1 Tablet 1 
Analysis of the first tablet produced a TIC with a distinct peak at 9.71 min, which had a 
measured m/z of 231.1012 (Figure 3.9). From this, potential molecular formulae were 
generated, with the best match being C14H15O3. A ChemSpider search of the formula 
yielded 1,351 results, with naproxen listed as the first match. The product ions for 
naproxen were ascertained as 185.0961, 170.0726, 153.0670, and 115.0542 from 
mzCloud. All of these ions were identified in the MS2 spectra at 9.71 min (Figure 3.9c). 
To confirm the retention time, an aqueous solution (1 mg/L) of a reference standard of 








Figure 3.9 – Analysis of an extract of Tablet 1 (see Figure 3.8) showing a) the TIC, 


















































3.3.2.2 Tablet 2 
The second tablet had lettering on it, and was identified as paracetamol through 
searching the TICTAC database (Figure 3.10). On analysis, the TIC had a large peak at 
3.57 min, with observed m/z 152.0703 (Figure 3.11). The theoretical m/z for 
paracetamol is 152.0706, giving a mass measurement error of -1.97 ppm. 
The dominant product ion for paracetamol is m/z 110.0600 (mzCloud). Other product 
ions include m/z 111.0441, 93.0335, and 65.0386. All product ions, with the exception 
of the 65.0386 ion, were detected in the MS2 spectrum at 3.57 min. The 65.0386 ion 
was not detected as the lower limit for the scan range is set at 70 m/z in the method 
(Section 2.2.4). 
 




Figure 3.11 – Analysis of an extract of Tablet 2 (see Figure 3.8) showing a) the TIC, 







3.3.2.3 Tablet 3 
Analysis of the third tablet produced a TIC with a large peak present at 1.68 min, with 
an observed m/z of 170.0808 (Figure 3.12). Potential molecular formulae were 
generated, with the best match being C8H12O3N. A ChemSpider search of the formula 
yielded 1,290 results with pyridoxine listed as the first match. Pyridoxine (Vitamin B6) 
is a common dietary supplement. The main product ions for pyridoxine were obtained 
from mzCloud as m/z 152.0706, 134.0600, and 124.0757, which were all present in the 
MS2 spectrum at 1.68 min (Figure 3.12c). 
Figure 3.12 – Analysis of an extract of Tablet 3 (see Figure 3.8) showing a) the TIC, 






3.3.2.4 Patient Urine Sample 
To assess whether the patient had taken paracetamol and/or naproxen, a urine sample 
from the time when she was admitted to hospital was analysed. Vitamin B6 is naturally 
present in the body from dietary sources, thus additional intake cannot be readily 
assessed. 
Only 2 % of a paracetamol dose is excreted as unchanged drug in urine, with the 
remainder excreted as conjugates; 45-55 % as a glucuronide, 20-30 % as a sulfate, and 
15-55 % as cysteine and mercapturic acid conjugates (Baselt, 2014). A small peak for 
paracetamol was detected in the urine sample, and peaks corresponding to the masses of 
the sulfate and glucuronide metabolites were also apparent (Figure 3.13). 
Naproxen is metabolised to O-desmethylnaproxen, with both compounds also 
undergoing glucuronidation. After a daily dose, approximately 10 % is excreted as 
unchanged drug, 60 % as naproxen glucuronide, 5 % as O-desmethylnaproxen, and 23 
% as O-desmethylnaproxen glucuronide (Baselt, 2014). Naproxen was not detected in 
the urine sample. Possible peaks corresponding to the glucuronide metabolites were 




Figure 3.13 – Extracted ion chromatograms for a) paracetamol (m/z 152.0706), b) 
paracetamol sulfate (m/z 232.0274), and c) paracetamol glucuronide (m/z 328.1027) 







Figure 3.14 – Extracted ion chromatograms for a) naproxen (m/z 231.1016), b) O-
desmethylnaproxen (m/z 217.0859), c) naproxen glucuronide (m/z 407.1337), and d) 




3.3.3 Possible use of a novel psychoactive drug 
A urine sample from a 47-year-old male with a history of paranoid schizophrenia, anti-
social personality disorder and polysubstance misuse (mainly stimulants) was submitted 
for screening. The individual was an inpatient at a psychiatric unit, but had unescorted 
leave for community outreach programmes. The clinician suspected he was obtaining 
and using a ‘novel stimulant’ whilst on leave, however the local biochemistry laboratory 
had reported negative results on their standard drug screen. At the time of sampling, the 
individual was prescribed olanzapine and venlafaxine.  
The TIC showed many chromatographic peaks in the sample extract when compared to 
the negative urine calibrator (Figure 3.15), with most eluting between 6.5-8.5 min. The 
mass spectra for this time period showed four main ions; m/z 220.1315, 248.1624, 
264.1936, and 278.2091 (Figure 3.16). These masses were extracted from the TIC to 
produce four separate XIC, which gave distinct chromatographic peaks (Figure 3.17). 
Knowing the individual was prescribed olanzapine and venlafaxine enabled expected 
masses to be screened for (Table 3.2). The two chromatographic peaks with m/z 
264.1952 were identified as N- and O-desmethylvenlafaxine, and the single peak with 
m/z 278.2091 as venlafaxine, all by comparison with reference standards. The peaks 
with m/z 220.1327 and 248.1640 were not accounted for by prescribed medication and 
thus potential chemical structures were calculated in Xcalibur and subsequently 
searched in ChemSpider to identify potential compounds. ChemSpider gave 15,198 
matches for C15H21NO2 and 9,696 matches for C13H17NO2. Recognisable drugs, with 
misuse potential, from these matches were further investigated (Table 3.3). 
Individual aqueous solutions (1 mg/L) of reference standards for pethidine, 
methoxetamine and ritalinic acid (Sigma Aldrich) were analysed to ascertain the 
retention time for each compound. Neither pethidine, nor methoxetamine co-eluted with 
the peak observed for m/z 248.1641 (Figure 3.18) eliminating these drug from the 
investigation. The retention time for ritalinic acid matched the retention of the unknown 
compound of m/z 220.1329, and was further confirmed through identification of the 
product ion m/z 84.0808. Ethylphenidate was also confirmed in the sample through 
comparison with a reference standard (obtained from TICTAC Communications Ltd) 
for retention time and MS2 product ions (Figures 3.19 and 3.20). Methylphenidate 
(Ritalin) was not detected in the sample, and thus was unlikely to have been the drug 
taken. Internet searches revealed that ethylphenidate is sold as a drug in its own right, 











































































Figure 3.17 – Extracted ion chromatograms of the urine sample for the dominant 
precursor ions (see Figure 3.16): a) m/z 220.1327, b) m/z 248.1640, c) m/z 264.1952, 













Table 3.2 – Expected m/z from venlafaxine, olanzapine and some urinary 
metabolites 
Drug/metabolite Expected m/z 
Venlafaxine 








































Table 3.3 – Potential compounds identified from ChemSpider searches which may 



















































Figure 3.18 – Extracted ion chromatograms (m/z 248.1641) for a) the patient urine 













Figure 3.19 – Comparison of MS2 spectra at 8.10 min for ethylphenidate and at 





































































































































                                                           
b) 










Figure 3.20 – Comparison of XIC for ethylphenidate (m/z 248.1641), methylphenidate (m/z 234.1489), and ritalinic acid (m/z 220.1332) in a) the 




3.3.4 Sedation of a young child 
A 7-year-old child presented to an accident and emergency department floppy and 
unresponsive. He was stabilised and monitored, and his condition improved. His 
condition was noted to worsen again after his parents visited. At this time a packet of 
diazepam was found near the child’s bed. Ward clinicians suspected that the child was 
being given the diazepam, which would account for his sedated state. However, 
immunoassay screening results done at a local biochemistry laboratory were negative 
for benzodiazepines. The sample was referred for analysis by LC-HRMS, but neither 
diazepam nor its metabolites were detected in the urine sample (Figure 3.21). 
To ascertain if other compounds were present in the urine sample, the TIC for the 
sample was compared against that of the negative calibrator. This revealed peaks 
present in the urine sample between 5.3-5.7 min (Figure 3.22). The observed m/z from 
this time period showed the dominant ion to be m/z 405.1072 (Figure 3.23a). From 
studying the mass spectra, a chlorine atom was identified in the compound (presence of 
the M+2 peak; Figure 3.23b). 
Potential molecular formulae were generated using Xcalibur (Table 3.4); from these one 
formula contained a single chlorine atom and showed the smallest deviation in mass to 
the observed m/z. ChemSpider search results for “C17H17O4N6Cl” gave 39 possible 
compounds. One of the compounds identified was zopiclone N-oxide.  
Zopiclone is a ‘Z-drug’ that has similar pharmacological properties to benzodiazepines, 
thus ingestion of this drug was compatible with the clinical picture. In cases of 
overdose, an individual may present with excessive sedation and depressed respiration 
(Boniface and Russell, 1996). Zopiclone is extensively metabolised; the principal 
metabolites are N-desmethylzopiclone and zopiclone N-oxide (Figure 3.24). A single 
oral dose  is excreted in the 24 h urine as parent drug (4.5 %), zopiclone N-oxide (11 
%), and N-desmethylzopiclone (15 %) (Baselt, 2014). 
The full scan data were filtered for zopiclone and both metabolites, with the retention 
time for zopiclone confirmed through comparison with an aqueous solution (1 mg/L) of 
reference standard (Sigma Aldrich) (Figure 3.25). Product ions for zopiclone were 
identified as 263.0330, 245.0225, 217.0276, and 130.0052 from mzCloud, and were all 










Figure 3.21 – Comparison of XIC filtered for diazepam and selected metabolites in a) the urine sample, and b) reference solutions (see Section 
3.3.4) 
a)                                                                                                       b) 













































































Figure 3.23 – Mass spectra from 5.3-5.7 min showing a) scan range m/z 100-750, 


























































Table 3.4 – Top 5 elemental composition suggestions based on the observed m/z 
389.1123 from Xcalibur software 
 Molecular formula Mass difference (mmu) 
1 C17H18O4N6Cl -0.03 
2 C6H17O11N10 -0.05 
3 C20H15O5N5 0.46 
4 C14H21O3N7Cl2 -0.51 
5 C15H27O8Cl2 -0.52 
 
 




















































 Figure 3.25 – Confirmation of zopiclone by a) retention time, b) product ions, c) 










































Zopiclone reference standard 

















b) MS2 spectrum at 5.14 min 
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Figure 3.25 (cont.) – Confirmation of zopiclone by a) retention time, b) product 































































LC-HRMS is a powerful analytical tool for aiding compound identification either in 
solid form, or present within a biological sample. However it is important to note that 
even high mass accuracy (<1 ppm) alone is not enough to exclude all potential 
candidate compounds. For definitive identification a reference standard of the 
compound is required to enable direct comparison of spectra and retention time. In some 
cases it may not be possible to identify compounds present in a substance, and some 
substances may not be soluble in methanol or may be at too low concentration to enable 
detection.  
Screening for unknown compounds using LC-HRMS remains a largely manual process. 
It is therefore important to glean as much background information on the substance and 
patient history (including prescribed medications) from clinicians or others. Useful 
information may include clinical features, the origin of any substance they have taken 
(e.g. bought on a website), product name, and product claims (e.g. sexual performance, 
weight-loss aid). By gaining this information, initial investigations can be targeted 
towards potential drugs/drug classes. 
3.4.1 Further work 
Continual work in building up an ‘in-house’ database is required to aid compound 
identification. This task is on-going as drugs, particularly NPS, which are available on 
the street are constantly changing. Compilation of a laboratory and method specific 
database of pure reference compounds is of benefit to unknown screening using LC-
HRMS, and may enable faster identification of an unknown compound. The database 
should include as many confirmation criteria as possible. Inclusion of retention time 
data (specific to a laboratory’s method) is crucial to enable compound identification, 
and may enable differentiation of isobaric compounds.  
As demonstrated, manual interrogation for unknown substances is a complex process 
which can be time-consuming and is dependent on the analyst’s level of expertise. For 
unknown screening to become more commonplace in a clinical laboratory significant 
improvement in data processing software is required. As software is developed by 
instrument manufacturers, it will be important to test whether it is suitable for purpose 









4 Incorporation of new analytes into an existing LC-HRMS method: 
Achiral analysis of methylphenidate, ethylphenidate, and ritalinic 



















Methylphenidate is a psychostimulant prescribed as first-line treatment in Attention 
Deficit Hyperactivity Disorder (ADHD) (Seixas et al., 2012). Methylphenidate 
hydrochloride is supplied as a racemic mixture, but its therapeutic effects are mainly 
due to the R,R- isomer (Heal and Pierce, 2006; Kimko et al., 1999). Methylphenidate 
acts by blocking dopamine and noradrenaline transporters through allosteric binding, 
and thus inhibits catecholamine reuptake and increases catecholamine availability in the 
synaptic cleft in cortical and subcortical regions (Arnsten and Pliszka, 2011; Kuczenski 
and Segal, 2002; Seu et al., 2009). 
Methylphenidate is prescribed for oral use and is available in immediate (e.g. Ritalin, 
Novartis) or prolonged-release (e.g. Concerta XL, Janssen-Cilag) formulations. 
However, different routes of administration, such as insufflation or intravenous 
injection, may be used to increase bioavailability when methylphenidate is abused for 
its stimulant properties. After oral administration, methylphenidate is rapidly and 
completely absorbed, but is hydrolysed quickly to an inactive metabolite, ritalinic acid 
(Figure 4.1). Less than 1 % of an oral dose of methylphenidate is excreted unchanged in 
urine, whilst 80 % is excreted as ritalinic acid (Baselt, 2014). The peak duration of 
action is around 2-4 h for immediate release, and 3-8 h for sustained release 
formulations. When methylphenidate is taken concurrently with ethanol, S,S-
ethylphenidate may be formed by enantioselective transesterification (Dinis-Oliveira, 
2017; Patrick et al., 2013). More recently, ethylphenidate has been marketed as a ‘legal 
high’ (Ho et al., 2015; Krueger et al., 2014). Ethylphenidate is also metabolised to 
ritalinic acid. Details of six other phenidate analogues marketed as ‘legal highs’ have 
been published (Klare et al., 2017; Markowitz et al., 2013). Of these, the alkyl analogue 
isopropylphenidate, and possibly also N-benzyl-ethylphenidate, would be likely to give 
rise to ritalinic acid in vivo. 
Marked inter-individual variability in methylphenidate dose-response is recognised, and 
thus the dose is titrated to gain optimal effect and minimise the risk of toxic effects such 
as hypertension (Castells et al., 2011; Faraone et al., 2004; Scharman et al., 2007). 
Adherence to treatment is also an important factor that may influence outcome (Retz et 
al., 2012), and therapeutic drug monitoring would be of particular relevance given the 
serious consequences of inadequate treatment (Kessler et al., 2006; Pitts et al., 2015). 
Although metabolism is enantioselective after oral dosage, the plasma concentrations of 
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R,R-methylphenidate being higher than those of S,S-methylphenidate, the plasma half-
life of total methylphenidate is very short (1-4 h) and degradation to ritalinic acid 
continues in plasma in vitro, limiting the value of plasma methylphenidate assay. 
However, methylphenidate and ritalinic acid are stable in urine for at least 6 months 
when stored at -20 oC (Paterson et al., 2012). No formal stability studies have been 
conducted for ethylphenidate in urine, but it would be expected to behave in a similar 
manner to methylphenidate.  
Figure 4.1 – Metabolic pathways of methylphenidate and ethylphenidate 













This chapter aims to explore one of the benefits of LC-HRMS, i.e. rapid incorporation 
of new analytes into existing analytical methods. Three analytes (methylphenidate, 
ethylphenidate and ritalinic acid) will be added to the LC-HRMS method for drug 
detection in urine (Chapter 2). Measurement of methylphenidate and metabolites may 
aid clinicians to monitor adherence to methylphenidate treatment and also to detect 
illicit use of either methylphenidate, or ethylphenidate. In order to explore the utility of 
the assay for assessing patient adherence, methylphenidate, ethylphenidate and ritalinic 
acid will be measured in urine samples from a small cohort of adult ADHD patients. 
Whether ingestion of ethylphenidate can be differentiated from concurrent use of 


























4.2 Materials and Methods 
4.2.1 Chemicals and Reagents 
Methanolic solutions of racemic methylphenidate, ethylphenidate, methylphenidate-D9 
and ritalinic acid-D10, and solid ritalinic acid (racemic mixture) were from Sigma 
Aldrich (Poole, UK). Screw-cap polypropylene tubes (2 mL) were from Alpha 
Laboratories (Eastleigh, UK). For all other chemicals and reagents see Section 2.2.1.  
4.2.2 Instrumentation  
All instrumentation is detailed in Section 2.2.2.  
4.2.3 Preparation of Calibration and Internal Quality Control Solutions  
Individual stock solutions of methylphenidate and ethylphenidate (1000 mg/L) were 
used as supplied, and a stock solution of ritalinic acid (100 mg/L) was prepared in 
methanol. Stock solutions were diluted as appropriate with methanol to give a working 
solution (10 mg/L each methylphenidate, ethylphenidate and ritalinic acid). All 
solutions were stored at -20 °C when not in use. Appropriate volumes of either the 
working solution or stock solutions were evaporated to dryness and reconstituted with 
analyte-free human urine to prepare the calibrators (0.05, 0.50, 5.00 mg/L) and IQC 
solutions (0.10, 0.25, 0.75 and 2.50 mg/L). Calibrator and IQC solutions were stored in 
approximately 500 µL portions in 2 mL screw-cap polypropylene tubes at -20 °C until 
needed.  
4.2.4 Internal Standard Solution  
A working IS solution containing methylphenidate-D9 and ritalinic acid-D10 (both 0.05 
mg/L) was prepared by appropriate dilution of individual stock solutions (both 100 
mg/L) with eluent A (see Section 2.2.3). 
4.2.5 Sample Preparation 
Centrifuged urine samples/calibrators/IQCs (50 µL) were diluted with 450 µL working 
IS solution using an automated Hamilton dilutor directly into HPLC vials. The vials 
were capped and transferred to a pre-cooled (10 oC) autosampler tray. 
4.2.6 Liquid Chromatography and Mass Spectrometry 
The LC and MS method settings were identical to those used for the LC-HRMS method 
described in Chapter 2 (Sections 2.2.3 and 2.2.4).  
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4.2.7 Assay Calibration and Acceptance Criteria 
Calibration standards (N = 3) and a matrix blank (analyte-free urine) were included at 
the beginning and end of each batch analysis, with IQCs included after the first set of 
calibrators and immediately before the last set of calibrators. Alternating IQC solutions 
were analysed after every 10 patient samples throughout the batch. Assay acceptance 
criteria were (i) linear (R2 >0.98) calibration curves for each analyte, and (ii) at least 67 
% (4 out of 6) of IQC samples within 20 % of their respective nominal value.  
Peak area ratios (methylphenidate and ethylphenidate to methylphenidate-D9; ritalinic 
acid to ritalinic acid-D10) obtained on analysis of the calibration standards were plotted 
against concentration to construct calibration graphs. Linear regression intercepts were 
not forced through zero, and no line weighting was applied. Samples with analyte 
concentration >10 mg/L were diluted with analyte-free urine to within the calibration 
range and re-analysed. 
4.2.8 Method Validation Protocol 
Intra- and inter-assay accuracy (% nominal concentration) and precision (% RSD) was 
assessed for each analyte through replicate analysis of IQC solutions (N = 5) on the 
same day, and singleton analysis on 5 different days, respectively. The LoD was 
ascertained through successive serial dilution (1+1, v/v with analyte-free urine) of the 
low calibrator solution (0.05 mg/L) and was based upon the concentration at which the 
signal-to-noise ratio was >3, and the % RSD <20 (N = 5). The LLoQ was ascertained 
through assessing accuracy and precision of the low calibrator solution (0.05 mg/L). 
Linearity was assessed by replicate analysis (N = 6) of each calibrator, and was based 
upon accuracy within 80-120 % of the recalculated concentration. To assess whether 
sample dilution to within the calibration range was suitable, a 10 mg/L solution 
(containing all analytes) was diluted using analyte-free urine to within the calibration 
range, and was based upon accuracy within 80-120 % and the % RSD <20 (N = 3). To 
investigate matrix effects, solutions containing all analytes and internal standards were 
prepared in (i) deionised water, and (ii) analyte-free human urine from 10 independent 
sources. Prepared solutions were diluted (1+9, v/v) with eluent A and analysed in 
duplicate. The ratio of the peak area for each analyte to that of the relevant internal 
standard in analyte-free human urine samples was compared to that in deionised water. 
Carryover was assessed through consecutive analysis of a urine sample containing low 
(L) and high (H) analyte concentrations in the order L,L,L,H,H,H,L,L,L (L: all analytes 
0.05 mg/L, H: all analytes 10 mg/L). Finally, a urine sample from a 47-year-old male 
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suspected of ingesting ethylphenidate submitted for screening for the presence of drugs 
of abuse by LC-HRMS (Section 3.3.3) was analysed to assess the capability of the 
method in distinguishing use of ethylphenidate from use of methylphenidate. 
4.2.9 Patient Samples 
Anonymised random urine samples were collected into sterile plastic containers from 27 
adult male patients, who were diagnosed with ADHD according to the Diagnostic and 
Statistical Manual of mental disorders, and prescribed Concerta XL [N = 26, mean 
(range) daily dose 54 (18-90) mg/d] or Ritalin [N = 1, daily dose 20 mg]. Samples were 
stored at -20 oC for no longer than 6 months from the collection date prior to analysis. 
Patient age, body weight and current methylphenidate dose were recorded at the time of 
sample collection. Sample collection occurred about two months after treatment 
initiation for each patient, i.e. after dose titration. Patients were asked to consent to urine 
sampling without prior warning. Ethics approval for the study was granted to the NIHR 
Maudsley Biomedical Research Centre (Brain Connectivity in ADHD: a biomarker to 
predict treatment response; REC number 12/LO/0630).  
On the day of sample collection, clinical response to stimulants was measured through 
the Global Clinical Impression Scale-Improvement (Busner and Targum, 2007; Guy, 
1976) by a clinician blind to the assay results. The scale ranges from 1 (very much 
improved as compared to baseline) to 7 (very much worsened). The results were used to 
classify patients as ‘responders’ (≤ 2), ‘mild responders’ (3) and ‘non-responders’ (≥ 4). 
One-way ANOVA was used to measure group differences in creatinine-corrected 
concentration of (i) methylphenidate, (ii) ritalinic acid, and (iii) methylphenidate plus 
ritalinic acid. All samples were also screened for other stimulants (amfetamine, 
metamfetamine, MDMA, mephedrone, cocaine) using LC-HRMS (Chapter 2). 
To enable summation of methylphenidate and ritalinic acid concentration, all patient 
results were converted to molar units (methylphenidate (µmol/L) = methylphenidate 
(µg/L)/233.32; ethylphenidate (µmol/L) = ethylphenidate (µg/L)/247.33; ritalinic acid 
(µmol/L) = ritalinic acid (µg/L)/219.28). Creatinine-corrected analyte concentration 
(µmol/mmol) was calculated by dividing the analyte concentration (µmol/L) by 
creatinine concentration (mmol/L).  
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4.3 Results and Discussion 
4.3.1 LC-HRMS Method Validation 
Intra- and inter-assay accuracy and precision are summarised in Table 4.1. The LoD 
was 0.002 mg/L and the LLoQ was 0.05 mg/L for all analytes. Typical chromatograms 
are shown in Figure 4.2. Typical mass accuracy was <1 ppm for all analytes (Table 4.2). 
No significant ion suppression or enhancement was observed, and the internal standards 
compensated well for matrix effects (Table 4.3). The mean linear regression coefficients 
(N = 6) obtained for methylphenidate, ethylphenidate, and ritalinic acid were 0.9999, 
0.9993, and 0.9997, respectively. Recalculation of the calibrators demonstrated assay 
linearity with accuracy between 95-120 % (Table 4.4), and the assay was linear to at 
least 10 mg/L for all analytes (Figure 4.3). No significant carryover was observed at the 
concentrations studied (<1 % all analytes).  
 
Table 4.1 – Methylphenidate, ethylphenidate, and ritalinic acid assay: Summary 




Methylphenidate Ethylphenidate Ritalinic acid 








0.10 0.25 0.74 2.41 0.09 0.25 0.78 2.41 0.11 0.24 0.77 2.55 
% RSD 0.9 1.7 1.4 0.8 2.0 2.3 2.1 0.8 2.0 2.0 2.9 0.5 
Accuracy  
(% nominal) 99 99 99 96 89 101 103 97 107 97 102 102 








0.10 0.24 0.72 2.71 0.10 0.26 0.76 2.62 0.10 0.26 0.75 2.40 
% RSD 14.0 10.8 7.7 7.8 12.3 6.3 7.9 5.3 19.6 5.5 7.4 4.2 
Accuracy  










Figure 4.2 – Methylphenidate, ethylphenidate, and ritalinic acid assay: Typical extracted ion chromatograms showing all analytes ([M+H]+ 













































Table 4.3 – Methylphenidate, ethylphenidate, and ritalinic acid assay: Summary 
matrix effects data 
Solutions containing all analytes and internal standards were prepared in (i) deionised 
water, and (ii) analyte-free human urine from 10 independent sources. Prepared 
solutions were diluted (1+9, v/v) with eluent A and analysed in duplicate. The ratio of 
the peak area for each analyte to that of the relevant internal standard in analyte-free 
human urine samples was compared to that in deionised water. 
Analyte Mean Matrix Effect  (%) 
Relative matrix effect  
(%) 
Methylphenidate-D9 64 - 
Methylphenidate 65 101 
Ethylphenidate 65 101 
Ritalinic acid-D10 129 - 




Table 4.4 – Methylphenidate, ethylphenidate, and ritalinic acid assay: Summary 
linearity data 
Analyte 







Methylphenidate 110 (109-112) 101 (100-102) 100 (99-102) 
Ethylphenidate 119 (116-120) 103 (100-105) 99 (96-101) 
Ritalinic acid 104 (102-105) 96 (95-99) 100 (98-102) 
 
 
Figure 4.3 – Methylphenidate, ethylphenidate, and ritalinic acid assay: Linearity of 








4.3.2 Patient Results 
The patient sample results are summarised in Table 4.5. Methylphenidate and ritalinic 
acid were detected in 18 and 24 samples, respectively. Ethylphenidate was detected in 
one sample (0.27 µmol/L) in addition to methylphenidate and ritalinic acid (6.20 and 
95.7 µmol/L, respectively). No other stimulants were detected in any samples. Response 
to methylphenidate ranged from 1 to 4 (14 responders, 9 mild responders, 4 non-
responders). Three samples had no methylphenidate, or ritalinic acid, detected. Two of 
these patients were classified as responders and one as a mild responder (Table 4.6).  
Table 4.5 – Methylphenidate, ethylphenidate, and ritalinic acid assay: Summary 
patient data 
MPH = methylphenidate, RA = ritalinic acid 
  N Mean SD  Median Minimum Maximum 
Age (y) 27 29 8 30 20 45 
Daily dose (mg) 27 49 14 54 36 90 
Body weight (kg) 27 81 12 80 54 102 
Daily dose (mg/kg) 27 0.62 0.17 0.64 0.43 1 
Urine creatinine 
(mmol/L) 27 15.4 9.3 13.2 1.4 40.5 
Urine MPH (µmol/L) 18 2.50 2.55 1.69 0.27 10.5 
Urine RA (µmol/L) 24 82.0 65.0 78.2 20.5 266 
Urine MPH:RA ratio 18 0.029 0.018 0.033 0.003 0.069 
Urine MPH + RA 
(µmol/L) 24 83.9 66.8 68.1 20.5 277 
The creatinine-corrected urine methylphenidate, ritalinic acid and methylphenidate plus 
ritalinic acid concentrations compared to the clinical response achieved over the 
duration of methylphenidate therapy are summarised in Figure 4.4. There was no 
significant difference between the 3 response groups in the creatinine-corrected ritalinic 
acid concentration (F(2,21) = 0.70 p = 0.51) or creatinine-corrected methylphenidate 
plus ritalinic acid concentration (F(2,21) = 0.81 p = 0.46). However, the creatinine-
corrected methylphenidate concentration was significantly different between the 3 
groups (F(2,16) = 37.53, p <0.001) with the median creatinine-corrected 
methylphenidate concentration being much higher in non-responders (clinical response 
4) as compared to responders (clinical response 2/3). It should be noted that the trial 
participants had no prior warning of the request to provide a urine specimen, hence it 
might have been thought that ‘topping up’ with drug prior to the clinic visit to ensure 
detection in urine could be excluded, but this does seem nevertheless to be the most 










Table 4.6 – Methylphenidate, ethylphenidate, and ritalinic acid assay: Patient results 
MPH = methylphenidate, ETH = ethylphenidate, RA = ritalinic acid 



















(µmol/mmol) MPH + RA (µmol/L) 
Creatinine-corrected 
MPH + RA  
(µmol/mmol 
creatinine) MPH ETH RA MPH ETH RA 
1 29 54 3 - 10.9 0.53 <0.20 89.1 0.05 - 8.17 89.6 8.22 
2 38 54 4 - 12.3 6.20 0.27 95.7 0.50 0.02 7.78 101.9 8.29 
3 45 54 2 2 11.6 0.46 <0.20 65.0 0.04 - 5.60 65.5 5.64 
4 20 36 2 3 19.7 <0.21 <0.20 <0.23 - - - - - 
5 29 18 3 5 13.2 <0.21 <0.20 <0.23 - - - - - 
6 26 54 4 2 9.5 <0.21 <0.20 47.8 - - 5.03 47.8 5.03 
7* 22 20 3 3 1.4 <0.21 <0.20 31.3 - - 22.36 31.3 22.4 
8 18 54 2 3 3.8 <0.21 <0.20 35.6 - - 9.36 35.6 9.36 
9 32 54 2 3 10.8 <0.21 <0.20 <0.23 - - - - - 
10 20 36 3 3 23 2.13 <0.20 77.6 0.09 - 3.37 79.8 3.47 
11 22 36 2 3 12.2 1.00 <0.20 29.4 0.08 - 2.41 30.4 2.49 
12 33 54 2 2 22.1 1.57 <0.20 148.8 0.07 - 6.73 150.4 6.81 
13 34 54 2 2 14 <0.21 <0.20 70.8 - - 5.06 70.8 5.06 
14 20 36 2 2 21.1 1.26 <0.20 93.3 0.06 - 4.42 94.6 4.48 
15 21 90 3 3 16.7 1.26 <0.20 32.0 0.08 - 1.91 33.2 1.99 










Table 4.6 (cont.) – Methylphenidate, ethylphenidate, and ritalinic acid assay: Patient results 




















MPH + RA 
(µmol/L) 
Creatinine-corrected 
MPH + RA  
(µmol/mmol 
creatinine) 
17 40 36 2 - 9.4 0.40 <0.20 32.6 0.04 - 3.47 33.0 3.51 
18 24 54 4 3 6.1 1.71 <0.21 41.0 0.28 - 6.71 42.7 6.99 
19 21 54 3 2 10 1.67 <0.21 40.7 0.17 - 4.07 42.4 4.24 
20 34 36 2 3 16.9 2.80 <0.21 80.3 0.17 - 4.75 83.1 4.92 
21 34 54 2 3 19.9 3.09 <0.21 78.7 0.16 - 3.96 81.8 4.11 
22 22 54 3 2 40.5 4.80 <0.21 229.7 0.12 - 5.67 234.5 5.79 
23 35 72 3 3 32.6 3.37 <0.21 189.7 0.10 - 5.82 193.0 5.92 
24 29 54 4 - 29.1 10.5 <0.21 266.1 0.36 - 9.15 276.7 9.51 
25 42 54 2 2 3.6 <0.21 <0.21 36.5 - - 10.14 36.5 10.1 
26 29 54 4 3 4.5 1.83 <0.21 44.5 0.41 - 9.89 46.3 10.3 














Figure 4.4 – Box and whisker plots (median, 25th-75th percentiles, whiskers 10th and 90th percentiles) to show the measured urinary 
concentration of a) methylphenidate (µmol/mmol creatinine), b) ritalinic acid (µmol/mmol creatinine), and c) methylphenidate + ritalinic acid 




The presence of ethylphenidate in the urine of one patient may be a result of direct 
ethylphenidate ingestion, or as a result of co-ingestion of methylphenidate with ethanol. 
Ethylphenidate formation has been reported in vitro using a rat liver preparation 
incubated with methylphenidate and ethanol (Bourland et al., 1997). This 
biotransformation appears to be a carboxylesterase-dependent transesterification 
process, and may be analogous to that involved in the formation of cocaethylene 
(benzoylecgonine ethyl ester) by human hepatic esterase(s) after concomitant cocaine 
and ethanol use (Boyer and Petersen, 1992). The presence of ethylphenidate in addition 
to methylphenidate in urine can function as a marker for clinical or forensic evidence of 
concomitant methylphenidate-ethanol exposure (Patrick et al., 2014). 
4.3.3 Differentiating Ethylphenidate and Methylphenidate Administration 
As regards distinguishing ethylphenidate from methylphenidate ingestion, 
methylphenidate is not a metabolite of ethylphenidate and thus should not be present in 
urine after use of ethylphenidate. Analysis of the urine sample from an individual 
suspected of taking ethylphenidate contained 10.3 µmol/L ethylphenidate and 108 
µmol/L ritalinic acid (methylphenidate not detected). No other drugs of abuse were 
detected. The high ethylphenidate concentration combined with the absence of 
methylphenidate is strongly suggestive that ethylphenidate, and not methylphenidate in 
conjunction with ethanol, had been ingested. The mean proportions of methylphenidate, 
ethylphenidate, and ritalinic acid excreted in urine (0-6 h post dose) after administration 
of 20 mg methylphenidate with ethanol (0.6 g/kg consumed 30 min after 
methylphenidate) were calculated as 1.4 ±0.8, 0.02 ±0.1, and 19.9 ±10.8 % of the 
methylphenidate dose respectively (Markowitz et al., 2000). This study concluded that 
the low concentration of ethylphenidate detected indicates that a single clinically 
relevant dose of methylphenidate in combination with moderate intake of ethanol is 
unlikely to result in substantial generation of ethylphenidate, as with the patient in this 
study. However, if only ritalinic acid is detected in urine distinguishing between use of 
methylphenidate, ethylphenidate, or other phenidate analogues is not possible on the 





4.4 Conclusions  
One of the key advantages of HRMS is the flexibility to add drugs and/or their 
metabolites quickly to an existing method. Through keeping sample preparation as non-
selective as possible (i.e. dilution) followed by collection of full scan MS data, addition 
of analytes is facilitated by simply adding their accurate molecular masses into 
processing software, provided the analyte is retained on the LC column and calibrators 
can be prepared. The incorporation of new analytes into the method is therefore without 
detriment to the original panel of analytes as no changes have been made to the analysis, 
only to data processing. 
Urinary methylphenidate, ethylphenidate, and/or ritalinic acid analysis can help identify 
non-adherence to methylphenidate in the clinical setting, and also detect illicit use of 
methylphenidate and ethylphenidate. Ingestion of ethylphenidate results in a high 
urinary ethylphenidate concentration and the absence of methylphenidate, and can be 
differentiated from ethylphenidate arising from methylphenidate ingestion in 
conjunction with ethanol. 
4.4.1 Further Work 
The method could be expanded to include other phenidate analogues that are marketed 
as NPS (e.g. isopropylphenidate). However, the use and availability of ethylphenidate 
appear to have declined over recent years and this may mean that other phenidate 




























5.1.1 Mephedrone  
Mephedrone (4-methylmethcathinone, 4-MMC) is a β-ketoamfetamine that has 
stimulant properties similar to those of other amfetamines (e.g. amfetamine, 
metamfetamine, MDMA), as well as causing hallucinations and other psychotropic 
effects (Busardò et al., 2015). Mephedrone contains a chiral centre and thus exists as S- 
and R-mephedrone. Both enantiomers have similar potency at dopamine transporters, 
but different potency at serotonin transporters with R-mephedrone lacking serotonergic 
actions (Gregg et al., 2015). The clinical features of mephedrone intoxication are 
consistent with an acute sympathomimetic toxidrome, i.e. tachycardia, hypertension, 
and agitation (Adamowicz et al., 2013; Cosbey et al., 2013; Dickson et al., 2010; 
Gerace et al., 2014; Lusthof et al., 2011; Wood et al., 2010a, 2010b). Mephedrone is 
available in either tablet or powder form, with the predominant routes of use through 
either nasal insufflation, or ingestion (Dargan et al., 2010; Winstock et al., 2011). 
Injection of mephedrone has also been reported (Hope et al., 2016; Péterfi et al., 2014). 
In 2010, mephedrone was scheduled as a Class B substance under the MDA within the 
UK, and by the end of 2010 mephedrone had been controlled across much of Europe 
(Kelly, 2011). Since 2010, mephedrone use has persisted, in particular amongst 16-24 
year olds, though such use has been declining (falling from 4.4 to 0.9 % among 16-24 
year olds from 2010 to 2016; Home Office, 2013-2016). The use of mephedrone is 
reported to be more common in males than females (Vardakou et al., 2011). 
5.1.2 Mephedrone Metabolism 
There is limited information regarding the pharmacokinetics of mephedrone, although 
metabolism has been extensively studied in rat hepatocytes (Khreit et al., 2013), and in 
human liver microsomes (Pedersen et al., 2013), as well as in vivo in rats (Meyer et al., 
2010) and humans (Pozo et al., 2015). CYP2D6 has been identified as the main enzyme 
responsible for the phase I in vitro metabolism of mephedrone (Pedersen et al., 2013). 
Mephedrone may be metabolised to N-desmethylmephedrone (normephedrone), β-
hydroxynormephedrone (4-methylnorephedrine), 4-hydroxymethylmephedrone, and 4-
hydroxymethylnormephedrone, with further conjugation of the hydroxylated 
metabolites (Meyer et al., 2010, Figure 5.1). Large inter-subject variability in 
metabolism has been reported, which may be due to either genetic variation in CYP2D6 










Figure 5.1 – Proposed metabolic pathway of mephedrone in humans, Meyer et al. (2010)  




















































5.1.3 Reported Mephedrone Concentrations in Biological Matrices 
The mean (range) post-mortem whole blood mephedrone concentration in 10 adults 
who died of acute mephedrone overdose was 4.5 (0.5-22) mg/L (Adamowicz et al., 
2013; Aromatario et al., 2012; Cosbey et al., 2013; Maskell et al., 2011a; Rojek et al., 
2014; Torrance and Cooper, 2010). The mean (range) blood mephedrone concentration 
detected in 32 impaired driving cases (mephedrone was the only drug detected in 9 
cases) was 0.21 (0.01-0.74) mg/L (Cosbey et al., 2013).   
Concheiro et al. (2015) screened urine samples from stimulant users for NPS and 
reported mephedrone, normephedrone, and 4-methylephedrine concentrations ranging 
from 0.012-3.60 mg/L (N = 11), 0.004-8.79 mg/L (N = 12), and 0.011-0.33 mg/L (N = 
6), respectively. Single case reports measured urinary mephedrone concentrations of 16 
mg/L in a known drug user (Hong et al., 2016), and 198 mg/L post-mortem from a case 
of accidental death attributed to multiple-drug toxicity of mephedrone and heroin 
(Dickson et al., 2010). Mephedrone has been shown to be stable in plasma and urine 
stored at -20 oC for at least 6 months (Olesti et al., 2017). 
5.1.4 Retrospective Data Interrogation  
The ability to reprocess data acquired during routine drugs of abuse screening to search 
for compounds that were not targeted initially can help improve knowledge of the 
metabolism of novel compounds. Analytes may also be quantified retrospectively 
through subsequent analysis of calibrator solutions containing the same internal 
standard (at the same concentration) added at the time of original analysis. The internal 
standard should largely account for any difference in instrument response between the 
initial analysis data and the later analysis of the calibration solutions.  
5.1.5 Aims 
This chapter aims to investigate another advantage of LC-HRMS, the ability to perform 
retrospective data interrogation. Recently, reference standards for some metabolites of 
mephedrone have become available commercially. Given the limited data on 
mephedrone and mephedrone metabolite urinary concentrations, data resulting from 
routine drug screening analyses where mephedrone was detected will be retrospectively 
analysed. In addition, the cross-reactivity of mephedrone and selected metabolites will 
be ascertained using a commercially available amfetamine-group immunoassay to 
assess the suitability of the assay for detecting the use of mephedrone.  
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5.2 Materials and Methods 
5.2.1 Chemicals and Reagents 
Mephedrone hydrochloride, buphedrone hydrochloride, and methcathinone 
hydrochloride were supplied as methanolic solutions (all 1 mg/mL free base) from 
Cerilliant (Sigma, Poole, UK). Normephedrone hydrochloride, 4-methylephedrine 
hydrochloride, and 4-methylpseudoephedrine hydrochloride were supplied as powders 
from Cayman Chemicals (Michigan, USA). Hydrochloric acid was from Sigma-Aldrich 
(Poole, UK). For all other chemicals and reagents see Section 2.2.1. 
5.2.2 Instrumentation  
All instrumentation is detailed in Section 2.2.2.  
5.2.3 Preparation of Calibration and Internal Quality Control Solutions  
Normephedrone, 4-methylephedrine, and 4-methylpseudoephedrine calibration and IQC 
stock solutions (1,000 mg/L free base) were prepared separately in aqueous 
hydrochloric acid (0.1 mol/L). Mephedrone (1,000 mg/L in methanol) was used as 
supplied. Separate calibration and IQC working solutions (5 mg/L, all analytes) were 
prepared by appropriate dilution of stock and reference solutions in volumetric 
glassware with aqueous hydrochloric acid (0.1 mol/L). 
Calibrators (0.01-1.0 mg/L, all analytes) and IQC solutions (0.02 and 0.25 mg/L, all 
analytes) were prepared by dilution of the stock or working solutions with analyte-free 
human urine. After thorough mixing and standing overnight (2-8 ºC), 1 mL portions of 
all solutions were transferred to 2 mL screw-cap polypropylene tubes, which were then 
capped and stored at -20 ºC until required.  
5.2.4 Internal Standard Solution  
IS solution was prepared as described in Section 2.2.7, and used for analysis of the 
mephedrone calibrators, IQC solutions, and re-analysis of patient samples. 
Mephedrone-D3 was not included in the IS solution at the time of the original sample 
analysis, so codeine-D6 was selected for the retrospective analysis. 
5.2.5 Sample Preparation 
Samples were prepared as described in Section 2.2.9.  
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5.2.6 LC-HRMS Method 
The LC-HRMS method (Chapter 2) was used for the original analysis of patient 
samples, and for subsequent analysis of samples, calibrator and IQC solutions.  
To ascertain the suitability of the method for the detection of urinary mephedrone 
metabolites, a brief validation study was conducted. Intra- and inter-assay accuracy and 
precision were measured by replicate analysis (N = 5) of the IQC solutions on the same 
day and by singlicate analysis on different days (N = 3), respectively. The LoD was 
ascertained through analysis of the low calibrator and was based upon a signal-to-noise 
ratio >3, and the RSD <20 % (N = 5). To investigate matrix effects, solutions containing 
all analytes at 0.2 mg/L were prepared in (i) analyte-free human urine from 10 
independent sources, and (ii) eluent A. Prepared solutions were diluted (1+9, v/v) with 
eluent A and analysed. The ratio of the peak area of each analyte to that of codeine-D6 
and mephedrone-D3 was compared for each analyte in the presence and absence of 
matrix. To investigate isobaric interferences, aqueous solutions of buphedrone and 
methcathinone (both 1 mg/L free base) were analysed to ascertain retention times and 
confirm the MS2 product ions.  
5.2.7 Assay Calibration and Acceptance Criteria 
5.2.7.1 LC-HRMS 
Calibration standards (N = 4), IQC solutions (N = 2), and a matrix blank (analyte-free 
human urine) were analysed up to 1.1 years after the original analyses. Assay 
acceptance criteria were (i) linear (R2 >0.98) calibration curves for each analyte, and (ii) 
IQC samples within 20 % of their respective nominal value.  
Peak area ratios (analyte to IS) obtained on analysis of the calibration standards were 
plotted against concentration to construct calibration graphs. Linear regression 
intercepts were not forced through zero, and no weighting was applied. 
5.2.7.2 CEDIA 
The assays were calibrated as necessary using the calibrators (S-metamfetamine 0, 0.5, 
1, 3 and 5 mg/L for amfetamine group assay; creatinine 0.18 and 1.8 mmol/L) supplied 
with the assay kits. IQC solutions were analysed prior to the analysis of patient samples. 
5.2.8 Assessment of CEDIA Cross-reactivity  
Mephedrone, normephedrone, 4-methylephedrine, and 4-methylpseudoephedrine were 
added to separate portions of analyte-free human urine at concentrations of 10, 20, and 
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50 mg/L (free base), and analysed in duplicate using the amfetamine-group CEDIA. The 
mean measured concentration of the 50 mg/L solution was used to calculate the relative 
cross-reactivity of each analyte with the assay [(mean measured concentration/nominal 
concentration) x 100 %].  
5.2.9 Patient Samples 
Data from urine samples analysed for routine clinical drug screening between March 
2015-January 2016 inclusive that had a detectable mephedrone concentration (>0.01 
mg/L) were analysed retrospectively for the presence of selected metabolites. 
Normephedrone, 4-methylephedrine, and 4-pseudomethylephedrine concentrations were 
estimated by comparison with the results of the analysis of calibrators prepared and 
assayed a maximum of 1.1 years after the original sample analysis. To assess the 
accuracy of the concentrations ascertained by retrospective analysis, all patient urine 
samples (stored at -20 oC since original analysis) were re-analysed with the prepared 
calibrators. On re-analysis, samples were analysed undiluted and after appropriate 
dilution (using analyte-free urine) to bring analyte concentrations within the calibration 
range. For samples where mephedrone was detected by LC-HRMS, analysis using the 
amfetamine-group CEDIA was also performed when the sample was originally received 
in the laboratory.  
Data analysis was performed by using Microsoft Excel 2010 (version 14.0.7166.5000) 
and Analyse-It (version 2.3). The Shapiro-Wilk test was used to test normality of data 
sets. For non-parametric data, the Mann-Whitney U test was used to compare data sets. 
To enable comparison of the proportions of mephedrone and each metabolite present in 
urine samples, all concentrations were converted to µmol/L (Equation 5.1). 
Equation 5.1 – Conversion of Analyte Concentration from µg/L to µmol/L 
Analyte molecular weight: mephedrone – 177.1154, normephedrone – 163.0997, 4-
methylephedrine/4-methylpseudoephedrine – 179.1310 
 
5.2.10 Ethics 
All patient samples were submitted to the laboratory for urine drug screening. Excess 




5.3 Results and Discussion 
5.3.1 CEDIA Cross-reactivity 
The analysis of analyte-free human urine to which mephedrone, normephedrone, 4-
methylephedrine, or 4-methylpseudoephedrine had been added (each 50 mg/L free base) 
showed a cross-reactivity of 0.9, 0.2, 0.6, and 0.6 %, respectively with the amfetamine-
group CEDIA. It was thus calculated that separate urinary mephedrone, normephedrone, 
4-methylephedrine, and 4-methylpseudoephedrine concentrations of 57, 250, 78, and 81 
mg/L, respectively, would be required to produce a positive amfetamine-group CEDIA 
result of 0.5 mg/L (Figure 5.2).  
5.3.2 Ascertaining LC-HRMS Assay Suitability 
Intra- and inter-assay accuracy and precision are summarised in Table 5.1. Typical 
chromatograms are shown in Figure 5.3. The LoD was 0.01 mg/L for all analytes (RSD 
was <4 % for all analytes). 
Of the internal standards present at the time of original analysis, codeine-D6 was 
selected for retrospective analysis as it had the closest retention time to the analytes of 
interest. Matrix effects were investigated for both mephedrone-D3 and codeine-D6 to 
ascertain their suitability as internal standards. Mephedrone-D3 compensated well for 
matrix effects for all analytes, with RSD <20 % for all analytes among the 10 different 
urines. Codeine-D6 did not compensate as well showing significant variation between 
the 10 matrices (RSD >20 % for all analytes), however for retrospective analysis was 










Figure 5.2 – Cross-reactivity of mephedrone, normephedrone, 4-methylephedrine, and 4-methylpseudoephedrine with the amfetamine-group 







Table 5.1 – Mephedrone assay: Intra- and Inter-assay accuracy and precision data  
Accuracy (% nominal IQC value) and precision (% RSD) 







Intra-assay (N = 5) 




























Inter-assay (N = 3, separate days) 





























Table 5.2 – Mephedrone assay: Summary matrix effects data 
Solutions containing all analytes and internal standards (0.2 mg/L free base) were 
prepared in (i) analyte-free human urine from 10 independent sources, and (ii) eluent A. 
Prepared solutions were diluted (1+9, v/v) with eluent A and analysed. The peak area of 
each analyte/internal standard was compared in the presence and absence of matrix to 
calculate the matrix effect. The ratio of the peak area of each analyte to that of the 
relevant internal standard was compared for each analyte in the presence and absence of 

















Mephedrone 41  101  2 125  28 
Normephedrone 52  130  8 161  25 
4-Methylephedrine 35  87  16 112  29 
4-Methylpseudoephedrine 43  109  18 128  38 
Mephedrone-D3 40  - - - - 











Figure 5.3 – Extracted ion chromatograms of mephedrone, normephedrone, 4-methylephedrine, and 4-methylpseudoephedrine in a) analyte-
free urine, b) the low calibrator (all 0.01 mg/L), and c) a patient sample (measured concentrations: mephedrone 6.80 mg/L; normephedrone 
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5.3.2.1 Isobaric Compounds 
Where possible, compounds known to be isobaric with mephedrone and its metabolites 
were analysed to ensure the compound of interest could be distinguished from potential 
sources of interference. LC resolution was achieved for the isobaric compounds tested, 
but different MS2 product ions could not be identified for all compounds (Table 5.3). 
Sufficient chromatographic resolution of 4-methylephedrine and 4-pseudo-
methylephedrine was observed at the concentration tested (1 mg/L both analytes). 
However, at higher concentration chromatographic resolution was lost (Figure 5.4). 
Samples with 4-methylephedrine and 4-methylpseudoephedrine concentration greater 
than 1 mg/L should thus be diluted with analyte-free urine to enable accurate detection 
and quantification of these analytes. 
Interference with the internal standard (mephedrone-D3, m/z 181.1415) was observed as 
a result of the naturally-occurring isotope (M+1) of 4-methylephedrine and of 4-
methylpseudoephedrine (both m/z 181.1416). Whilst these compounds are not isobaric, 
mass resolution was not possible as the compounds only differ by 0.0001 amu. 4-
Methylpseudoephedrine co-elutes with mephedrone-D3 which resulted in falsely 
elevated mephedrone-D3 peak area as 4-methylpseudoephedrine concentration increased 
(Figure 5.5). Mephedrone-D3 is therefore not an ideal internal standard for this assay. 
However, no other stable isotope-labelled analogues of mephedrone were commercially 
available at the time of re-analysis.  
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Table 5.3 – Chromatographic resolution and MS product ions for some 
compounds isobaric with mephedrone/mephedrone metabolites 
# Ions resulting from a water loss excluded 
* No reference compound available to analyse 
























Ethcathinone 132.0808 131.0730 
* 
Buphedrone 131.0730 132.0808 5.85 
5-(2-Aminopropyl)-2,3-























Figure 5.4 – Extracted ion chromatogram (m/z 180.1383) to show the influence of 
increasing the concentration of 4-methylephedrine and 4-pseudomethylephedrine 






















































































Figure 5.5 – The effect of 4-methylpseudoephedrine concentration on the measured 
mephedrone-D3 peak area 
Mean peak area (N = 2) for mephedrone-D3 was compared in urine samples containing 






5.3.3 Assessing the Accuracy of Data Generated from Retrospective Analysis 
Comparison of the calculated concentrations from re-analysis of undiluted samples 
using mephedrone-D3 as an internal standard to those calculated from retrospective data 
analysis using codeine-D6 as the internal standard showed poor agreement for all of the 
metabolites (Table 5.4, full data in Appendix A). Whilst the overall agreement between 
mephedrone concentrations calculated using mephedrone-D3 and codeine-D6 was good 
(R2 = 0.91), discrepancies were apparent when mephedrone concentration was >10 
mg/L. This may be due to the higher concentrations of 4-methylephedrine and 4-
methylpseudoephedrine in these latter samples giving rise to interference with 
mephedrone-D3 (see Section 5.3.1.1). For all other analytes, the calculated 
concentrations using codeine-D6 as the internal standard were generally lower than 
when mephedrone-D3 was used. This negative bias was more apparent at higher analyte 
concentration (>2 mg/L all analytes), which may be due to loss of chromatographic 
resolution between 4-methylephedrine and 4-methylpseudoephedrine causing inaccurate 
peak integration, and the resulting interference with mephedrone-D3. Most samples (76 
%) were stored frozen for longer than 6 months. As no stability data exists past this time 
frame for mephedrone, and none is published for the other analytes, it is possible that 
the analytes may have degraded since the time of the original analysis, contributing to 
the lower concentrations found on re-analysis.  
The re-analysis of samples after appropriate dilution showed that the measured 
concentrations from retrospective analysis (where samples were analysed undiluted) 
were likely underestimating the concentration of all the analytes studied (Table 5.5, full 
data in Appendix B). This underestimation is likely due to the interference from the 13C-
isotopes of 4-methylephedrine and 4-methylpseudoephedrine that caused the measured 
peak area of mephedrone-D3 to be falsely elevated. The increased internal standard peak 
area caused the peak area ratio of the analyte to internal standard to be reduced, 




Table 5.4 – Characteristics of x-y and Bland-Altman plots comparing the 
measured analyte concentration when using codeine-D3, as opposed to 
mephedrone-D3, as the internal standard  
NB. Full data is given in Appendix A 
Analyte R2 y-intercept Slope Bias  
Mephedrone 0.9115 2.20 0.95 1.67 
Normephedrone 0.7477 0.20 0.42 -2.50 
4-Methylephedrine 0.8271 0.27 0.38 -0.82 
4-Methylpseudoephedrine 0.5956 0.75 0.23 -1.94 
 
 
Table 5.5 – Characteristics of x-y and Bland-Altman plots comparing the 
measured analyte concentration from diluted urine samples as opposed to 
undiluted urine samples  
NB. Full data is given in Appendix B 
Analyte R2 y-intercept Slope Bias  
Mephedrone 0.7931 -13.4 4.2 27.3 
Normephedrone 0.5422 0.18 1.6 1.44 
4-Methylephedrine 0.5184 -0.47 2.4 0.95 




5.3.4 Interpretation of Results from Analysis of Patient Samples 
Twenty-five mephedrone-containing urine samples from 24 patients were analysed 
retrospectively for the presence of mephedrone metabolites. Nineteen samples were 
from males [median (range) age: 37 (22-58) y], and six from females [median (range) 
age: 32 (21-49) y]. Samples were received from community drug and alcohol 
rehabilitation teams (N = 10), referrals from other hospital laboratories (N = 11), 
general practitioners (N = 2), and critical care wards (N = 2). The reason for request was 
given for 16 samples, of which 10 were for routine monitoring as part of drug 
rehabilitation treatment and 6 were querying drug overdose (mephedrone specified in 2 
cases).  
5.3.4.1 Quantitative Data from LC-HRMS Analysis 
Due to the problems associated with retrospective analysis of samples mentioned in 
Section 5.3.2, the concentrations ascertained on re-analysis of urine samples using 
mephedrone-D3 as an internal standard (and after appropriate dilution where necessary) 
were deemed more accurate and are summarised in Table 5.6. Most samples (60 %) had 
other amfetamine-type drugs (amfetamine, metamfetamine, or MDMA) detected in 
addition to mephedrone. 
In the majority of the urine samples, mephedrone was the predominant species detected 
(Figure 5.6). No information was available regarding the time of mephedrone ingestion 
in relation to the time of sampling.  
 
Table 5.6 – Summary of mephedrone and metabolite concentration in urine 
samples on re-analysis using mephedrone-D3 as an internal standard, and after 
appropriate sample dilution where necessary 
Analyte N Concentration (mg/L) 
Mean Minimum Median Maximum 
Mephedrone 25 40.1 0.05 10.5 373.6 
Normephedrone 25 3.5 0.01 1.2 22.2 
4-Methylephedrine 23 1.7 0.02 0.7 11.9 





























































































































4-Methylpseudoephedrine Mephedrone concentration (mg/L)
Figure 5.6 – Relative proportion of mephedrone, normephedrone, 4-methylephedrine, and 4-methylpseudoephedrine in patient urines in 
relation to mephedrone concentration 
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5.3.4.2 Qualitative Identification of Other Metabolites from LC-HRMS Analysis 
Pozo et al. (2015) identified 10 metabolites of mephedrone in urine collected 4 h post-
ingestion of mephedrone (oral, 400 mg) from two male volunteers. For identification of 
metabolites that had no available reference material, the chromatographic data were 
filtered for the theoretical accurate precursor ion m/z and peak identity confirmed 
through the presence of product ions (Table 5.7). Metabolites identified in the patient 
urine samples are summarised in Table 5.8, and example chromatograms shown in 
Figure 5.7. No definitive chromatographic peaks were identified in patient samples 
which corresponded to the three glucuronide metabolites. As these metabolites are more 
polar, it is possible that they were not retained on the analytical column. 
 
Table 5.7 – Accurate precursor and product ion m/z for selected urinary 
metabolites of mephedrone ascertained by Pozo et al. (2015) 
Metabolite Observed precursor ion 
m/z 




















































Table 5.8 – Summary data: Qualitative identification of urinary metabolites of mephedrone in patient samples  
 
N Mean (range) peak area 
Mean RT  
(min) Theoretical m/z Mean measured m/z 
Mass accuracy  
(ppm) 
4-Hydroxymethylmephedrone 25 2.0 e
9  
(7.8 e6-2.1 e10) 2.26 194.1176 194.1173 -1.34 
N-Succinyl normephedrone 25 1.1 e
9 
(8.4 e6-3.7 e9) 8.29 264.1230 264.1225 -1.71 
4-Methylnorpseudoephedrine 25 9.3 e
8 
(1.1 e7-3.5 e9) 6.23 166.1226 166.1225 -0.53 
4-Methylnorephedrine 24 1.1 e
9 
(3.6 e7-3.3 e9) 6.03 166.1226 166.1225 -0.65 
N-Demethylmephedrone-3-
carboxylic acid 22 
1.3 e9 
(9.4 e7-7.5 e9) 7.01 194.0812 194.0810 -0.89 
4-Carboxymephedrone 16 4.5 e
9 
(4.4 e7-2.7 e10) 2.07 208.0968 208.0965 -1.53 
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Figure 5.7 – Extracted ion chromatograms to show selected mephedrone 
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RT: 0.00 - 13.50















































5.3.4.3 Analysis of Patient Samples by CEDIA  
The measured amfetamine-group CEDIA concentration in patient samples is 
summarised in Table 5.9. The median amfetamine-group concentration was 
significantly lower in samples containing mephedrone in the absence of other 
amfetamines than in samples where other amfetamines (amfetamine, metamfetamine, 
MDMA) were present (Mann-Whitney U test, p = <0.001 two-tailed). The majority of 
samples (90 %) in which only mephedrone was detected had negative CEDIA results. 
The mephedrone concentration (measured by LC-HRMS, Section 5.3.4.1) was not 
significantly different between samples where other amfetamines were present and 
those where only mephedrone was present (Mann-Whitney U test, p = 0.37 two-tailed).  
 
Table 5.9 – Summary of amfetamine-group CEDIA results in patient urine 
samples where mephedrone was detected by LC-HRMS (>0.01 mg/L), and 
categorisation according to whether other amfetamines were detected or not  


















All  25 15 1.14 (0.01-235) 10.5 (0.05-374) 
Other amfetamines 
detected* 
15 14 2.46 (0.10-235) 13.2 (0.05-271) 
No other amfetamines 
detected 




Collection of full scan data offers the possibility to analyse the data retrospectively. 
However, the process is not straight-forward and has limitations. At the time of the 
original sample analysis an appropriate internal standard may not have been included, 
thus analyte concentrations ascertained at a later date can only be estimations as the 
internal standard may not compensate appropriately for matrix effects. In addition, 
analyte concentrations may be above the linear range of the assay meaning that sample 
dilution would have been necessary for accurate results. In this case the sample should 
be re-analysed, but depending on how much time has passed since the original analysis 
the sample may have been discarded or the analyte may have degraded. For many NPS 
no stability data exist making it difficult to interpret results.  
Another limitation is that reference materials are still required for confirmation of an 
analyte. Even in cases where a reference material is available for the compound of 
interest, co-elution of an isobaric compound cannot be excluded. Identification of 
specific MS2 product ions may help minimise incorrect interpretation of results. For 
positional isomers, specific MS2 product ions may be difficult to identify. In this study, 
reference solutions of 2-MMC and 3-MMC (positional isomers of mephedrone) could 
not be obtained. It therefore cannot be ruled out that measurement may be of these 
compounds as opposed to mephedrone itself in the patient samples. 2-MMC and 3-
MMC were both identified in European drug seizures in 2014, with a greater quantity of 
3-MMC seized than mephedrone itself (388 kg v. 222 kg) (EMCDDA, 2016). 
Despite this, data gleaned from retrospective analyses are of value and can be used to 
guide future assay development, e.g. to gain information on appropriate calibration 
ranges and putative metabolites. This work confirms that normephedrone, 4-
methylephedrine, and 4-methylpseudoephedrine are urinary metabolites of mephedrone. 
In addition, five of the reported urinary metabolites identified by Pozo et al. (2015) 
were qualitatively identified in the patient urines studied. To date, 4-
methylpseudoephedrine and 4-methylpseudonorephedrine have not been reported as 
metabolites of mephedrone. This may be a result of previously published analytical 
methods not achieving chromatographic resolution between 4-methylephedrine and 4-
methylpseudoephedrine, and between 4-methylnorephedrine and 4-methylpseudo-
norephedrine. The estimated concentrations for mephedrone and its metabolites in this 
study are considerably higher than those reported by Concheiro et al. (2015), and 
provide more information on expected urinary concentrations from individuals who take 
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mephedrone. It may be that the individuals in our study population took higher doses of 
mephedrone, or that the purity of mephedrone was higher, which could explain the 
higher observed urinary concentrations. 
The low cross-reactivity of mephedrone and its metabolites in the CEDIA assay 
highlight that immunoassay methods may be inappropriate for detection of mephedrone, 
and potentially other beta-keto amfetamines (e.g. butylone, methylone). The majority of 
patient samples containing mephedrone in the absence of other amfetamine drugs had a 
CEDIA concentration <0.5 mg/L resulting in false-negative results. This emphasises the 
need to assay these novel substances using specific methodology such as LC-HRMS.   
5.4.1 Further Work 
Changing the internal standard to mephedrone-13C-D3 (now available from Alsachim) 
could be investigated to reduce interference from the isotopes of 4-methylephedrine and 
4-methylpseudoephedrine. However, for qualitative purposes based on a cutoff 
concentration of 0.2 mg/L (EWDTS guidelines) the use of mephedrone-D3 as an 
internal standard should not impact results. In addition the prevalence of mephedrone 
appears to have declined in the UK (Home Office, 2010-2016) meaning that there may 
































Transferring the process of urine drug screening to a single-step procedure (i.e. 
screening and confirmation in one assay) is a relatively new approach. Much of the 
established procedure for urine drug screening, including reporting of results, is based 
on the two-step process typically using cutoff concentrations to assess if a sample is 
‘positive’ or ‘negative’ for a drug or drug class. Whether this is still an appropriate 
approach, particularly in regard to reporting results, in light of the new technology being 
used and the range of NPS now available has not been investigated. Evaluation of the 
data resulting from routine analysis of urine samples using LC-HRMS (Chapter 2) may 
give additional information that can be used to aid the clinical interpretation of results.  
Ideally, knowledge of the clinical circumstances and the reason behind requesting a 
urine drug screen are required to enable bespoke interpretation of results. However, 
many of the samples received by the laboratory lack any clinical information 
whatsoever hence the results cannot be put in context. Be this as it may, most clinical 
samples received for urine drug screening are from drug and alcohol rehabilitation 
services, hence it can be assumed that the samples have been collected to ascertain 
whether an individual is compliant with prescribed medication, e.g. with methadone, 
and/or whether they are misusing other drugs.  
6.1.1 Aims 
The results and patient demographics from samples submitted for urine drug screening 
will be evaluated. The analytical interpretation of results will focus on the identification 
of sample adulteration, the ability to distinguish the use of heroin from pharmaceutical 
diamorphine, and ascertaining the prevalence of heroin use in individuals receiving OST 
in a user population. In addition, the impact of reporting results based on the limit of 







6.2.1 Patient Samples 
The results from the analysis of samples submitted for urine drug screening from UK 
patients to King’s College Hospital (November 2015-October 2016 inclusive) were 
audited. Information requested at the time of sample submission included requestor 
details, time and date of sample, patient date of birth, sex, tests required and prescribed 
medication (e.g. methadone, buprenorphine, benzodiazepines). 
6.2.2 Analytical Methods 
Most analytes were measured using LC-HRMS (Chapter 2). The use of 
benzodiazepines, cannabis, and barbiturates was detected using immunoassay (CEDIA, 
ThermoFisher Scientific). Ethanol was measured using an enzymatic assay (DRI, 
ThermoFisher Scientific). Creatinine was measured to monitor sample integrity (Section 
1.2.3.1) using the Jaffe reaction (Creatinine Detect, ThermoFisher Scientific). 
Barbiturate and ethanol assays were not performed routinely as part of a urine drug 
screen, but were available on request. 
For audit purposes, two sets of data were generated based on a) analytical detection 
limits (LoD), and b) cutoff concentrations (Section 2.3.4). For clinical purposes analytes 
were reported as either ‘positive’ or ‘negative’, based on the cutoff concentrations for 
LC-HRMS (Table 2.6) and according to immunoassay kit manufacturer instructions 
(benzodiazepine group and barbiturate group 300 µg/L, cannabis 50 µg/L). Results 
based on the LoD are reported as either ‘detected’ or ‘not detected’. For 
immunoassay/enzymatic assay the manufacturer stated LoD was used (barbiturates 36.3 
µg/L, benzodiazepines 8.3 µg/L, cannabis 11.8 µg/L, and ethanol 10 mg/100 mL) and 
for LC-HRMS the LoD ascertained during method validation was used (Table 2.13).  
Drug classes were defined as: amfetamines, benzodiazepines, buprenorphine, cannabis, 
cocaine, ketamine, methadone, opioids, and tramadol. 
6.2.3 Statistical Analysis 
The semi-quantitative results were used for statistical analyses. Statistical analyses were 
performed using Microsoft Excel 2010 (version 14.0.7166.5000) and Analyse-It 
(version 2.3). The Shapiro-Wilk test was used to test normality of data. For non-































6.3 General Findings 
There were 8,506 samples from 4,800 patients. Of these, 257 had barbiturate and 248 
had ethanol tests requested in addition to the routine screen (3 % of all samples received 
in both cases). 
6.3.1 Demographics 
There were 2,899 (60.4 %) males aged at the time of first sampling (median, range) 44 
years (0-89), and 1,901 (39.6 %) females aged at the time of sampling (median, range) 
35 years (0-84) (patient age not known for 6 samples, all males). The age and sex 
distribution of the individuals from whom urine samples were received is summarised 
in Figure 6.1. The number of samples per patient was as follows: 1 (3,601 patients), 2-5 
(948), 6-10 (193), 11+ (58). The maximum number of sample received from one patient 
was 53. 












Most samples were received from locations within the south-east of England, with the 
majority of requestors located in the boroughs of Southwark and Lambeth in London. 
Most requestors were part of drug and addiction services (42 %). Other requests came 
via external biochemistry laboratories (32 %), general practitioners (18 %), from within 
King’s College Hospital (7 %), and from mental health services (2 %).  
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6.3.2 Drug prevalence 
No drugs were detected in 1,976 samples (23.3 %). Most of these samples were from 
external biochemistry laboratories (65 %). The remaining samples were from within 
King’s College Hospital (15 %), from drug and addiction services (9 %), and from 
general practitioners (4 %).  
Where drugs were detected, the number of drug classes screened as positive in single 
urine sample ranged from 1 to 7 (Table 6.1).  
Table 6.1 – Number of drug classes positive in each urine sample 
Drug classes positive Number of samples % samples 
1 2,092 24.6 
2 1,824 21.4 
3 1,607 18.9 
4 800 9.4 
5 189 2.2 
6 17 0.2 
7 1 0.01 
 
The most commonly detected drug was methadone (38 % samples with methadone 
and/or EDDP detected), followed by morphine (32 % samples). Detection was relatively 
infrequent for amfetamines (2 %) (Table 6.2). In samples where a barbiturate test was 
requested, only 2 samples (0.8 %) gave positive results. In both cases, administration of 





Table 6.2 – Drugs screened as ‘positive’ in samples analysed at King’s College 
Hospital November 2015-October 2016 inclusive (N = 8,506)  
* Specific drugs within a drug class are italicised, a sample was defined ‘positive’ for a 
drug class if at least one of the listed drugs was positive 
 
# 41 samples were positive for amfetamine and metamfetamine, with the presence of 
amfetamine likely a result of metamfetamine metabolism  
Drug class/Drug 
No. of ‘positive’ samples 


































Cannabis 2,508 29.5 




























Ketamine 45 0.5 




6.4 Sample Adulteration  
6.4.1 Background 
Sample adulteration is one of the problems encountered in urine drug screening (Section 
1.2.3.1). Individuals may directly add prescribed medication (e.g. methadone, 
buprenorphine) to their urine sample in an attempt to appear adherent. These cases may 
be distinguished analytically through detection of either a high concentration of parent 
drug in relation to its metabolites, or the absence of metabolites.  
Buprenorphine immunoassays cannot differentiate between buprenorphine and 
metabolites, thus adulteration cannot be detected using this methodology (Belsey et al., 
2014). Specific immunoassays exist for both methadone and EDDP meaning that 
adulteration cases can be detected, but this requires two separate assays which increases 
laboratory expenditure (Preston et al., 2003). Most clinical laboratories using 
immunoassay will solely use the EDDP assay, which will provide information on 
methadone adherence; however, cases of adulteration will be missed. LC-MS methods 
are capable of detecting metabolites in addition to the parent drugs, and are well suited 
to identifying cases of sample adulteration. 
As methadone is a liquid, direct addition of the medication to urine will result in sample 
dilution. Dilution of a sample may be ascertained through creatinine measurement. 
Urine samples may be classified as dilute, and very dilute, when creatinine is <1.8 and 
<0.2 mmol/L, respectively (SAMHSA, 2012). 
6.4.2 Results and Discussion 
6.4.2.1 Direct Addition of Methadone and Buprenorphine 
Based on reporting according to cutoff concentrations, 117 samples were positive for 
methadone and negative for EDDP. The median (range) methadone concentration in 
these samples was 9.9 (0.3-773) mg/L. EDDP was detected below the cutoff (0.25 
mg/L) in 50 of these samples. The median (range) EDDP concentration was 0.15 (0.02-
0.24) mg/L. Where EDDP was detected, the methadone-to-EDDP ratio was calculated 
and compared with the methadone concentration (Figure 6.2). A methadone-to-EDDP 
ratio >50 appears suggestive of sample adulteration. Cases of adulteration were 
identified by samples having a high methadone concentration in combination with either 




In 1,500 patient samples where buprenorphine and/or buprenorphine metabolites were 
detected, the proportions of each species (data converted to µmol/L) present were 
calculated. Buprenorphine comprised <15 % of the total species in urine in 93 % 
samples, with norbuprenorphine glucuronide usually being the predominant species 
present. Cases of adulteration were clearly identified by the disproportionately high 
buprenorphine concentration (Figure 6.3). Eighteen samples were positive for 
buprenorphine with no metabolites detected. The median (range) buprenorphine 
concentration in these samples was 47.1 (5.7-16,000) µg/L. Seven samples had a 
buprenorphine concentration >1,000 µg/L indicating adulteration. In samples where 
buprenorphine and at least one metabolite were detected (N = 535), the buprenorphine 
concentration and the buprenorphine-to-metabolites ratio was compared (Figure 6.4). 
Data suggest sample adulteration when urinary buprenorphine concentration is >1,000 
µg/L and the buprenorphine-to-metabolites ratio is >1.  
Overall, 153 samples from 91 patients were identified as adulterated with either 
methadone (83 samples from 57 patients) or buprenorphine (70 samples from 34 
patients) (Table 6.3).  
6.4.2.2 Creatinine  
Thirteen samples (0.2 % total samples) from 9 individuals (6 males, 3 females) had no 
creatinine detected (<0.07 mmol/L). Of these, 11 samples were adulterated through 
addition of methadone, and 1 sample through addition of buprenorphine. The remaining 
sample had no buprenorphine or methadone detected, but was observed to have a high 
6-AM concentration (~34 mg/L) in the absence of morphine and codeine suggesting 
possible addition of diamorphine or heroin (Section 6.5). 
Twenty-two samples (0.3 %) from 15 individuals (12 males, 3 females) were classed as 
‘very dilute’, based upon a creatinine concentration <0.2 mmol/L. Of these, 9 samples 
were adulterated with methadone, and 3 samples were adulterated with buprenorphine. 
The remaining 10 (45 %) samples had no clear evidence of sample adulteration. 5 of 
these samples had no drugs detected. It is possible that these urine samples were 
purposefully diluted to obtain negative results, either by direct addition of a liquid or 
















































































Methadone (mg/L) Methadone-to-EDDP ratio
Figure 6.2 – Comparison of the methadone concentration and methadone-to-EDDP ratio in methadone positive patient urine samples where 







































































































































Figure 6.3 – Percentage of buprenorphine and metabolites (µmol/L) in a subset of patient urine samples (N = 100, selected samples were the 
first 100 positive buprenorphine samples from the audit data) 


































































































Buprenorphine (µg/L) Buprenorphine-to-metabolites ratio
Figure 6.4 – Comparison of the buprenorphine concentration and buprenorphine-to-metabolites ratio in patient urine samples where 
buprenorphine and at least one metabolite was detected (N = 535)  
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Table 6.3 – Summary of the analytical findings in patient urine samples that were 
adulterated by direct addition of methadone or buprenorphine  








High methadone concentration, 
no EDDP detected 9 8 50 
Methadone-to-EDDP ratio >50 2 1 13 
Buprenorphine 
adulterations 
Buprenorphine >1000 µg/L, no 
metabolites detected 0 1 6 
Buprenorphine-to-metabolites 
ratio >1 1 2 60 
 
6.4.3 Conclusions 
1.8 % of all samples received were identified as adulterated through direct addition of 
methadone or buprenorphine.  Identification of these cases could not solely be based 
upon a positive result for the parent drug and negative result for metabolites, 
particularly for buprenorphine. Calculation of the parent drug-to-metabolite ratio 




6.5 Detection of 6-AM in conjunction with low total morphine concentration  
6.5.1 Background 
6-AM is the hydrolytic product of diamorphine, and is present in heroin and in 
pharmaceutical diamorphine (McLachlan-Troup et al., 2001). The presence of 
diamorphine in urine is unexpected due to its rapid hydrolysis in vivo. It has been 
suggested that high concentrations of diamorphine and/or 6-AM may inhibit the enzyme 
responsible for glucuronidation of morphine (UGT 2B7), however free morphine would 
be expected in urine if this were the case (von Euler et al., 2003).  
The presence of 6-AM in the absence of morphine and/or morphine glucuronide has 
been reported (Andersson et al., 2015; Beck and Böttcher, 2006; Glass et al., 1997; von 
Euler et al., 2003). Several reasons for this atypical pattern have been proposed 
including; sample timing (i.e. heroin intake was immediately prior to sampling), a result 
of a metabolic defect (e.g. lack of esterases that metabolise 6-AM to morphine), and 
inhibition of carboxylesterase from a substance co-ingested with heroin (either an 
unknown constituent of the heroin preparation, or a different drug). Genetic 
polymorphism in the enzymes involved in diamorphine/6-AM metabolism is deemed 
unlikely to cause this atypical pattern as studies have demonstrated the same individual 
can produce the atypical and ‘normal’ excretion pattern on different occasions 
(Andersson et al., 2015; von Euler et al., 2003). An alternative explanation is that 
diamorphine and 6-AM may be present as a result of direct addition of heroin to a urine 
sample. 
6.5.2 Results and Discussion 
From the entire data set, 49 samples from 35 individuals had positive 6-AM results with 
negative total morphine and total codeine results (i.e. less than the cutoff concentration, 
300 µg/L). 22 of these samples had no morphine or codeine (or their glucuronides) 
detected. A high proportion of these samples (57 %) were adulterated through direct 
addition of methadone (45 %) or buprenorphine (12 %). Diamorphine (m/z 370.1649) 
was qualitatively identified in 48 samples through retrospective analysis. 
Twenty-seven of the individuals had submitted at least one other urine sample during 
the study period. The majority of these individuals (81 %) showed a normal excretion 
pattern in urine samples collected at a different time. This supports the finding of 
Andersson et al. (2015) and von Euler et al. (2003), suggesting that the observed results 





The cause of this different excretion pattern in selected urine samples could not be 
established. Adulteration by direct addition of heroin to the urine sample cannot be 
excluded, particularly considering that the majority of the samples with the atypical 






6.6 Differentiation between pharmaceutical diamorphine and heroin use 
6.6.1 Background 
Heroin-assisted treatment (HAT) refers to the prescribing of diamorphine to opioid-
dependent individuals. There is in such cases a clinical need to differentiate between the 
administration of prescribed diamorphine and heroin use. A number of alkaloids in 
addition to morphine are produced by Papaver somniferum (opium poppy), including 
codeine, noscapine, papaverine, meconin, and thebaine. The alkaloids present in heroin  
vary, and depend on the climatic conditions the poppy was grown under and the 
extraction method used to concentrate morphine (Bogusz et al., 2001). These co-
extracted alkaloids and their acetylated derivatives are absent in pharmaceutical 
diamorphine, and offer potential markers of concurrent heroin use in patients prescribed 
diamorphine (McLachlan-Troup et al., 2001). 
To date, 6-acetylcodeine has been identified as the most specific marker of illicit heroin 
use. However, due to rapid conversion to codeine in vivo, 6-acetylcodeine has a short 
urinary detection window (<8 h) which limits its clinical utility (Bogusz et al., 2001; 
Brenneisen et al., 2002; O’Neal and Poklis, 1997, 1998). In addition, co-administration 
of codeine and pharmaceutical diamorphine may produce 6-acetylcodeine in vivo 
(Brenneisen et al., 2002). 
Other opium alkaloids (e.g. papaverine, noscapine) may be present in urine samples as a 
result of the ingestion of poppy seeds, and thus cannot be used as specific markers of 
heroin use. Noscapine and papaverine may also result from administration of medicines. 
Noscapine is a component of some OTC cough suppressants, and papaverine may be 
used to treat impotence and cardiovascular disease (Paterson et al., 2005). Papaverine 
has also been detected in individuals administered atracurium, a neuromuscular relaxant 
administered to facilitate tracheal intubation, as a result of dehydrogenation of 
laudanosine (the major metabolite of atracurium) (Seetohul et al., 2013). Both 
noscapine and papaverine are extensively metabolised. Papaverine has a short plasma 
half-life (0.8-1.5 h) and is metabolised mainly to 6-hydroxypapaverine and other 
hydroxylated metabolites, all of which may be glucuronidated. Noscapine has a longer 
plasma half-life (4.5 h) and is more likely than papaverine to be detected as unchanged 





A novel marker of illicit heroin use has recently been reported, acetylated-thebaine-4-
metabolite glucuronide (ATM4G) (Chen et al., 2014). ATM4G is not formed 
metabolically after poppy seed ingestion, and therefore may enable detection of heroin 
consumption (Chen et al., 2014; Maas et al., 2017). Currently no reference material is 
commercially available for this compound; hence quantitative measurement is not 
possible. 
An alternative approach to identifying heroin use through calculation of the morphine to 
codeine ratio in either blood or urine has been proposed. Studies have suggested that a 
ratio greater than 1 is suggestive of heroin use (Ceder and Jones, 2001; Jones et al., 
2008; Konstantinova et al., 2012). 
6.6.2 Results and Discussion 
6.6.2.1 Heroin Markers 
Papaverine was typically detected at lower concentration and less frequently than 6-
acetylcodeine and noscapine (Table 6.4). 6-AM was present in most samples containing 
these markers, confirming the use of heroin. To assess the suitability of each marker for 
identifying the use of heroin, the concentration of the marker in 6-AM positive samples 
was compared to that in 6-AM negative samples (Figure 6.5). 6-Acetylcodeine was the 
only marker observed to have a significantly higher median concentration in 6-AM 
positive samples (p <0.01). If 6-acetylcodeine is used as a marker of heroin use, an 
additional 43 samples where 6-AM was either detected below the cutoff concentration 
(40 %) or not detected (60 %) could be identified. Identification of heroin use based 
solely on detection of noscapine or papaverine is unreliable as a significantly higher 
concentration in 6-AM positive samples was not observed.   
 
Table 6.4 – Prevalence of 6-acetylcodeine, noscapine, and papaverine in urine 
samples 
Marker N 
% samples with 
6-AM detected 
Concentration (µg/L) 
Mean Median Min Max 
6-Acetylcodeine 1,077 98 412 145 3 6,600 
Noscapine 1,668 77 271 49 5 135,000 











Figure 6.5 – Box and whisker plots (median, 25th-75th percentiles, whiskers 10th and 90th percentiles) to show the difference in heroin marker 










 6-Acetylcodeine            Papaverine                 Noscapine 
       p < 0.01               p = 0.18         p = 0.10 
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6.6.2.2 Morphine-to-codeine Ratio 
2,258 samples contained morphine and codeine, with 1,269 (56 %) positive for 6-AM 
(>10 µg/L). For samples where 6-AM was positive, a morphine-to-codeine ratio >1 was 
observed in 99 % of the cases. There was a statistically significant difference in the 
morphine-to-codeine ratio between 6-AM positive samples, 6-AM negative samples 
with heroin markers detected, and 6-AM negative samples without heroin markers 
detected (χ2(2) = 445.05, p <0.0001). The median morphine-to-codeine ratio was lower 
in samples where no heroin markers were detected as opposed to samples where heroin 
markers were detected in both the presence and absence of 6-AM (2.1 compared to 8.8 
and 8.0, respectively) (Figure 6.6). 
Fifteen samples had a very high morphine-to-codeine ratio (>50) in the absence of 6-
AM and heroin markers (Figure 6.7). Prescription of morphine (either oramorph or 
morphine sulfate) was stated on the request form for the majority (60 %) of these 
samples which would account for a high morphine concentration in the absence of 6-
AM. Codeine present in these samples may have arisen from co-ingestion of codeine; 
however neither the use of heroin, nor ingestion of poppy seeds can be excluded. A 
higher than expected morphine-to-codeine ratio may be also seen in CYP2D6 ultra-
rapid metabolisers after codeine administration, which could be misinterpreted as heroin 




Figure 6.6 – Box and whisker plots (median, 25th-75th percentiles, whiskers 10th 
and 90th percentiles) to show the difference in morphine-to-codeine ratio between 
patient urine samples where a) 6-AM was positive, b) 6-AM was negative, but 
heroin markers were detected, and c) 6-AM was negative and no heroin markers 











Figure 6.7 – The observed morphine-to-codeine ratio in patient urine samples 
according to whether 6-AM was positive or negative, and whether heroin markers 
were detected or not 
 
 
p < 0.0001 
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6.6.3 Conclusions   
Detection of 6-acetylcodeine, noscapine, and papaverine may be useful for 
differentiating the use of heroin and prescribed diamorphine. The detection of 6-
acetylcodeine provides conclusive evidence that heroin as opposed to pharmaceutical 
diamorphine has been used. However, the detection window for 6-acetylcodeine in 
urine is short which limits its utility as a heroin marker. Data show 6-acetylcodeine is 
typically detected in samples where 6-AM is also detected. For identifying the use of 
heroin or diamorphine in the absence of 6-AM, the morphine-to-codeine ratio does offer 
interpretative value. However, this marker cannot be used alone as higher ratios may be 
a result of co-ingestion of morphine and codeine, or from poppy seed ingestion.  
6.6.3.1 Further Work   
Retrospective interrogation of data for the presence of ATM4G, particularly in relation 
to the presence of 6-AM, other heroin markers, and the morphine-to-codeine ratio, 
would be of value to assess its potential as an additional qualitative identifier of heroin 
use. However, due of the vast quantity of data the process of retrospective interrogation 
would take a long time to complete. 
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6.7 Heroin use in individuals receiving opioid substitution therapy 
6.7.1 Background 
In the UK, most individuals undergoing substitution therapy will be prescribed either 
methadone or buprenorphine. Both drugs are effective at reducing the use of heroin 
(Mattick et al., 2009, 2014). However, a proportion of patients enrolled in substitution 
therapy will continue to misuse opiates. Limited data are available regarding the use of 
pharmaceutical diamorphine as OST, but preliminary results suggest there is a reduction 
in heroin use when compared to individuals receiving methadone (Ferri et al., 2011). 
It is unclear whether the prevalence of heroin use is different between individuals 
prescribed buprenorphine and methadone. Many studies report no significant difference 
in opiate misuse between individuals prescribed buprenorphine or methadone (Gerra et 
al., 2004; Mattick et al., 2002; Pani et al., 2000). However, some studies have found 
that patients prescribed buprenorphine have a lower prevalence of heroin use when 
compared to those receiving methadone (Curcio et al., 2011; Giacomuzzi et al., 2003; 
Vigezzi et al., 2006). Buprenorphine possesses stronger affinity for µ opioid receptors 
than many opioid agonists (e.g. diamorphine, morphine, methadone), which blocks the 
effects of heroin and thus may discourage use. At adequate doses methadone will also 
block the effects of additional opiates, however if doses are inadequate individuals may 
use heroin in order to prevent withdrawal symptoms (Vigezzi et al., 2006). 
6.7.2 Method 
To ascertain the rate of concurrent heroin use amongst individuals receiving either 
methadone or buprenorphine treatment, patient urine samples which were positive for 
either methadone or buprenorphine and had evidence of recent heroin use were 
compared to the total number of samples positive for methadone and buprenorphine. 
Recent heroin use was identified in samples where 6-AM and at least one heroin marker 
were detected, and the morphine-to-codeine ratio was greater than 1. A chi-squared test 
was used to compare the two treatment groups with respect to urinalysis results. 
Urine samples positive for methadone or buprenorphine were taken to be a result of 




6.7.3 Results and Discussion 
The proportion of individuals using heroin was significantly different between those 
prescribed methadone and those prescribed buprenorphine, 32 % and 16 % respectively 
(χ² (1, N = 1,540) = 40.78, p <0.001). Interpretation of these data is difficult due to the 
lack of clinical information. Differences may exist between the two sets of patients, 
which might account for the observed difference in heroin use. For example, a greater 
number of patients may be at the start of treatment in the methadone group and the 
correct dosage may not have been established, which could cause a higher rate of heroin 
use in these individuals.  
The interpretation is also limited by the fact that no information on whether methadone 
or buprenorphine was prescribed was available. It therefore cannot be ruled out that the 
methadone or buprenorphine present in these samples was a result of non-prescribed 
use.  
6.7.4 Conclusions 
Overall, 27 % individuals receiving OST (either methadone or buprenorphine) had used 
heroin during the study period. This may be an underestimation of heroin use as some 
urine samples will not contain 6-AM if sample collection was more than 24 h after 
heroin administration. Despite this, the data show that continued heroin use is a problem 
amongst individuals receiving methadone and also those receiving buprenorphine. 
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6.8 Reporting using cutoff concentrations and limits of analytical detection 
6.8.1 Background 
The use of analyte or group cutoff concentrations largely originates from the use of 
immunoassays for drug screening where false positive results occur due to limitations 
with the methodology. Using selective methodology such as LC-HRMS for drug 
screening should minimise the occurrence of false positive results, and it may therefore 
be more appropriate to use the limit of analytical detection as opposed to a cutoff 
concentration to minimise the reporting of false negative results.  
Analytical detection limits will likely be lower than assigned cutoff concentrations. As a 
result, the window of drug detection will be extended. In some cases this may be 
beneficial, for example in cases where drug exposure may have been a single event, e.g. 
DFSA, drug administration to children. However, for monitoring chronic drug use in 
individuals it may make clinical interpretation more difficult as recent drug use may be 
more difficult to distinguish from historic use. 
6.8.2 Results and Discussion 
Drugs were detected in a number of patient urine samples, but at a concentration below 
the cutoff concentration (Table 6.5). Amfetamines, particularly MDMA and 
mephedrone, were commonly detected at concentrations below the cutoff. It may be that 
these are cases of occasional drug use, and the urine sample was collected some days 
after drug administration.  
Buprenorphine and its metabolites have the lowest assigned cutoff concentration of the 
analytes studied (5 µg/L). After therapeutic administration, the urinary concentration of 
free (unconjugated) buprenorphine is often less than 1 µg/L (Debrabandere et al., 1991). 
It is therefore not surprising that the buprenorphine concentration was below the cutoff 
in 38 % samples where buprenorphine was detected. For buprenorphine metabolites, 
only a small proportion of samples had a metabolite detected below the cutoff. 
Buprenorphine metabolites are reported as a summed total (as buprenorphine 
equivalents, Section 2.3.4), and when calculated no samples had a total concentration 
below the cutoff. In this case, there would be little difference when basing the 
interpretation of results on the LoD as opposed to cutoff concentration. 
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Table 6.5 – The number of patient urine samples where drugs were detected below 
the cutoff concentration 
*
























































































Ketamine* 63 45 29 (0) 
Tramadol* 475 265 44 (5) 
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In samples where benzoylecgonine was detected, the measured concentration was below 
the cutoff (150 µg/L) in approximately one fifth of samples. Following cocaine use, the 
urinary elimination of benzoylecgonine is initially rapid, but is followed by a slower 
phase meaning benzoylecgonine may be detected up to 3 weeks after use (Nickley et al., 
2017). This may be a result of drug leaching out of body tissue. Reporting according to 
the cutoff will be indicative of recent cocaine use, which may be more clinically 
relevant for monitoring cocaine use in chronic drug users. 
A small proportion of samples had methadone and EDDP detected below the cutoff 
concentration. Reporting these analytes based on the LoD would be unlikely to offer 
much clinical benefit in terms of patient management, and may make missed methadone 
doses harder to identify. When a daily methadone dose is missed, the methadone 
concentration is likely to be lower in a urine sample collected the following day whilst 
the EDDP concentration is less affected (Preston et al., 2003). Identifying a missed dose 
is difficult from analytical results alone due to the variability in methadone 
concentration. Inter-individual differences mainly arise from either genetic variation in 
cytochrome P450 enzymes, or drug-drug interactions which cause induction or 
inhibition of methadone metabolism (Eap et al., 2002).  
As 6-AM is a unique marker of heroin/diamorphine use it has significant clinical value. 
Whilst only a small proportion of samples had 6-AM detected below the cutoff 
concentration, reporting that 6-AM was detected could influence the treatment and 
ongoing clinical management of an individual. Conversely, basing the reporting of 
morphine and codeine on the LoD would be unlikely to influence the treatment of 
patients in drug rehabilitation.   
In samples where dihydrocodeine was detected, the total dihydrocodeine concentration 
was below the cutoff (300 µg/L) in approximately one third of the cases. The 
concentration of dihydrocodeine glucuronide was estimated (based on dihydrocodeine 
calibration) as no reference standard was available at the time of assay development. 
This may be underestimating the actual concentration in urine, and could account for 
samples screening negative. 
Pholcodine was detected below the cutoff (300 µg/L) in the majority of samples where 
it was found. Pholcodine may be detected in urine samples 4-6 weeks after ingestion of 
a single therapeutic dose (Johansen et al., 1990). The observed low concentrations may 
be a result of the urine sample being collected a long time after drug intake.  
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A high proportion of samples had tramadol (and metabolites) detected below the cutoff 
concentration. Inclusion of tramadol in the urine drug screen is intended to identify 
misuse as opposed to therapeutic use. It is likely that urine tramadol concentration will 
be higher when it is misused as opposed to when it is used therapeutically. Basing 
reporting on the LoD may detect more cases of therapeutic use but have minimal impact 
on the number of abuse cases that are identified. 
6.8.3 Conclusions  
Results from this audit suggest that basing result interpretation on the LoD as opposed 
to the cutoff concentrations would affect a large number of results, particularly for 
amfetamines. Whether it would be clinically useful to report results based on the LoD 
would largely depend on the clinical circumstances. Reporting results based on cutoff 
concentrations will largely monitor recent drug use, whereas reporting according to the 
detection limits will extend the window of detection and may relate to less recent drug 
use. As the majority of samples received by our laboratory are from drug and 
rehabilitation services where chronic drug use is being assessed, it is unlikely that 
significant clinical benefit would be gained from more sensitive, extended detection of 
drugs. In addition, defining the timeframe of drug misuse may be difficult as exposure 
to the drug could extend to some weeks ago. Identification of more recent drug misuse 
may be ascertained by comparison of the creatinine-corrected drug concentration in 
subsequent samples. Conversely, in cases where single or low-dose administration of a 
drug is suspected, a high sensitivity screen with analytes reported as ‘detected’ or ‘not 
detected’ based on analytical detection limits may be beneficial. If analytical detection 
limits were used, there would be a greater risk of false positives as a result of analyte 
carryover from analysis of previous samples. Offering a separate ‘high-sensitivity’ 
assay may be the best approach. In this scenario, a blank sample could be analysed prior 
to each patient sample to ensure no analyte carryover.  
6.8.3.1 Further Work  
A reference standard is now available for dihydrocodeine glucuronide, which will 
enable the accuracy of estimated concentrations to be ascertained. Ideally, 
dihydrocodeine glucuronide should be incorporated into the assay calibrators to ensure 









7 Quantitative Drug Assay: Measurement of naloxone, naltrexone 



















7.1.1 Naloxone  
Naloxone may be administered as an antidote in cases of acute opioid poisoning. 
Historically, naloxone has been given by healthcare professionals in clinical settings. 
Distribution of naloxone to the wider community has been termed ‘take-home 
naloxone’. The concept of take-home naloxone is not new (Strang and Farrell, 1992; 
Strang et al., 1996), with pilot studies started in the USA in 1996 and in Europe in 1998 
(Dettmer et al., 2001). However, it is only recently that the concept has been more 
widely accepted and more countries are employing schemes for wider naloxone 
provision to the community. This movement is now reflected by WHO guidelines that 
recommend countries expand naloxone access to those likely to witness opioid 
overdoses (World Health Organisation, 2014b). 
An increased risk of death as a result of opioid overdose has been identified in certain 
situations. Particular groups at high risk are; individuals leaving hospital against 
medical advice after opioid overdose who risk re-entering overdose after naloxone has 
worn off, and individuals re-entering the community (e.g. after prison release, or 
discharge from an in-patient treatment programme). At these times an individual’s 
tolerance is decreased and overdose is likely a result of erroneous judgement of dose 
when returning to opioid use. Provision of naloxone to these high-risk groups may aid 
reduction of opioid overdose deaths.  
Many surveys have shown that a large proportion, typically over 75 %, of injecting 
heroin users have witnessed another individual experience overdosage (Strang et al., 
2000; Seal et al., 2003; Tracy et al., 2005; Gaston et al., 2009; Enteen et al., 2010). This 
provides a workforce with the potential to intervene and who have demonstrated a 
willingness to aid in an overdose situation (Wright et al., 2006). Currently, peer 
members may try to help an individual who has overdosed, but give ineffective or 
incorrect treatment, e.g. administering cocaine, immersion in a cold bath, inflicting pain 
(Beswick et al., 2002; Strang et al., 2013). Adequate intervention is only possible if 
witnesses are aware of the signs of overdose. It has been shown that when adequate 
training is provided, this group are capable of providing life-saving intervention (Clark 
et al., 2014; Seal et al., 2005; Strang et al., 2008; Williams et al., 2014) 
The effectiveness of take-home naloxone programmes has been demonstrated. 
Participation in opioid overdose prevention programs is associated with successful 
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administration to naloxone to reverse opioid overdose (Clark et al., 2014), and the ‘risk 
of opioid-related overdose fatalities is significantly lower in communities providing 
naloxone distribution and overdose management education than in communities without 
programme implementation’ (EMCDDA, 2015). These findings have been reinforced 
by a recent systematic review that demonstrated improved survival rates among 
participants, contributing to reduced overdose mortality rates in the community, and 
also demonstrated a low rate of adverse events associated with naloxone use (McDonald 
and Strang, 2016). 
7.1.2 Administration of Naloxone 
Naloxone (as naloxone hydrochloride in solution, all concentrations as free base) is 
available in the UK as ampoules at 20 µg/mL (2 mL volume) or 400 µg/mL (1 mL), or 
in a pre-filled syringe at 1 mg/mL (2 mL) (Joint Formulary Committee, 2015). In cases 
of opioid overdose, naloxone is ideally administered by intravenous (IV) injection. IV 
administration provides the fastest clinical response, but a suitable vein may be difficult 
to identify and this may hinder timely drug delivery. In these cases subcutaneous (SC) 
or intramuscular (IM) injection may be used, as despite having a slower onset of action 
a comparable clinical response time may be achieved (Clarke and Dargan, 2002; 
Wanger et al., 1998).  
For the purpose of take-home naloxone, injectable naloxone is not an ideal 
administration route. The use of needles increases the risk of blood-borne disease 
transmission and there is a level of skill required to administer the drug correctly. To try 
and aid users in injecting naloxone, a handheld auto-injector device (‘Evzio’, Kaleo 
Inc., Richmond, VA, USA) was approved by the FDA (April 2014). The device talks 
the user through the procedure to administer a single 0.4 mg dose of naloxone, injected 
via a retractable needle IM or SC. Greater success of laypersons administering naloxone 
using the auto-injector has been demonstrated (Edwards et al., 2015). However, the cost 
of this device is likely to limit its use. 
Alternative administration routes are now being explored with the hope to expand the 
use of naloxone in the community. Three main routes have been identified: intranasal, 
buccal, and sublingual (Strang et al., 2016). All these routes have the advantage of 
bypassing the digestive system, and hence first pass metabolism, which will improve 
naloxone bioavailability. There are few data relating to naloxone pharmacokinetics (PK) 
via these alternative routes to aid comparison with the injectable routes. 
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7.1.2.1 Intranasal Naloxone 
To date, the use of intranasal naloxone has been explored in greatest detail. The nasal 
mucosa has attracted attention as an alternative non-invasive drug administration route 
as it has a large absorptive surface with a rich vascular plexus providing a direct route 
for drug absorption. This minimises first-pass metabolism and enables the rate of 
absorption and the plasma concentration achieved to be comparable to IV 
administration for many drugs (Pires et al., 2009).  
Intranasal naloxone has been adopted as an ‘off-label’ use in some American states, 
Australia, and some European countries (e.g. Norway) (Doe-Simkins et al., 2009; 
Hansen, 2014). Typically, 1 mL of 1 mg/mL naloxone hydrochloride solution is sprayed 
into each nostril, thus 2 mg drug is administered. Studies by Barton et al. (2005, 2002) 
demonstrate clinical efficacy of intranasal naloxone with 83 % individuals having 
overdosed being shown to respond by regaining consciousness on administration solely 
by the intranasal route. However, mixed data on naloxone bioavailability via intranasal 
administration exists with early rat studies suggesting 101 % bioavailability (Hussain et 
al., 1984), but more recent human studies reporting just 4 % (Dowling et al., 2008). For 
the Dowling (2008) study, volumes of up to 2 mL were administered in each nostril and 
significant loss of drug from the nasal cavity either by drainage into the nasopharynx or 
external run-off may account for the apparent low bioavailability (Wermeling, 2013). A 
specifically designed nasal product with a more concentrated solution delivered in a 
smaller volume may give more representative data on the relative bioavailability of 
intranasal naloxone. A pilot study of the PK of intranasal naloxone commenced in 
Norway in 2013 (Clinical Trials identifier NCT01939444). The first data from this work 
suggests bioavailability via the nasal route of 54 % and 52 % for 0.8 mg and 1.6 mg 
formulations, respectively (Tylleskar et al., 2017). 
Two specific nasal spray products have now been manufactured, with one gaining FDA 
approval on 18 November 2015 (‘Narcan’, Adapt Pharma Limited, Radnor, 
Pennsylvania, USA). Data from the approved device demonstrate that the critical PK 
characteristics of intranasal naloxone are at least equivalent to those when naloxone is 
administered  IM (Table 7.1, Krieter et al., 2016).  
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Table 7.1 – PK parameters for naloxone after nasal administration, and 
comparison to IM administration (Krieter et al., 2016) 
a Mean (SD) for all parameters except Median (Range) for Tmax 
b  
 
PK Parameter IM administration Intranasal administration 
Dose (mg) 0.4 2 4 8 
Tmax (h) a 0.4 (0.1-2.1) 0.3 (0.3-1.0) 0.5 (0.2-1.0) 0.3 (0.2-1.0) 
Cmax (µg/L) a 0.9 (0.3) 3.1 (1.1) 5.3 (2.4) 10.3 (3.9) 
AUCinf (ng*h/mL) a 1.8 (0.4) 4.7 (1.4) 8.5 (3.3) 15.8 (3.6) 
t1/2 (h) a 1.3 (0.4) 1.9 (0.7) 2.2 (0.6) 2.2 (0.9) 
F (%) b - 52 47 44 
 
Whilst intranasal naloxone may be clinically effective in many cases, damage to the 
nasal mucosa (e.g. epistaxis, trauma, and deformity) may hinder drug administration. 
Damage to the mucosa may also be a result of concurrent or past nasal insufflation of 
other illicit drugs, e.g. cocaine (Ashton and Hassan, 2006). Mechanical problems may 
also be encountered when trying to use the nasal spray on an individual who is in a 
seated or supine position (Dowling et al., 2008). 
7.1.2.2 Buccal Naloxone 
A rodent study reported high bioavailability of naloxone (70 %) from buccal 
administration (Hussain et al., 1987) thus providing some evidence that buccal 
administration in humans may be a viable drug delivery route. 
Formulation of naloxone in conjunction with buprenorphine as a mucoadhesive buccal 
film (BUNAVAIL, BioDelivery Sciences) is FDA approved for maintenance treatment 
of opioid dependence. Manufacturer data does not state the bioavailability of naloxone 
via buccal administration.   
7.1.2.3 Sublingual Naloxone 
Sublingual administration of naloxone (dose of 2 mg or greater) has been shown to 
precipitate withdrawal in opioid-dependent individuals, suggesting sufficient absorption 
through this route (Preston et al., 1990). The only published PK data for the sublingual 





Table 7.2 – PK parameters for naloxone after sublingual administration (in 
combination with buprenorphine, Chiang and Hawks, 2003) 
a Mean (SD) for all parameters  
PK Parameter Sublingual Administration 
Dose (mg) 4 8 
Tmax (h) a 0.9 (0.3) 1.0 (0.3) 
Cmax (µg/L) a 0.66 (0.53) 0.93 (0.71) 
F (%) 9 7 
 
7.1.3 Suboxone 
Suboxone is a co-formulation of buprenorphine and naloxone (4:1 by weight, 
respectively) used for the treatment of opioid addiction. Naloxone is added to deter 
buprenorphine misuse (e.g. by injection or insufflation, i.e. ‘snorted’) as symptoms of 
opioid withdrawal will be induced due to the greater naloxone bioavailability via these 
routes as opposed to when it is taken sublingually. 
Over recent years OST has become more widely available within prisons, with 13 % of 
the prison population in England and Wales receiving either methadone or 
buprenorphine (EMCDDA, 2013). The misuse and diversion of OST is known to be a 
problem, particularly of buprenorphine, which has been named as the third most 
misused drug in UK prisons (Tompkins et al., 2009). The higher prevalence of 
buprenorphine diversion may be due to its formulation as a tablet or film, which makes 
supervising its consumption more difficult compared to that of an oral liquid, e.g. 
methadone linctus. To minimise diversion and misuse of buprenorphine within prisons, 
Suboxone may be prescribed which is known to be less desirable than Subutex 
(buprenorphine only formulation) (Wright et al., 2014). Urinary detection of naloxone 
and its metabolites may enable differentiation of Suboxone and Subutex use. This may 
have clinical value in identifying buprenorphine misuse. Urinary detection of naloxone, 
in addition to buprenorphine, may also enable cases of urine adulteration by direct 







Naltrexone has demonstrated success in preventing re-use of heroin after detoxification 
(Rawson et al., 1979; Shufman et al., 1994). Naltrexone was originally approved as an 
oral tablet, however its effectiveness is often limited due to poor adherence, with studies 
consistently showing only approximately a third of patients complete treatment 
(Minozzi et al., 2011). Adherence to naltrexone therapy is lower than with agonist 
therapies, probably as a result of naltrexone’s lack of reinforcing properties and of 
withdrawal manifestations on cessation, thus naltrexone therapy has to date been largely 
confined to highly motivated individuals (Kjome and Moeller, 2011). A sustained 
release preparation, administered either via depot injection, or implantation, may 
improve adherence (Comer et al., 2006).  
7.1.4.1 Injectable Formulations 
To date, three sustained release naltrexone injections have been developed and tested in 
humans; Depotrex® (Biotek Inc, Woburn, MA), Naltrel® (DrugAbuse Sciences SAS, 
Paris, France), and Vivitrol® (Alkermes, Waltham, MA) (Bartus et al., 2003). Of these, 
only Vivitrol has received FDA approval for treatment of opioid addiction (October 
2010). Vivitrol is administered I.M. in the gluteal region, and gives  sustained plasma 
naltrexone concentrations for 30 days (Kjome and Moeller, 2011). 
7.1.4.2 Implant Formulations 
Several different forms of naltrexone implant have been developed by Australian 
(O'Neil Implant®, Go Medical Industries), Russian (Prodetoxone®, Fidelity Capital), 
Chinese (Civil Life Scientific Company) and American (Wedgewood Implant®, 
Wedgewood Pharmacy) companies. Currently none of the implant formulations are 
approved for clinical use. The implants have comparable or longer duration of action to 
Vivitrol injection. Typically the duration of action for the developed implants is 6-8 
weeks, however the O’Neil Implant is said to last for 5-6 months (Brewer and Streel, 
2010; Hulse et al., 2004).  
7.1.5 Purpose of Measuring Naloxone and Naltrexone 
Most methods for naloxone and naltrexone have been used for PK studies. Clinical 
measurement of naloxone is not usually necessary as efficacy is based on clinical 
response (i.e. increased respiratory rate after opioid overdosage) as opposed to reaching 
a target plasma concentration. Clinical measurement of naltrexone has been employed 
for TDM, largely for individuals trying to prevent relapse of alcohol dependence 
CHAPTER 7 
200 
(Danışmant et al., 2012). Naltrexone TDM for individuals being treated for opioid 
addiction has been advocated (Brünen et al., 2011). As previously mentioned, detection 
of naloxone and its metabolites in urine may be beneficial for identifying the misuse of 
Suboxone (Section 7.1.3). 
7.1.6 Analytical Methods for the Measurement of Naloxone and Naltrexone 
A wide range of analytical methods have been reported for the measurement of 
naloxone and naltrexone. These include radioimmunoassay, TLC, HPLC coupled with 
electrochemical detection (ED), ultra-violet detection (UV) or mass spectrometric 
detection (MS), and GC coupled with flame ionisation detection (FID), electron capture 
detection (ECD) or MS detection.  
Naloxone and naltrexone were both developed in the 1960s. Analytical methods at this 
time used radioimmunoassay. The radioimmunoassay used for naloxone measurement 
lacked selectivity, with studies demonstrating that whilst naloxone glucuronide and 
nornaloxone were not recognized by the antibody, naltrexone and 6-hydroxynaloxone 
were able to displace naloxone-3H from the antibody (Berkowitz et al., 1975). 
Early LC methods used either UV or ED for the measurement of naloxone (Albeck et 
al., 1989; Reid et al., 1993). ED offers greater sensitivity when compared to UV 
detection, however UV is often more robust with ED susceptible to contamination and 
often requiring longer equilibration time (Brünen et al., 2010). Early GC methods used 
FID (Cone et al., 1974) or ECD (Verebey et al., 1980) for measurement of naltrexone. 
More recently, the coupling of chromatographic techniques to mass spectrometry has 
led to huge advances in both assay selectivity and sensitivity. GC-MS methods are 
widely used in drug analysis. However they often require an extensive sample 
preparation step, which may take days to complete. Many analytes require derivatisation 
to enable their detection by GC-MS. Problems can arise in converting an analyte to a 
single suitable derivative, which may limit assay sensitivity. The derivatization of 
naltrexone for GC-MS is associated with partial derivatization of the enolic form of the 
ketone group (Nelson et al., 1993), for example. LC-MS offers a more versatile 
methodology, with no derivatisation required. LC-MS (and LC-MS/MS) methods have 
been widely adopted for measuring naloxone and naltrexone (Brünen et al., 2010; 
Clavijo et al., 2008; Eckart et al., 2015; Jiang et al., 2011; Moreno-Vicente et al., 2015; 
Slawson et al., 2007; Yun et al., 2007). Most methods employing mass spectrometry as 
a detection method are targeted (e.g. SIM, SRM) which gives high selectivity. The 
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disadvantage of this approach is the inability to detect co-medication and look 
retrospectively for other analytes, e.g. minor metabolites. Collection of full scan data 
captures the maximum amount of information from a sample analysis, but in the past 
this has meant a compromise in assay selectivity. More recently, the advent of high-
resolution mass spectrometers coupled with accurate mass measurement has led to 
improved selectivity when capturing full scan data. 
7.1.6.1 Limits of Analytical Detection and Quantitation 
As analytical technology has advanced, analytes can be detected and measured at lower 
concentrations. Using LC-ED detection limits reached 1 µg/L for naloxone (Reid et al., 
1993) and 0.25 µg/L for naltrexone (Davidson et al., 1996) in plasma. The current 
lowest published quantitation limits for each analyte in plasma are listed in Table 7.3, 
and all utilise LC-MS/MS methods. 
Table 7.3 – Lowest quantitation limits published for naloxone, naltrexone and 
metabolites in plasma using LC-MS/MS 
Analyte LLoQ (µg/L) Reference 
Naloxone 0.001 Liu et al. (2016) 
Nornaloxone 0.5 Fang et al. (2009) 
6-β-Naloxol 0.4 Jiang et al. (2011) 
Naloxone glucuronide 0.5 Dong et al. (2013); Jiang et al. (2011) 
Naltrexone 0.005 Clavijo et al. (2008) 
6-β-Naltrexol 0.005 Clavijo et al. (2008) 
 
7.1.6.2 Published Analyte Stability 
A summary of published stability data for naloxone, naltrexone and their metabolites in 
human plasma is given in Table 7.4. To date no stability data have been published for 6-
β-naloxol in human plasma. The stability of 6-β-naloxol in mouse plasma has been 
investigated, with results showing stability for 26 h at room temperature and 40 days at 






Table 7.4 – Naloxone/naltrexone assay: Analyte stability in human plasma  
a
 stored at -80 oC, b stored at -70 oC 
Analyte Study 








Ambient [h] -20 oC [days] 
Naloxone 
Liu et al. (2016) 6.2 606 4 
Fang et al. (2009) 24 468 3 
Moody et al. 
(2002) 24 - 3 
Moreno-Vicente 
et al. (2015) - 93
 a
 3 
Nornaloxone Fang et al. (2009) 24 468 3 
Naloxone 
glucuronide 





Clavijo et al. 
(2008) 12 - 3 
Chan et al. (2001) 
- 
21 
42 a - 
Huang et al. 
(1997) 24 - 2 
Slawson et al. 
(2007) 24 - 3 
Yun et al. (2007) 6 30b 3 
6-β-Naltrexol 
Clavijo et al. 
(2008) 12 - 3 









Yun et al. (2007) 6 30b 3 
 
7.1.7 Aims 
The aim of method development was to simultaneously assay naloxone, naltrexone and 
selected metabolites (nornaloxone, 6-β-naloxol, naloxone-3-glucuronide, and 6-β-
naltrexol). The method will be validated for plasma and whole blood for use in PK 
studies, and where possible the LoD for analytes will be improved compared to 
published methods. The method will also be validated for urine, and will be utilised to 
attempt to differentiate Suboxone and Subutex use. 
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7.2 Materials and Methods 
7.2.1 Chemicals and Reagents 
Naloxone-D5, naloxone-3-glucuronide, naloxone-3-glucuronide-D5, 6-β-naloxol, 6-β-
naltrexol, naltrexone-D4, and naltrexone-D7 were supplied as powders (Alsachim, 
Illkirch-Graffenstaden, France). Naloxone, naloxone N-oxide, and 6-AM were supplied 
as 1 g/L solutions and naltrexone hydrochloride as powder (Sigma Aldrich, Poole, UK).  
HPLC grade acetone and 2-propanol were all from Rathburn (Walkerburn, UK). 
Ammonium acetate, ammonium bicarbonate, and trichloroacetic acid were from Sigma-
Aldrich, and coarsely filtered, pooled human serum was from Sera Labs (Haywards 
Heath, UK). 1.5 mL Eppendorf tubes were from Elkay (Basingstoke, UK). For all other 
chemicals and reagents see Section 2.2.1. 
7.2.2 Instrumentation  
All instrumentation is detailed in Section 2.2.2.  
7.2.3 Liquid Chromatography 
System eluents were as follows: (A) 0.1 % (v/v) formic acid in water, and (B) 0.1 % 
(v/v) formic acid in acetonitrile:methanol (1+1). Prepared samples were directly 
injected (100 µL) onto a Raptor Biphenyl HPLC column (2.7 µm aps, 100 x 2.1 mm 
I.D., Restek, High Wycombe, UK).  The column was fitted with an UltraShield 0.2 µm 
pre-column filter (Restek), and maintained at 30 °C. Gradient elution (total flow 0.6 
mL/min) was used. The starting conditions were 98 % A 2 % B ramped to 75 % A 25 % 
B over 2 min, and then ramped to 10 % A 90 % B over 1.5 min, held for 1.5 min, then 
returned to initial conditions for 2 min to re-equilibrate. The total analysis time was 7 
min. 
7.2.4 Mass Spectrometry 
MS was carried out in positive ionisation mode using heated ESI [spray voltage 4.5 kV; 
temperatures: vaporiser 450 oC, capillary 250 oC; auxiliary, sheath and sweep gases 15, 
55, and 0 (arbitrary units, respectively), S-lens voltage 90 V]. Full-scan MS data were 
acquired using a resolution setting of 35,000 defined as FWHM at m/z 200, with a scan 
range of 200-700 m/z (Orbitrap settings: maximum injection time 10 ms, AGC 1 x 105 
ions).   
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7.2.5 Preparation of Calibration and Internal Quality Control Solutions  
Individual stock solutions of each analyte (all 100 mg/L except; 91.6 mg/L naloxone-3-
glucuronide; 93 mg/L naloxone-3-glucuronide-D5; 75.3 mg/L naltrexone-D4; 102.3 
mg/L naltrexone-D7) were prepared in methanol. All stock solutions were stored at -20 
°C. Nominal concentrations of analytes present in plasma and urine calibrator and IQC 
solutions are given in Table 7.5. 
Table 7.5 – Naloxone/naltrexone assay: Analyte concentration in a) plasma, and b) 
urine, calibrator and IQC solutions  
 
Nominal concentration (µg/L) 
Calibrator IQC 
1 2 3 4 5 6 7 A B C 
a) Plasma 
Naloxone 0.05 0.1 0.2 0.5 1 5 10 0.15 2.5 7.5 6-β-Naloxol 
Nornaloxone 
0.1 0.2 0.4 1 2 10 20 0.3 5 15 Naltrexone 
6-β-Naltrexol 
Naloxone-3- 
glucuronide 0.5 1 2 5 10 50 100 1.5 25 75 
b) Urine 
Naloxone 







7.2.5.1 Plasma  
Stock solutions were diluted as appropriate with methanol to give working solutions A 
(50 µg/L each naloxone and 6-β-naloxol; 100 µg/L each nornaloxone, naltrexone, and 6-
β-naltrexol; 500 µg/L naloxone-3-glucuronide) and B (500 µg/L each naloxone and 6-β-
naloxol; 1000 µg/L each nornaloxone, naltrexone, and 6-β-naltrexol; 5000 µg/L 
naloxone-3-glucuronide). Appropriate volumes of working solutions were evaporated to 
dryness in 10 mL volumetric flasks under a gentle stream of compressed air and 
reconstituted with pooled human plasma to prepare calibration standards and IQC 
solutions. After thorough mixing and equilibration (24 h, 2-8 °C), the prepared 
calibration and IQC solutions were stored in approximately 600 µL portions in 2 mL 
polypropylene screw-top tubes at -20 °C until required.   
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7.2.5.2 Urine  
Appropriate volumes of stock solutions were evaporated to dryness in 10 mL 
volumetric flasks under a gentle stream of compressed air and reconstituted with 
analyte-free human urine to prepare calibration standards and IQC solutions. After 
thorough mixing and equilibration (24 h, 2-8 °C), the prepared calibration and IQC 
solutions were stored in approximately 250 µL portions in 2 mL polypropylene screw-
top tubes at -20 °C until required.  
7.2.6 Internal Standard Solutions  
The plasma working IS solution containing 0.2 µg/L of both naloxone-D5 and 
naltrexone-D7, and 2 µg/L of naloxone-3-glucuronide-D5, was prepared by appropriate 
dilution of the stock solutions with acetonitrile containing 0.1 % (v/v) formic acid. The 
solution was stored and used at -20 oC. 
The urine working IS solution containing 10 µg/L of naloxone-D5, naltrexone-D7 and 
naloxone-3-glucuronide-D5 was prepared by appropriate dilution of the stock solutions 
with eluent A. The solution was stored at 2-8 °C. 
7.2.7 Sample Preparation 
For blood samples, samples/calibrators/IQCs (250 µL) were mixed with 750 µL 
working internal standard into Eppendorf tubes. The tubes were capped, vortex-mixed 
(1 min) and centrifuged (13,500 rpm, 5 min). The upper layer was transferred to a new 
Eppendorf tube and evaporated to dryness under a stream of compressed air at 40 oC. 
The sample was reconstituted in 125 µL eluent A (vortex-mix 30 s), and transferred to a 
0.2 mL glass vial. The vials were capped and transferred to a pre-cooled (10 oC) 
autosampler tray. 
For urine samples, centrifuged samples/calibrators/IQCs (50 µL) were diluted with 450 
µL working IS solution directly into HPLC vials. The vials were capped and transferred 
to a pre-cooled (10 oC) autosampler tray. 
7.2.8 Assay Calibration and Acceptance Criteria 
Calibration standards and matrix blanks were included at the beginning and end of each 
batch analysis, with IQCs included (i) after the first set of calibration standards and 
immediately before the last set, and (ii) after every ten injections throughout the 
sequence. Samples with concentrations exceeding the calibration range for an analyte 
were diluted as appropriate with analyte-free matrix and re-assayed. Assay acceptance 
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criteria were (i) linear (R2 >0.98) calibration curves for each analyte, and (ii) IQC values 
within ±15 % nominal concentrations for all analytes. 
7.2.9 Method Validation Protocol 
The method was validated according to the FDA/CDER guidance for bioanalytical 
method validation (FDA/CDER, 2013). Intra- and inter-assay accuracy (% nominal 
concentration) and precision (% RSD) were assessed for each analyte at three 
concentrations through replicate analysis of the IQC solutions (N = 5) on the same day 
and singleton analysis on 5 different days, respectively. The LLoQ was ascertained 
through replicate analysis of the lowest calibrator and was based upon a signal-to-noise 
ratio >10, and RSD <20 % (N = 5). To assess the linearity for each analyte, a high 
concentration sample (all analytes 500 µg/L in plasma, 10,000 µg/L in urine) was 
diluted using blank matrix to within the calibration range.  
To assess analyte recovery in plasma, aqueous solutions were prepared with all analytes 
and internal standards at 50 µg/L and at 100 µg/L. These samples were prepared and 
analysed as described except that 0.1 % formic acid in acetonitrile was added in place of 
IS solution. The mean peak areas (N = 3) obtained from analyses of the extracts of the 
aqueous solution (50 µg/L all analytes and internal standards) were compared to the 
mean peak areas (N = 3) obtained from direct injection of an aqueous solution (100 
µg/L all analytes and internal standards, to be comparable with extracted samples that 
undergo two-fold concentration). Analyte recovery was not necessary for urine samples 
as sample preparation only involved dilution with IS solution.  
Initially, matrix effects were assessed qualitatively in plasma using the post-column 
infusion method (Bonfiglio et al., 1999). Analyte-free plasma from 10 independent 
sources was analysed. These samples were prepared and analysed as described except 
that 0.1 % formic acid in acetonitrile was added in place of IS solution, and the detector 
response for each analyte was monitored whilst a methanolic solution containing all 
analytes and internal standards (1 mg/L, 20 µL/min) was infused by syringe post-
column. To further quantify matrix effects and ascertain if the internal standards 
selected were appropriate, addition experiments were undertaken in plasma, whole 
blood, and urine. Solutions containing all analytes and internal standards (50 µg/L) were 
prepared in (i) analyte-free human plasma/whole blood/urine from 10 independent 
sources, and (ii) deionised water. Samples were prepared and analysed as described 
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above except that 0.1 % formic acid in acetonitrile for the plasma/blood method and 0.1 
% formic acid in water for the urine method were added in place of the IS solutions.  
Analyte carryover was assessed through consecutive analysis of a sample containing 
low (L) and high (H) analyte concentrations in the order L, L, L, H, H, H, L, L, L (L: all 
analytes 0.5 µg/L and H: all analytes 50 µg/L in plasma; L: all analytes 10 µg/L and H: 
all analytes 2000 µg/L in urine). 
7.2.9.1 Stability Studies 
Stability studies were conducted in plasma only. The stability of all analytes was 
assessed through analysis of portions of IQC solutions stored (i) at ambient temperature 
for 48 hours, (ii) refrigerated for 2 weeks, and (iii) after multiple (N = 4) freeze-thaw 
cycles. Temperatures were monitored using automated software with measurements 
every 15 min at each condition (Comark, Norwich UK). For each storage condition, 
analyte concentrations were assessed against calibrators stored frozen and thawed for 
the first time immediately prior to use. Three separate portions of each IQC were 
analysed under each condition, and the mean concentration used to assess stability. 
Analyte instability was defined as a deviation >20 % from the expected concentration. 
7.2.10 Differentiating Suboxone and Subutex Use 
Fourteen urine samples from patients known to be taking Suboxone were analysed to 
provide information on the typical urinary naloxone and metabolite concentrations 
achieved during routine Suboxone therapy. Buprenorphine and metabolites were 
measured in these samples using the urine drug screening method (Chapter 2). 
7.2.11 Patient Samples and Ethics Considerations 
Excess blood from samples submitted for TDM and excess urine from samples 
submitted for urine drug screening were used to ascertain matrix effects and to ascertain 
if the method was fit-for-purpose; these samples would normally have been discarded 
following the normal ethics guidelines. No records kept during method development 
permitted identification of patients. For differentiating Suboxone from Subutex use, 
excess urine submitted for drug screening from individuals known to be taking 
Suboxone were sent anonymised to our laboratory from St. James's University Hospital 
(Leeds, UK), and urine samples sent to King’s College Hospital for routine drug 
screening which stated Subutex as a prescribed medicine on the request form were used 
to assess any potential interference with the naloxone assay.  
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7.3 Results and Discussion 
7.3.1 Liquid Chromatography Method Development 
7.3.1.1 Choice of LC column 
Most published methods for measurement of naloxone and naltrexone have used 
reverse-phase chromatography, typically with a C18-modified silica column (Table 7.6). 
For the measurement of naloxone glucuronide, hydrophilic interaction liquid 
chromatography (HILIC) has also been reported (Dong et al., 2013).  
Initially an Accucore Phenyl Hexyl column and a Hypersil Gold C18 column (both 100 
x 2.1mm, ThermoFisher Scientific) were evaluated, but naloxone-3-glucuronide did not 
retain well on either column. An alternative column, Hypercarb (porous graphitised 
carbon, ThermoFisher Scientific), was investigated due to its capability to retain more 
polar analytes. Good retention of all analytes on a Hypercarb column was achieved and 
an LC method optimised, but when switching to a newly manufactured column the 
peaks and column performance were not reproducible. Due to this lack of robustness, a 
third stationary phase with a biphenyl ligand (Raptor Biphenyl 2.7 µm, 100 x 2.1mm, 





Table 7.6 – Some published LC methods for the detection of naloxone and 
naltrexone  
Abbreviations: aps – average particle size, I.D. – Internal diameter, C18 – octadecyl, 
CN – cyano, RP – reverse phase. 
Analytes in method LC Column Details Reference 
Naltrexone, 6-β-
naltrexol 
C18 (50 x 4.6 I.D. mm; 1.8 µm aps, 
Agilent XDB) 




C18 (125 x 4 I.D. mm; 5 µm aps, 
ThermoFisher Hypersil) 




C18 (150 x 2.1 I.D. mm; 5 µm aps,  
ThermoFisher Hypersil) 




C18 (150 x 4.6 I.D. mm; 5 µm aps, 
Supelco Supelcosil) 




CN (30 x 4.6 I.D. mm; 5 µm aps, 
Phenomenex Luna) 




Phenyl (100 x 4.6 I.D. mm; 3 µm aps, 
YMC) 
Davidson et al. 
(1996) 
Naloxone, naltrexone & 
6-β-naloxol 
Phenyl hexyl (100 x 2.1 I.D. mm;1.8 
µm aps, Zorbax Eclipse) 
Eckart et al. 
(2015) 
Naloxone & naltrexone Phenyl (150 x 4.6 I.D. mm; 5 µm aps, Waters X-Bridge) 
Moreno-Vicente 
et al. (2015) 
Naloxone C18 (50 x 2.1 I.D.  mm; 2.5 µm aps, Waters X-Bridge) 
Krieter et al. 
(2016) 
Naloxone C18 (50 x 2.1 I.D. mm; 3 µm aps, 
Imtakt Unison) Liu et al. (2016) 
Naloxone C18 (100 x 2.1 I.D. mm; 4 µm aps, Phenomenex Gemini) 
Heikman et al. 
(2014) 
Naloxone C18 (50 x 2 I.D. mm; 3 µm aps, YMC) Moody et al. (2002) 
Naloxone C18 (150 x 4.6 I.D. mm; 5 µm aps, Alltech Econosphere) 




C18 (50 x 2.1 I.D. mm; 5 µm aps, 
ThermoFisher Aquasil) 









Naloxone, nornaloxone C18 (50 x 2.1 I.D. mm; 3.5 µm aps, Waters XTerra) 




HILIC 100A (50 × 2.1 I.D. mm; 2.6  
µm aps, Phenomenex Kinetex) 





7.3.1.2 Aqueous eluent selection 
When first testing the biphenyl column, a simple gradient (2-100 % organic eluent [0.1 
% (v/v) formic acid in methanol] over 6 minutes) was used. The column temperature 
was maintained at 50 oC, and the LC flow rate was 0.4 mL/min. Initially, the aqueous 
phase tested was 0.1 % (v/v) formic acid in deionised water. Under these conditions 
nornaloxone, the first eluting peak, was not completely retained on the column. 
Nornaloxone lacks the branched alkene/cyclopropane moiety that the other analytes 
possess, which may account for less interaction with the biphenyl column. The biphenyl 
column is stable over a pH range of 1.5-8.0. To attempt to improve retention of 
nornaloxone, the addition of volatile ammonium salts (all 10 mmol/L) to the aqueous 
phase was investigated over the pH range 3.0-7.5 (Table 7.7).  
Table 7.7 – Ammonium salts used to investigate the effect of pH on analyte 
retention 











Retention of nornaloxone was improved at higher pH, with greatest retention at pH 7.5 
(Figure 7.1). Unfortunately, whilst ammonium bicarbonate is LC-MS compatible it was 
found that the biphenyl column showed increased back pressure rapidly when using this 
method. Ammonium bicarbonate is not very soluble in methanol or acetonitrile, and as a 
result was likely precipitating in the column. Unfortunately, no other LC-MS 
compatible buffers are capable of buffering at higher pH. As a result the aqueous eluent 
used was returned to 0.1 % (v/v) formic acid in water, as both ammonium formate and 
ammonium acetate caused significant peak fronting, and alternative approaches to 
improve nornaloxone retention were considered. 
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Figure 7.1 – Extracted ion chromatograms (m/z 288.1230) to show the influence of 
pH on LC retention of nornaloxone [Biphenyl (100 x 2.1 I.D. mm) column, Restek] 











7.3.1.3 LC flow rate and column temperature 
Analyte retention may be influenced through LC flow rate and column temperature. A 
lower flow rate will increase analyte retention, but may emphasise peak broadening. 
When using ESI, a lower flow rate also offers the benefit of improved assay sensitivity. 
Increased column temperature may reduce analyte retention enabling analysis time to be 
shortened, and may result in sharper chromatographic peaks due to more efficient solute 
transfer between the mobile phase and the stationary phase (Vanhoenacker et al., 2010). 
To assess the impact of LC flow rate, the column was held at 30 oC whilst the total LC 
flow rate was altered (range 0.3-0.6 mL/min). Improved MS response was noted at 
lower flow rate (Table 7.8), however peak shape deteriorated significantly and thus the 
flow was maintained at 0.6 mL/min. The optimum column temperature over 30-50 oC 
was then investigated in steps of 5 oC. Fronting of the nornaloxone peak worsened at 
temperatures over 40 oC, and thus the column oven temperature was kept at 30 oC 


































Table 7.8 – Naloxone/naltrexone assay: The impact of decreasing LC flow rate on 
analyte peak areas  
The relative analyte peak area (%) to the observed peak area with the LC flow rate at 
0.6 mL/min is given. 
Analyte LC flow rate (mL/min) 0.5 0.4 0.3 
Nornaloxone 136 % 155 % 192 % 
Naloxone-3-glucuronide 131 % 158 % 206 % 
Naloxone 115 % 130 % 165 % 
6-β-Naloxol 119 % 132 % 153 % 
Naltrexone 115 % 136 % 164 % 
6-β-Naltrexol 117 % 134 % 158 % 
 
 
Figure 7.2 – Extracted ion chromatograms (m/z 288.1230) to show the influence of 
column temperature on the retention of nornaloxone [Biphenyl (100 x 2.1 I.D. mm) 










































7.3.1.4 Organic eluent selection 
Three organic eluents were investigated; 0.1 % (v/v) formic acid in i) acetonitrile, ii) 
acetonitrile:methanol (1+1), and iii) methanol. The best peak shape was observed when 
using solely acetonitrile, however chromatographic resolution was improved when 
using methanol. Acetonitrile:methanol (1+1) offered a good compromise and was thus 
used for the developed method. 
Alteration of the organic eluent was also important for improving assay selectivity. 6-
AM is isobaric with naloxone (m/z 328.1543). As 6-AM is the primary metabolite of 
diamorphine, it is possible that 6-AM and naloxone could both be present in a sample. 
To ensure accurate quantitation of naloxone, it was important that 6-AM was 
chromatographically resolved from naloxone. This was achieved through alteration of 
the organic phase, with 0.1 % (v/v) formic acid in acetonitrile:methanol (1+1) providing 
good resolution (Figure 7.3). 
Other possible sources of interference in the assay are N-oxides. N-Oxides can undergo 
in-source decomposition to their parent compound and thus interfere with analyte 
quantitation if not resolved chromatographically, or removed by sample preparation 
procedures. The extent of N-oxide deoxygenation using ESI is significantly lower than 
when using APCI (Ibrahim et al., 2013). However, deoxygenation of naloxone N-oxide 
may occur ([(M+H)-O]+, m/z 328.1544). Naloxone (2.71 min) is chromatographically 
resolved from the N-oxide (3.09 min) in the method developed (Figure 7.3). Naloxone 
N-oxide is an impurity in pharmaceutical formulations of naloxone, and may also be a 
potential metabolite. There is nothing to suggest metabolism of naltrexone to naltrexone 
N-oxide, and no reference material is available commercially.  
Figure 7.3 – Extracted ion chromatograms to show chromatographic resolution of 
a) naloxone (m/z 328.1543) from b) 6-AM (m/z 328.1543)  and c) naloxone N-oxide 




































7.3.2 Mass Spectrometry Method Development 
7.3.2.1 Optimisation of Source Conditions 
An aqueous solution containing all analytes (100 µg/L) was analysed (N = 3) under 
different instrument settings, and the mean peak area compared to ascertain the 
optimum settings. The parameters assessed were: S-lens voltage (50-100 V, in 10 V 
steps), distance of the ESI probe from the mass spectrometer source (levels A-D, as 
described in Section 2.3.3.2), and capillary temperature (250-450 oC, in 50 oC steps).  
Most analytes were little affected by the change in S-lens voltage, with the exception of 
naloxone-3-glucuronide, which had a markedly increased response at higher S-lens 
voltages. For most analytes, response peaked at probe height setting C, and analyte 
response declined as capillary temperature increased (Figure 7.4). 
To ascertain the other source conditions, including gas flow rates, spray voltage and 
vaporiser temperature, the instrument software was used to give the default settings 











Figure 7.4 – Optimisation of source conditions for naloxone/naltrexone assay: the influence of a) S-lens voltage, b) ESI probe height, and c) 
capillary temperature on analyte peak area (see Section 7.3.2.1) 















7.3.2.2 Mass Resolution 
Mass resolution relates to the ability of a mass spectrometer to separate peaks of one 
mass-to-charge ratio from another, with higher resolution giving improved separation. 
However, increasing mass resolution increases the time required for each scan. For 
accurate quantitation it is suggested that a minimum of 10 scans are collected across 
each chromatographic peak. To assess the impact of increasing mass resolution on the 
number of MS scans collected over a chromatographic peak, an aqueous solution (all 
analytes 100 µg/L) was analysed using different resolution settings (Figure 7.5). As the 
chromatographic peaks were narrow, the resolution selected for the method was 35,000, 
which provided an adequate number of data points per peak. 
 
Figure 7.5 – Extracted ion chromatograms (m/z 328.1543) to show the reduction in 
MS scans collected over the naloxone peak due to an increase in mass resolution 
















































7.3.2.3 MS Scan Experiments 
A key parameter for naloxone/naltrexone assay for PK purposes is sensitivity. The 
highest sensitivity will be achieved from quantifying on the parent ion as opposed to 
product ions, thus either a full scan or SIM may be used. Full scan data were selected 
for the method as this gives the potential to interrogate data retrospectively if necessary. 
This may be beneficial for looking for other minor metabolites, e.g. naloxone N-oxide, 
and co-prescribed medications. 
Inclusion of an MS2 scan, in addition to the full scan, to provide further analyte 
confirmation through the presence of product ions was investigated. The scan number 
across the peak, particularly at low analyte concentration, was too low to justify 
inclusion of this additional experiment. As accurate mass is being used, the certainty of 
analyte identification is greatly improved as compared to using nominal mass, 
especially when coupled with other confirmatory parameters such as isotope pattern and 




7.3.3 Sample Preparation 
The physicochemical properties of each analyte (Table 7.9) were studied prior to 
devising a sample preparation procedure. The pKa is important as it gives information 
on the charge of each analyte species at differing pH values. Log P (partition 
coefficient) was used to study how the polarities of analytes varied with pH, which is 
particularly relevant to liquid-liquid extraction. 
Table 7.9 – Naloxone/naltrexone assay: Physicochemical properties of the analytes 
studied (theoretical values calculated using MarvinSketch, version 6.3.0, 
ChemAxon Ltd) 
Analyte pKa Log P 
Naloxone 7.84 1.62 
Nornaloxone 9.36 0.51 
6-β-Naloxol 8.54 1.21 
Naloxone-3-glucuronide 8.52 -0.33 
Naltrexone 8.88 1.67 
6-β-Naltrexol 9.47 1.26 
 
In addition to studying the properties of the analytes, a literature search was performed 
to ascertain the sample preparation methods used previously. Protein precipitation has 
been used either as a sole preparation method (Brünen et al., 2010; Dong et al., 2013), 
or in conjunction with a further sample preparation step (Clavijo et al., 2008). Liquid-
liquid extraction has been widely used, but not for all analytes; no published method has 
used this technique for naloxone-3-glucuronide or for nornaloxone (Davidson et al., 
1996; Heikman et al., 2014; Heinälä et al., 2012; Liu et al., 2016; Moody et al., 2002; 
Nelson et al., 1993; Verebey et al., 1980). Solid phase extraction, typically with C18 
cartridges, has also been used (Albeck et al., 1989; Chan et al., 2001; Fang et al., 2009; 
Huang et al., 1997; Reid et al., 1993; Toennes et al., 2004; Ventura et al., 1988; 
Zuccaro et al., 1991).  
7.3.3.1 TurboFlow 
TurboFlow coupled to LC-MS has been used for opioid analysis in plasma, but 
naloxone and naltrexone have not been analysed using this sample preparation 
technology. Three different TurboFlow columns were evaluated: Cyclone-P, C18-P-XL 
and Cyclone-MAX (ThermoFisher Scientific). All columns have reverse phase 
chemistry, with the Cyclone-MAX also having anion exchange capacity. Initial studies 
showed the C18-P-XL column did not retain naloxone-3-glucuronide and thus it was 
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not studied further. Improved retention of naloxone-3-glucuronide was observed using 
the Cyclone-MAX column, as opposed to the Cyclone-P, and thus conditions were 
optimised using the former column. 
Retention of analytes on the Cyclone-MAX TurboFlow column during the loading step 
was investigated by setting up a simple method that changed sequentially through 
deionised water, methanol [formic acid in methanol (0.1 % v/v)] and mixed solvent 
(acetonitrile:2-propanol:acetone; 2+2+1) eluents, reflecting the loading, transfer, and 
wash stages respectively, prior to re-equilibration for the next analysis. No analytical 
column was used, and flow was directed constantly to the MS, rather than to waste. 
Ideally peaks should be observed during the transfer step, and not in the loading or 
washing stages.  
The aqueous eluent was varied to investigate the impact of loading pH on analyte 
retention, with three pH values being studied: 3 (0.1 % v/v formic acid in deionised 
water), 6 (10 mmol/L aqueous ammonium acetate), and 9 (10 mmol/L aqueous 
ammonium carbonate). An aqueous solution containing all analytes (100 µg/L) was 
analysed (N = 3) and mean peak areas in the loading, transfer and washing steps 
measured. 
Retention of all analytes, particularly naloxone-3-glucuronide, was best when loading at 
pH 9.  Retention of naloxone-3-glucuronide on the Cyclone-MAX column can be 
attributed mainly to anion exchange, with negatively-charged species predominating at 
pH 9 (Table 7.10). With all other analytes the predominant retention mechanism is 
through reverse phase chemistry as only a small proportion of the analyte will carry a 
negative charge at pH 9. 
 
Table 7.10 – Percentage of analyte species negatively charged at pH 9 (theoretical 
values calculated using MarvinSketch, version 6.3.0, ChemAxon Ltd) 









Analyte recovery from the Cyclone-MAX column was assessed via analysis of an 
aqueous solution (all analytes 100 µg/L) through a) the complete TurboFlow process, 
and b) with the TurboFlow system bypassed (i.e. injection directly onto the analytical 
column). The mean peak areas (N = 3) of each analyte subjected to the complete 
TurboFlow process were compared to those observed from injection onto the analytical 
column only, in which the latter was assumed to represent 100 % recovery. Good 
recovery for all analytes from the Cyclone-MAX column was observed using these 
conditions with the exception of nornaloxone (Table 7.11a). Poor recovery of 
nornaloxone was attributed to loss in the loading step. To improve the retention of 
nornaloxone, a Cyclone-P TurboFlow column was added in tandem after the Cyclone-
MAX column to retain nornaloxone (Figure 7.6). Through inclusion of this second 
TurboFlow column, recovery of nornaloxone was improved (Table 7.11b). 
 
Table 7.11 – Naloxone/naltrexone assay: Recovery from a) Cyclone-MAX 
TurboFlow column, and b) Cyclone-MAX and Cyclone-P TurboFlow columns in 
tandem  
Recovery was assessed through peak area comparison of an aqueous solution containing 
all analytes (100 µg/L) injected onto i) the TurboFlow column/s (N=3), and ii) directly 
injected on the analytical column (N=3). 
Analyte 
TurboFlow Recovery (%) 
a) Cyclone MAX Only b) Cyclone MAX & Cyclone-P 
Naloxone 94 89 
Naloxone-D5 88 89 
Nornaloxone 15 65 
6-β-Naloxol 85 91 
Naloxone-3-glucuronide 76 84 
Naltrexone 96 91 
Naltrexone-D4 94 91 




Figure 7.6 – Naloxone/naltrexone assay: Retention of analytes on a) Cyclone-MAX 
TurboFlow column, and b) Cyclone-MAX and Cyclone-P TurboFlow columns in 
tandem  
The loading, transfer, and eluting steps are represented by the red, yellow, and green 
shaded areas respectively. For maximum analyte recovery, peaks should appear only in 












Due to the change in LC method first from the Hypercarb to the Biphenyl column, and 
subsequently the change from ammonium bicarbonate to aqueous formic acid eluent, 
compatibility of the TurboFlow method with the LC method was reassessed. To 
ascertain the maximum organic content of the injection solvent possible without 
impacting nornaloxone retention, solutions containing all analytes (0.05 µg/L) from 0-
50 % organic content (in 5 % increments) were analysed using the LC method, i.e. 
bypassing the TurboFlow column (Figure 7.7). 
The retention of nornaloxone was affected when 5 % methanol was present in the 
injection solvent, thus ideally the injection solvent should contain no organic solvent. 
On this basis, using TurboFlow would not be possible as organic solvent is introduced 
during the transfer step. Liquid-liquid extraction and protein precipitation were thus 
investigated as alternative sample preparation methods. 
 
 








































Figure 7.7 – Naloxone/naltrexone assay: The influence of increasing the proportion of methanol (%) in the injection solvent on the retention of 
nornaloxone [Biphenyl (100 x 2.1 I.D. mm) column, Restek] 
 a) 0 % methanol                                            b) 5 % methanol                                        c) 10 % methanol 
Time (min) Time (min) Time (min) 
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7.3.3.2 Liquid-Liquid Extraction 
A simple LLE protocol (Figure 7.8) was used for initial investigations. The median 
(range) pKa for the analytes was 8.6 (7.8-9.5). For optimum analyte extraction the pH 
should be 2 units above analyte pKa, thus pH 10.6 was initially tried. 
Figure 7.8 – Naloxone/naltrexone assay: LLE protocol 
Pipette 100 µL sample + 100 µL Tris buffer (pH 10.6) + 25 µL IS solution into Eppendorf tube 
 
Add 200 µL butyl acetate:butanol (9+1) 
 
Transfer upper extract to a new Eppendorf tube 
 
Reconstitute in 100 µL 0.1 % formic acid (aqueous) 
 
To access the effect of pH on extraction efficiency, the aqueous phase pH was altered 
over the range 5-10.5 (in 0.5 pH unit increments). The same protocol was used, but with 
the buffer varied (2 mol/L Tris pH 7.5-10.5, 2 mol/L ammonium acetate pH 5-7). 
Naloxone-3-glucuronide and nornaloxone exhibited poor extraction, with naloxone-3-
glucuronide not extracted at any pH and the best recovery for nornaloxone reaching 
only 8 %. For the other analytes, pH 9 gave the best recovery (Table 7.12). 
Table 7.12 – Naloxone/naltrexone assay: Recovery of analytes under different pH 
conditions using LLE 
Analyte Analyte recovery at varying pH (%) 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 10.5 
Naloxone-3-glucuronide 0 0 0 0 0 0 0 0 0 0 0 0 
Nornaloxone 0 0 0 0 0 1 3 5 7 8 7 3 
Naloxone 12 26 48 62 74 83 82 80 86 83 78 79 
6-β-Naloxol 1 2 5 13 25 59 62 64 71 68 61 58 
Naltrexone 4 6 24 44 62 87 91 87 94 92 84 88 
6-β-Naltrexol 0 1 2 5 12 46 58 62 75 75 67 72 
‘Salting out’ has been shown to encourage some more polar analytes to move into the 
organic phase during LLE (Flanagan et al., 2006; Kole et al., 2011). To access whether 
‘salting out’ might improve the recovery of naloxone-3-glucuronide and nornaloxone, 
50 µL of saturated NaCl solution was added at the initial pipetting stage. Results 
showed no improvement. Whilst LLE gave good results for most analytes, the more 
polar analytes were not extracted, and thus LLE was deemed unsuitable for the assay. 
Vortex mix 5 s 
Vortex mix 30 s 
Centrifuge (13,500 rpm, 5 min) 




7.3.3.3 Protein Precipitation 
Protein precipitation is non-selective which may be beneficial when analytes possess 
different physicochemical properties; however more matrix interferences are likely to 
remain which may affect analyte quantitation. Two of the most effective precipitants for 
protein removal are acetonitrile and aqueous trichloroacetic acid (TCA) (Polson et al., 
2003). TCA precipitation was investigated first as addition would negate the need for a 
drying down step. 50 µL aqueous TCA (10 % w/v) were added to 200 µL plasma 
sample (standard 1, see Table 7.5) in an Eppendorf tube. The contents of the tube were 
vortex-mixed (30 s) and then centrifuged (5 min, 13,500 rpm). The upper layer was 
transferred to a HPLC vial and 100 µL of extract were injected. Results showed that the 
sample dilution associated with TCA precipitation was unacceptable, with some 
analytes not being detected in the lowest calibrator. Whilst protein precipitation using 
acetonitrile necessitates a drying down step, and hence is a lengthier sample preparation 
procedure, it also facilitates sample concentration. A basic protocol (Figure 7.9) was 
thus used for initial investigations using acetonitrile precipitation.  
To ascertain the optimum ratio of sample to solvent, the volume of IS solution added 
was varied. A balance between improved protein removal and additional drying time 
needed to be assessed. Optimum results were observed using a ratio of 1+3 
sample:solvent (IS solution). To reduce drying time, the time to dry samples in a 
heating block at 40 oC was compared to the time to dry samples at ambient temperature. 
No analyte degradation was noted and drying time was reduced, thus drying at 40 ºC 
was included in the protocol. To improve assay sensitivity, sample concentration during 
the reconstitution step was evaluated. Optimum results were observed when the sample 
was concentrated by a factor of 2. To ascertain the minimum mixing time required for 
complete protein precipitation the procedure was assessed over the range of 0.5-10 min. 
No benefit was observed when mixing was longer than 1 min, thus this was set as the 
optimum time in the final method (Figure 7.10). Analysis of the lowest calibration 




Figure 7.9 – Initial protein precipitation protocol using acetonitrile 









Reconstitute in 150 µL 0.1 % formic acid (aqueous) 
 
 
Figure 7.10 – Naloxone/naltrexone assay: Final protein precipitation protocol 








Reconstitute in 125 µL 0.1 % formic acid (aqueous) 
Vortex mix 1 min 
Centrifuge (13,500 rpm, 5 min) 
 
Dry under stream of compressed air, 40 oC 
 
Vortex mix 10 min 
Centrifuge (13,500 rpm, 5 min) 











Figure 7.11 – Comparison of protein precipitation techniques for naloxone/naltrexone assay: Injection of a) an aqueous solution (comparable 
to standard 1) was compared to standard 1 prepared by protein precipitation using b) acetonitrile, and c) TCA  
 












































      6-β-Naltrexol 
a)                                                         b)                                                                   c)  
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7.3.4 Assay Calibration 
7.3.4.1 Selection of a suitable calibration range 
Reported peak plasma concentrations via different routes of administration are given in 
Table 7.13. There are minimal data regarding the concentration of naloxone metabolites 
in plasma after administration of naloxone. Plasma nornaloxone concentrations of less 
than 0.5 µg/L were reported for 3 individuals maintained on sublingual 16 mg 
buprenorphine/4 mg naloxone for 2 weeks (Fang et al., 2009).  
The literature suggests that steady state plasma naltrexone and 6-β-naltrexol 
concentrations are in the range of 3-25 µg/L and 25-70 µg/L, respectively (Brünen et 
al., 2010; Ferrari et al., 1998). 
 
Table 7.13 – Reported plasma naloxone PK parameters via differing 
administration routes 
a
 bolus followed by infusion (0.24 mg/min for 5 h) 
* co-formulated with buprenorphine (dose ratio 4:1 buprenorphine:naloxone) 








Krieter et al., 2016 29 Intramuscular 0.4 0.9 24 
Baselt, 2014 6 Intramuscular 0.8 1.4 15 
Krieter et al., 2016 29 Intranasal 2 3.1 18 
Krieter et al., 2016 29 Intranasal 4 5.3 18 
Krieter et al., 2016 29 Intranasal 8 10.3 18 
Baselt, 2014 6 Intranasal 2 0.8 10 
Baselt, 2014 9 Intravenous 0.4 10 2 
Reid et al., 1993 2 Intravenous 20a 69-84 - 
Baselt, 2014 20 Oral 5 0.032 300 
Baselt, 2014 20 Oral 20 0.099 300 
Moody et al., 2002 3 Sublingual* 2 0-0.2 30 
Fang et al., 2009 3 Sublingual* 4 0.139 ±0.062 30 
Chiang & Hawks, 2003 9 Sublingual* 4 0.66 ±0.53 56 ±15 





7.3.4.2 Internal Standards 
Initially deuterated analogues of each parent drug, naloxone-D5 and naltrexone-D4, were 
selected as internal standards.  
Naltrexone-D4 was later replaced by naltrexone-D7 due to interference from a naturally 
occurring isotope of 6-β-naltrexol in the analysis. The second natural isotope (M+2) of 
6-β-naltrexol (m/z 346.1910) is close in mass to naltrexone-D4 (m/z 346.1951). These 
two masses could not be completely resolved even using high resolution MS (Figure 
7.12). As a result, the peak area of naltrexone-D4 was falsely elevated as the 6-β-
naltrexol concentration increased. This did not occur when naltrexone-D7 was used as 
the internal standard, with the naltrexone-D7 peak area remaining consistent between 
calibrators and IQCs (Figure 7.13).  
Naloxone-3-glucuronide was subject to a far greater matrix effect than the naloxone-D5 
which was being used as an internal standard. To resolve the issue, naloxone-3-
glucuronide-D5 was added to the method (see Section 7.3.5). 
 
Figure 7.12 – Mass chromatograms to show the effect of increasing resolution to 
attempt to remove 6-β-naltrexol interference on naltrexone-D4  
The 10 ppm extraction window based upon naltrexone-D4 (m/z 346.1951) is represented 










Theoretical = 17,500 
Actual = 14,981 
 
 
Theoretical = 35,000 
Actual = 28,514 
 
 
Theoretical = 70,000 
Actual = 58,531 
 
 
Theoretical = 140,000 






















Figure 7.13 – The effect of 6-β-naltrexol concentration on naltrexone-D4 peak area 
 Mean peak areas (N = 2) for (i) naltrexone-D4, and (ii) naltrexone-D7 were compared in 













7.3.5 Assay Validation 
Intra- and inter-assay accuracy and precision are summarized in Tables 7.14 and 7.15, 
respectively. The limit of accurate measurement was taken as the lowest calibrator, with 
good precision observed for all analytes in both urine and plasma (RSD <10 %). 
Calibration graphs were linear (R2 ≥0.99 for all analytes) over the calibration ranges 
(Figures 7.14 and 7.15). Linearity was good for naloxone, naloxone-3-glucuronide, and 
naltrexone above the top calibrator in both urine and plasma (Figure 7.16). However, 
the accuracy of the measured concentration of 6-β-naloxol, 6-β-naltrexol, and 
nornaloxone deteriorated at higher concentration indicating that reanalysis after sample 
dilution is required for accurate quantitation of these analytes. Analyte recovery from 
plasma was good (Table 7.16). No significant carryover/carryunder was observed in 
plasma or urine samples (Table 7.17). Ion suppression was identified (Figure 7.17), but 
the internal standards used compensated well for matrix effects, except that nornaloxone 
showed some variability in plasma and whole blood samples (Table 7.18). 
CHAPTER 7 
230 
Table 7.14 – Plasma naloxone/naltrexone assay: Summary intra- and inter-assay 














































































































































































Table 7.15 – Urine naloxone/naltrexone assay: Summary intra- and inter-assay 















































































































































































Figure 7.14 – Naloxone/naltrexone assay: Typical calibration curves for all 
analytes in plasma 
 






























Y = -0.266669+3.7382*X   R 2^ = 0.9940   W: 1/X










Y = -0.421265+6.56603*X   R 2^ = 0.9938   W: 1/X
















Y = -0.502716+4.49756*X   R 2^ = 0.9963   W: 1/X



















Y = -0.304578+11.0575*X   R 2^ = 0.9962   W: 1/X
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Figure 7.15 – Naloxone/naltrexone assay: Typical calibration curves for all 
analytes in urine 
 












 = 0.9973 
Y = -0.15742+0.0192258*X   R 2^ = 0.9969   W: 1/X
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Table 7.16 – Naloxone/naltrexone assay: Analyte recovery from plasma 
Analyte No extraction 
mean peak area 
Post extraction 
mean peak area 
Recovery 
(%) 
Naloxone 1.13 e8 1.03 e8 91 
Nornaloxone 3.91 e8 3.42 e7 87 
6-β-Naloxol 1.47 e8 1.34 e8 91 
Naloxone-3-glucuronide 2.36 e7 2.25 e7 96 
Naltrexone 1.19 e8 1.13 e8 95 
6-β-Naltrexol 2.39 e8 2.16 e8 90 
Naloxone-D5 9.39 e7 8.63 e7 92 
Naloxone-3-glucuronide-D5 1.88 e7 1.78 e7 95 
Naltrexone-D7 9.97 e7 9.52 e7 95 
 
 
Table 7.17 – Naloxone/naltrexone assay: Analyte carryover in plasma and urine 
Carryover was assessed through comparison of the measured concentration of a low 
concentration sample (L) analysed after a high concentration sample (H) to the mean 
measured concentration of the low concentration sample analysed prior to the high 
concentration sample (N = 3). 
Plasma: L = all analytes 0.5 µg/L, H = all analytes 50 µg/L 
Urine: L = all analytes 10 µg/L, H = all analytes 2000 µg/L  
 
Analyte Carryover (%) 
Plasma Urine 
Naloxone 0  0  
Nornaloxone 6  -1 
6-β-Naloxol 5  -9 
Naloxone-3-glucuronide -3  1 
Naltrexone 3  -5 







Figure 7.17 – Naloxone/naltrexone assay: Post-column infusion of analytes to 
qualitatively assess matrix effects in human plasma. Extracted ion chromatograms 
for each analyte to show a) the solvent blank (black trace), b) matrix blank (red 
trace), and c) analyte retention time (green trace) 
Ion suppression is identified where the trace for the matrix blank is lower than the trace 
for the solvent blank. 
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Table 7.18 - Naloxone/naltrexone assay: Observed matrix effects in a) plasma, b) 
whole blood, and c) urine 
Matrix effect (%) is defined as the ratio of the analyte peak area in the presence of 
matrix to that in the absence of matrix. The relative matrix effect (%) was calculated 
through comparison of the analyte matrix effect with that of its internal standard. 
Analyte 
Peak area in 
the absence of 
matrix 











Naloxone 1.24 e8 7.98 e7 65 112 
Nornaloxone 4.04 e7 3.08 e7 76 132 
6-β-Naloxol 1.33 e8 8.81 e7 66 115 
Naloxone-3-glucuronide 2.15 e7 7.53 e6 35 101 
Naltrexone 1.29 e8 7.36 e7 57 105 
6-β-Naltrexol 2.00 e8 1.11 e8 56 102 
Naloxone-D5 1.10 e7 6.32 e7 58 - 
Naloxone-3-glucuronide-D5 1.23 e7 4.24 e6 35 - 
Naltrexone-D7 9.16 e7 5.01 e6 55 - 
b) Whole blood 
Naloxone 4.95 e8 3.93 e8 79 98 
Nornaloxone 2.52 e8 9.88 e7 39 48 
6-β-Naloxol 5.40 e8 3.84 e8 71 88 
Naloxone-3-glucuronide 1.93 e8 1.71 e7 9 104 
Naltrexone 5.10 e8 3.75 e8 73 110 
6-β-Naltrexol 8.02 e8 5.56 e8 69 103 
Naloxone-D5 6.24 e8 5.05 e8 81 - 
Naloxone-3-glucuronide-D5 2.11 e8 1.80 e7 9 - 
Naltrexone-D7 6.01 e8 4.03 e8 67 - 
c) Urine 
Naloxone 2.65 e7 2.10 e7 79 107 
Nornaloxone 7.59 e6 5.29 e6 70 94 
6-β-Naloxol 3.82 e7 2.40 e7 63 85 
Naloxone-3-glucuronide 4.26 e6 3.71 e6 87 108 
Naltrexone 2.74 e7 2.12 e7 77 104 
6-β-Naltrexol 6.10 e7 4.18 e7 69 92 
Naloxone-D5 5.14 e7 3.80 e7 74 - 
Naloxone-3-glucuronide-D5 7.75 e6 6.30 e6 81 - 




7.3.5.1 Patient Samples 
A summary of the samples analysed to clinically validate the developed assay and 
demonstrate it was fit-for-purpose are given in Tables 7.19 and 7.20. The dose of drug 
and the time since drug administration were unknown. 
Table 7.19 – Analyte concentration in urine: summary of naloxone, naltrexone, 
and their metabolites in urine from patients administered a) naloxone, b) 
Suboxone, and c) naltrexone 
*cases of Suboxone adulteration excluded (N = 7) 
Drug administered N Concentration (µg/L) 
Mean Median Min Max 
Naloxone  18     
Naloxone 8 33 14 11 114 
Nornaloxone 2 33 33 14 51 
6-β-Naloxol 5 21 17 15 35 
Naloxone-3-glucuronide 18 720 418 92 2,370 
Suboxone* 11     
Naloxone 3 23 24 15 30 
Nornaloxone 4 22 19 12 37 
6-β-Naloxol 1 20 - - - 
Naloxone-3-glucuronide 11 968 405 29 6,310 
Naltrexone 6     
Naltrexone 6 237 172 28 736 
6-β-Naltrexol 6 19,000 20,000 4,540 35,400 
 
Table 7.20 – Analyte concentration in plasma: summary of naloxone, naltrexone, 
and their metabolites in plasma from patients administered a) naloxone, and b) 
naltrexone 
Drug administered N Concentration (µg/L) 
Mean Median Min Max 
Naloxone  5     
Naloxone 5 1.29 0.45 0.07 2.89 
Nornaloxone 2 0.13 0.13 0.11 0.15 
6-β-Naloxol 5 0.45 0.33 0.16 1.06 
Naloxone-3-glucuronide 5 9.65 6.59 1.24 30.6 
Naltrexone 1     
Naltrexone 1 0.12 - - - 




7.3.6 Analyte Stability in Human Plasma 
7.3.6.1 Ambient Temperature 
IQC solutions (N = 3) stored at room temperature were analysed over a 48 h period. The 
median (range) ambient temperature over this time period was 18.7 (15.3-23.0) oC. The 
results showed that all analytes were stable for at least 48 h at room temperature (Figure 
7.18). 
Figure 7.18 – Naloxone/naltrexone assay: Analyte ambient temperature stability  
Mean accuracy calculated through comparison of mean measured concentration (N = 3) 
to the target IQC concentration. Acceptable accuracy is delimited by dashed lines, and 





7.3.6.2 Refrigerator Temperature 
IQC solutions (N = 3) stored refrigerated were analysed over a 2-week period. The 
median (range) temperature over this time period was 5.4 (1.5-9.9) oC. The results 
showed that all analytes are stable for at least 2 weeks (Figure 7.19). 
Figure 7.19 – Naloxone/naltrexone assay: Analyte refrigerator stability  
Mean accuracy calculated through comparison of mean measured concentration (N = 3) 
to the target IQC concentration. Acceptable accuracy is delimited by dashed lines, and 





7.3.6.3 Freeze-thaw stability 
IQC solutions (N = 3) were analysed after 4 successive freeze-thaw cycles. The median 
(range) freezer temperature over this time period was -26.7 (-17.4 to -28.2) oC. IQC 
solutions were thawed by inversion mixing at room temperature prior to each analysis. 
The samples were returned to freezer storage conditions for at least 24 h prior to 
removal for the next freeze thaw cycle. All analytes were stable following 4 freeze-thaw 
cycles (Figure 7.20). 
Figure 7.20 – Naloxone/naltrexone assay: Analyte freeze-thaw stability  
Mean accuracy calculated through comparison of mean measured concentration (N = 3) 
to the target IQC concentration. Acceptable accuracy is delimited by dashed lines, and 





7.3.6.4 Extract Stability 
Separate vials of prepared standard solutions (N = 3) were stored at 4 oC on the 
autosampler and analysed every 2 hours over a 12 h period. Data showed all analytes 
are stable on the autosampler for at least 12 h (Figure 7.21). The maximum number of 
patient sample which can be analysed in a batch within this timeframe is 90 samples.  
Figure 7.21 – Naloxone/naltrexone assay: Analyte autosampler stability  
Accuracy calculated through comparison of measured concentration to the target 
standard concentration. Acceptable accuracy is delimited by dashed lines, and Standards 




7.3.7 Differentiation of Suboxone and Subutex Use 
Naloxone-3-glucuronide was detected in 12 of the 14 urine samples collected from 
individuals known to be taking Suboxone. The median (range) naloxone-3-glucuronide 
concentration was 754 (39-6,150) µg/L. 6-β-Naloxol was detected in one sample (41 
µg/L). Naloxone and nornaloxone were not detected in any of the samples. Analysis of 
urine samples from individuals prescribed Subutex had no naloxone or metabolites 
detected. 
In both samples where naloxone-3-glucuronide was not detected, the summed 
concentration of buprenorphine metabolites was low (41 and 112 µg/L). Both samples 
were positive for 6-AM, morphine, and codeine, indicating recent heroin use. Many 
chromatographic peaks were observed in the XIC for naloxone-3-glucuronide between 
1-3 min in these samples. These peaks elute near naloxone-3-glucuronide and may 
interfere with detection, particularly if naloxone-3-glucuronide is present at low 
concentration in the urine sample. To ascertain whether these interfering compounds 
were a result of heroin metabolism, urines from individuals taking codeine (identified 
by a morphine-to-codeine ratio <1, Section 6.6.2.2), heroin (identified by the presence 
of 6-AM, and a morphine-to-codeine ratio >1), and from an individual known to have 
consumed poppy seeds were analysed. No interfering peaks were observed in the 
samples from individuals who had ingested codeine or poppy seeds, but were observed 
in all the samples from individuals who had recently used heroin (Figure 7.22).  
The use of Suboxone as opposed to Subutex may be ascertained through urinary 
detection of naloxone-3-glucuronide. However, detection of naloxone-3-glucuronide 
may be difficult in individuals who have recently used heroin due interfering peaks in 
the XIC.  
7.3.8 Identification of Suboxone Adulteration in Urine Samples 
Analysis of urine samples from individuals taking Suboxone showed that naloxone was 
not detected, but most samples contained naloxone-3-glucuronide (Section 7.3.7). 
Conversely in samples adulterated through addition of Suboxone, a high concentration 
of naloxone, in addition to buprenorphine, was observed with no glucuronide 
metabolites present (Figure 7.23).  
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Figure 7.22 – Extracted ion chromatogram for naloxone-3-glucuronide (m/z 




















































































Figure 7.23 – Extracted ion chromatogram of naloxone, buprenorphine, and selected metabolites in patient urine samples to differentiate a) 
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The method developed is simple, robust and rapid. It is capable of detecting and 
measuring a range of metabolites as well as parent drugs in both plasma and urine. The 
simultaneous measurement of naloxone and naltrexone in conjunction with this range of 
metabolites has not been reported before. In addition, the LLoQ for nornaloxone and 6-
β-naloxol in plasma has been improved to 0.1 and 0.05 µg/L, respectively, as compared 
to published methods.  
Urinary detection of naloxone and metabolites may be useful to i) detect cases of 
Suboxone adulteration, and ii) differentiate Suboxone and Subutex ingestion. Detection 
of naloxone-3-glucuronide is indicative of Suboxone use, provided no naloxone has 
been administered. A limiting factor is that interference as a result of heroin use may 
hinder the detection of naloxone-3-glucuronide.  
7.4.1 Further Work 
Analysis of more urine samples from patients taking Suboxone to ascertain the 
frequency with which naloxone-3-glucuronide is not detected would help assess 
whether naloxone-3-glucuronide is a reliable marker for Suboxone use. Ideally the daily 
Suboxone dose and the time of last dose are required to aid interpretation of results. 
Whether a correlation exists between either the dose, or the time since last dose, and the 
concentration of naloxone-3-glucuronide could also be ascertained.  
The developed method may be used for analysing the plasma samples collected for 
naloxone PK studies. A novel buccal naloxone formulation has been developed by 
King’s College London (Alqurshi et al., 2016), and pilot studies to ascertain the PK of 















LC-HRMS methods have been developed for qualitative and quantitative drug detection 
in biological matrices. The qualitative assay developed for urinary drug detection 
(Chapter 2) has enabled screening and confirmation of selected drugs to be completed in 
a single analytical step, which reduces cost and turn-around-time. The method is 
appropriate for use in a clinical setting, but barbiturates, benzodiazepines, and cannabis 
assay is still best performed by immunoassay initially. The quantitative assay developed 
for measurement of naloxone, naltrexone, and selected metabolites (Chapter 7) has good 
sensitivity, and is suitable for application in PK studies. The method was also used to 
analyse urine samples, and ascertained that urinary naloxone-3-glucuronide assay may 
be used to differentiate Suboxone and Subutex use. 
8.1 Benefits of Using LC-HRMS for Analysis of Drugs in a Clinical Setting 
LC-HRMS analysis has two key advantages in regard to advancing drug detection; the 
ability to rapidly incorporate new analytes into an existing method, and to 
retrospectively analyse data. To exploit these benefits fully, sample preparation methods 
should be kept non-selective to allow as much data as possible to be captured from 
sample analysis. This approach is well-suited to address the current requirements of a 
urine drug screening service, where detection of novel drugs may be required in a short 
time-frame. The other advantage of keeping methods non-selective is that a wider range 
of analytes may be assayed. By keeping the sample preparation non-selective for the 
naloxone assay, the more polar analytes (nornaloxone and naloxone-3-glucuronide) 
could be included in the method. 
The established methodology for drugs of abuse testing in most clinical laboratories has 
not been adapted to account for the change observed in the drug market over recent 
years. As a result, the use of novel drugs may go undetected. Improving detection of 
novel compounds is of increasing importance to the scientific community to enable 
accurate diagnosis and treatment of individuals who abuse these substances. 
Immunoassays, which are widely used by clinical laboratories for urinary drug 
detection, may be inappropriate for the detection of NPS. Poor cross-reactivity of 
mephedrone and its metabolites with the CEDIA amfetamine-group assay has been 
shown in this study, and analysis of patient samples containing mephedrone in the 
absence of other amfetamine drugs gives negative results (Chapter 5). The development 
of immunoassays is a slow process, meaning by the time a kit is commercially available 
it is likely that targeted drug is no longer in circulation rendering the assay obsolete. On 
the other hand, LC-HRMS has the advantage of being a versatile and adaptable 
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methodology which enables the rapid incorporation of NPS into existing methods, as 
demonstrated through the inclusion of methylphenidate, ethylphenidate, and ritalinic 
acid, into the drug screening method (Chapter 4).  
The ability to retrospectively interrogate data may be used to improve knowledge of a 
compound’s metabolism, particularly for NPS where little is known regarding in vivo 
metabolism. From retrospectively analysing urine samples containing mephedrone, 
normephedrone, 4-methylephedrine, and 4-methylpseudoephedrine were confirmed as 
urinary metabolites of mephedrone. In addition, five of the reported urinary metabolites 
tentatively identified by Pozo et al. (2015) were qualitatively identified in most of the 
urine samples from mephedrone users that were analysed. Two novel urinary 
metabolites of mephedrone, 4-methylpseudoephedrine and 4-methylpseudo-
norephedrine, were also tentatively identified (Chapter 5). 
8.2 Limitations of LC-HRMS  
Many of the benefits of LC-HRMS can only be exploited if sample preparation is kept 
as non-selective as possible. However, this may compromise the ability to accurately 
quantify an analyte as matrix effects are often significant when minimal sample 
preparation is used. Choosing appropriate internal standards may overcome this 
problem, as shown through inclusion of naloxone-3-glucuronide-D3 in the quantitative 
assay developed. The other impact of minimal sample preparation is that assay 
sensitivity may be compromised due to ion suppression from matrix components. To an 
extent, HRMS is able to compensate for this loss by allowing an analytes signal to be 
extracted from near-isobaric background signals, but in some cases targeted analysis 
may be necessitated to achieve the required sensitivity.   
Whilst there is the capability to retrospectively analyse data, the process is not always 
straight-forward. The current instrument software is not able to reliably process data, 
particularly in regard to performing unknown screens, which makes it a time-consuming 
process. Currently, screening for unknown compounds using LC-HRMS remains a 
largely manual process and requires skilled analysts to interpret data. Unlike GC-MS, 
no searchable universal compound library exists for LC-HRMS. The work presented in 
this thesis is in agreement with Maurer (2013), that the development of an instrument-
specific in-house compound library based upon analysis of reference standards is 
required to enable definitive compound identification. In most cases, results that are 
generated from retrospective analysis may only be used for qualitative information. 
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Accurate quantitation is reliant on an appropriate internal standard being included at the 
time of original analysis, and the analyte concentration being within its linear range. Re-
analysis of samples may be undertaken, but the sample may have been discarded or the 
analyte may have degraded. The long-term physical storage of data may also be 
problematic due to the vast amount of data generated for each sample.  
Whilst the use of HRMS is highly selective, interferences still arise. Isobaric 
interferences cannot be overcome using mass spectrometry alone, which can make 
identification of unknown substances difficult. As a result, reference standards are still 
required for definitive compound identification. Even in cases where a reference 
material is available for the compound of interest, co-elution of an isobaric compound 
cannot be excluded. This is particularly relevant for positional isomers, where specific 
MS2 product ions often aren’t available to differentiate analytes. In this study, 
measurement of mephedrone in urine samples was undertaken but it could not be 
excluded that 2-MMC or 3-MMC were actually the compound detected. Non-isobaric 
interference was also observed from isotopes of analytes, as seen by the M+1 isotope of 
4-methylephedrine/4-methylspeudoephedrine and the M+2 isotope of 6-β-naltrexol 
influencing the apparent peak area of the internal standard. Using selective mass 
spectrometry (e.g. SRM) may overcome these interferences, provided specific product 
ions can be identified. However, the capacity for capturing all data from a sample is 
then lost, and as a result the ability to effectively analyse data retrospectively.  
Many drugs, in particular NPS, contain chiral centres. The pharmacological potency of 
NPS enantiomers may differ as it is already known that other R- and S- isomers of other 
drugs possess different efficacy and toxicity profiles (e.g. methcathinone, mephedrone, 
amfetamine). The development of analytical methods for the chiral separation of NPS 
may be important in furthering knowledge of these compounds. A limitation of MS is 
that it is an achiral technique meaning that chiral compounds cannot be differentiated, 
i.e. the mass spectra of an enantiomeric pair are identical. When coupled with LC, 
analytical separation of the enantiomers is possible using a chiral stationary phase. 





8.3 Future Opportunities for Drug Screening 
Adulteration of samples remains a problem with urine drug screening, with 
approximately 1 in 50 samples received by our laboratory identified as adulterated 
through addition of either buprenorphine or methadone. Advances in analytical methods 
enable identification of these cases through separate detection of parent drug and 
metabolites, but does not address the main problem. Collection of oral fluid, as opposed 
to urine, may minimise sample adulteration as oral fluid is a non-private sample. 
However, other issues such as sample contamination, by sublingual administration of 
medications (e.g. buprenorphine), and analytical challenges, e.g. low analyte 
concentration, analyte adsorption to collection devices, need to be overcome. 
The use of LC-HRMS for drug screening could warrant a change in reporting results. 
Results from the audit showed that basing result interpretation on the LoD as opposed to 
the cutoff concentrations would affect a large number of results. Reporting results based 
on analyte detection limits enables the window of drug detection to be extended which 
may be clinically relevant for cases where single or low-dose administration of a drug is 
suspected (e.g. DFSA, drug administration to children). In addition, routinely reporting 
to the limit of detection may be beneficial for selected analytes, most notably 6-AM. 
The audit showed that through reporting the presence of 6-AM based on the LoD, an 
additional 93 cases of recent diamorphine or heroin use could have been identified 
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Mephedrone Assay: x-y and Bland-Altman plots to compare the analyte concentrations 
calculated when analysing undiluted and diluted urines 
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Appendix C   
Publications 
 
Included herein is a complete copy of a relevant publication produced prior-to this 
project: 
- Belsey S.L., Couchman L., and Flanagan R.J. (2014). Buprenorphine detection in 
urine using liquid chromatography-high-resolution mass spectrometry: comparison 
with cloned enzyme donor immunoassay (ThermoFisher) and homogeneous 
enzyme immunoassay (Immunalysis). J. Anal. Toxicol. 38, 438–443.  
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